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While DNA profiling makes it possible to individualize biological stains, the 
identification of the stain itself can present forensic serologists with a significant 
challenge. Current antibody- and enzyme activity-based assays used by forensic 
practitioners for biological stain identification yield only presumptive results. Positive 
results with non-target body fluids or cross-reactivity with non-human sources has also 
been well documented. Some tests can consume unacceptable quantities of precious 
evidence while for some body fluids (vaginal fluid and menstrual blood) there are simply 
no available tests at all.  
This research presented here aims to develop and rigorously test a fast, accurate, and 
sensitive multiplex assay for the simultaneous identification of saliva, semen, urine, 
peripheral blood, menstrual blood, and vaginal secretions. This research is based on the 
following three research phases: 
1. Biomarker Identification – Utilizing multidimensional protein separation 
technologies, bioinformatics tool, and tandem mass spectrometry a database of 
fluid-specific candidate markers will be developed for each body fluid. 
2. Biomarker Verification – Using the most promising candidates from Phase 1 a 
targeted multiplex assay will be developed on a Quadruple Time-of-Flight mass 
spectrometer to verify the specificity of these candidate biomarkers with single 
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source laboratory samples as well as single and mixed source casework type 
samples. 
3. Prototype Validation – Development and testing of a case working laboratory 
prototype assay on a triple quadrupole mass spectrometer using single and mixed 
source casework-type samples.  
This work has the potential to significantly improve the accuracy and sensitivity of 
forensic serological testing. It will provide practitioners with greatly improved tests for 
saliva and seminal fluid while also enabling the identification of vaginal secretions for 
which there are currently no accurate tests.  The multiplex design will eliminate the need 
to perform separate tests on an unknown stain. In short, the successful completion and 
implementation of this research will provide the forensic community with a powerful tool 
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The development of DNA typing technologies has transformed the world of 
forensic science by allowing the routine individualization of biological stains. Despite 
this tremendous power of this technology, it is not difficult to point to situations where 
the unambiguous identification of a biological fluid can be very informative and even 
critical for investigators. Obtaining a confirmatory identification of a biological stain, 
however, can present a challenge. Currently, there are no dependable tests for vaginal or 
menstrual fluids. Other fluids (e.g., saliva) have well established assay protocols for 
detection but theses can provide only presumptive results.  
 
1.1 History and Importance of Forensic Serology  
Forensic serology can be broadly defined as the discipline concerned with the 
characterization of biological fluids present on evidentiary material. Currently, the 
identification of unknown biological stains relies upon the use of microscopic 
visualization, immunological affinity, chemical reaction and enzymatic activity tests in 
order to locate and/or identify the source of a stain on a piece of evidentiary material. 
Once located, stains are processed further in order to generate DNA profiles to identify 
specific the individual who was the source of the material. 
In the context described above, forensic serology is being used as a first-pass 
screen of evidentiary material prior to and independent of DNA analysis. Traditionally, 
however, serological assay techniques attempted to combine both stain characterization 
as well as the individualization of a stain. The most notable example of this being the 





implemented for forensic practice by Leon Lattes in the early 1900’s
[2]
. While Lattes’ 
agglutination method can successfully identify blood, the discriminating power of the 
technique for individualizing bloodstains is so low that there is a nearly 40% chance that 
any two randomly selected unrelated individuals will have the same blood type
[3]
. 
Furthermore, the agglutination-based test lacked sensitivity and, the result indicating an 
“AB” type could not be differentiated from that of a failed test result since the 
identification relies upon the lack of a lack of an agglutination  reaction
[4]
. After decades 
of research and development, the goal of individualizing stains using serological markers 
produced only moderate advances. One notable method combined ABO markers along 
with polymorphic proteins markers such as phosphoglucomutase (PGM) into a single 
testing system
[5, 6]
. While the combination of these two markers was an improvement, 




In recent years, modern DNA typing has allowed for the individualization of 
biological stains such that the chance of finding an unrelated individual, selected at 
random from the general population, having the same DNA type as that of a suspect in a 
criminal can be as low as one out of billions to one out of quadrillions
[7]
. Because the 
discrimination power of DNA is so high, compared to historical serological typing 
methods, individualization by serological typing has largely been abandoned. As such, 
serological testing in a modern forensic laboratory is considered to be strictly a screening 
device for locating biological material which will be subsequently used for DNA 
profiling. Nonetheless, serological screening still has important value as an investigative 
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tool in many forensic cases. The largest reason for this being that DNA is unable to 
provide insight as to the tissue source of a DNA profile.  Specifically, DNA alone cannot 
indicate whether it profile originated from saliva, vaginal fluid, or blood – information 
which may be able to provide context to a criminal investigation.  
For example, consider the case of an alleged sexual assault where DNA consistent 
with the victim is recovered from the neck of a bottle. The victim alleges that the suspect 
vaginally penetrated her with the bottle while the suspect claims that no sexual contact 
occurred – offering instead that the alleged victim had simulated oral sex on the bottle. 
Both stories “explain” the presence of the victim’s DNA profile on the bottle. The ability 
to unambiguously detect saliva vs. vaginal fluids or a mixture of saliva and vaginal fluids 
could potentially help investigators to refute one of these opposing claims. A number of 
other scenarios could easily be imagined where the ability to characterize body fluids and 
to clearly detect and identify even microscopic traces of  urine, seminal fluid and saliva 
or to differentiate between menstrual blood and peripheral blood, would have important 
probative value. Such capabilities would have clear benefits for criminal investigations 
and would enable forensic analysts to make more definitive statements about the potential 
tissue source of a DNA profile. 
 
1.2 Serological Testing Assays  
Serological testing relies upon four general categories of testing. They include 
chemical reaction assays, enzyme activity assays, immunoassays, as well as microscopy 
based assays. Each individual test can be further classified as being presumptive or 
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confirmatory for its designated target fluid. Presumptive tests will reveal the possible 
presence of a particular body fluid whereas a confirmatory test will unambiguously 
identify an unknown stain as having a specific biological origin. The following section 
will describe the four general testing categories. 
1.2.1 Chemical Reaction Assays:   
Chemical reaction tests are based on the formation of crystals or a color change in  
assay reagents as they interact with substrates in a target fluid. One example of a 
colorimetric assay, the Kastle-Meyer test, produces a pink color when exposed to 
hemoglobin present in blood
[8, 9]
. In this reaction (Figure 1), phenolphathalin is prepared 
in an alkaline zinc solution and is added to the stain along with hydrogen peroxide.  
Hemoglobin in the blood has peroxidase-like activity producing water as well as oxygen-
free radicals. The oxygen radicals, in turn, catalyze the oxidation of the phenolphathalin 
to phenolphathalein, producing a bright pink color.  
 
 
Figure 1 - Kastle-Meyer reaction, phenolphthalein is oxidized in the presence of hydrogen peroxide and hemoglobin 





An example of a crystal-producing test is the Teichmann test for blood
[11]
.  
Crystals form as a result of the chemical reaction between the iron component of 
hemoglobin and the Teichmann reagent, a solution of potassium bromide, potassium 
chloride, potassium iodide and glacial acetic acid.  
While chemical reaction based assays are generally sensitive, false positives are 
common. Peroxides in plants as well as chemical oxidants are common causes of false 
positive results
[12]
.  In addition, assays requiring the formation of detectible crystals lack 
the sensitivity and reliability necessary to be of utility in cases where only trace quantities 
of evidentiary material are available.   
1.2.2 Enzyme Activity Assays 
Enzymes are proteins which catalyze chemical reactions between substrates to 
generate a specific product
[13]
. For enzyme molecules which are present in high 
concentration in a given body fluid, the specific catalytic activity of the enzyme can be 
used to screen for the possible presence of an unknown stain. One example, prostatic acid 
phosphatase (also known as seminal acid phosphatase or SAP), hydrolyzes the phosphate 
group from its substrate molecule. This enzyme is present in high amounts in the prostate 
gland and detection of its activity is one of the most common methods to screen evidence 
for the presence of seminal fluid 
[14]
.   In this test, the phosphate group on α-naphthyl 
phosphate (the assay substrate) is cleaved forming a reactive species. To carry out this 
test, sodium α-naphthyl phosphate and the dye Brentamine Fast Blue are applied to a 
suspected seminal fluid stain.  Enzymatically active SAP cleaves the phosphate group on 
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α-naphthyl phosphate which reacts with Brentamine Fast Blue to generate a dark purple 
color (Figure 2). 
 
Figure 2 – SAP overlay to localize potential seminal fluid stains. Moistened filter paper is pressed on top of the 
evidentiary material to draw out active enzyme by capillary action. Following the addition of α-naphthyl phosphate 
and Brentamine Fast Blue, a dark purple color indicates the presence of seminal fluid. 
While these tests are typically sensitive, the results are only presumptive for a 
target body fluid.  This is due primarily to the fact that although a given enzyme may be 
an abundant component of the body fluid to which the assay is targeted, the same enzyme 
may also be present in one or more non-target body fluids or tissues, albeit at lower 
concentrations.  The level of SAP in blood serum, for example, has been used as a marker 
for prostate cancer in males
[15]
. Additionally, proteins are subject to a loss of activity due 
to factors such as microbial degradation, exposure to chemical agents and inhibitors and 
extremes of temperature or pH
[16-18]





Immunoassays are analytical methods which employ antibody-antigen binding 
events to detect specific target molecules.  When properly and thoroughly characterized, 
it is usually possible to isolate antibodies that are highly specific and sensitive for nearly 
any target molecule of interest. In relation to forensic serology, antibodies are selected to 
target molecules which are specific to a particular body fluid. Early immunoassays 
commonly employed in case work labs were based on the visualization of a precipitation 
reaction between antigens and their corresponding antibody. Using the Ouchterlony 
double diffusion method, a series of wells are punched into an agarose gel such that there 
is a central “antibody well” surrounded by additional “antigen wells”. A solution 
containing antibodies against a specific protein is placed in the central well. Controls and 
extracts of questioned stains are added to the surrounding antigen wells. Diffusion of the 
sample antigens and the antibodies toward each other will occur and a precipitation line, 
indicating a positive result for the test, will appear if a sufficient quantity an antibody-
antigen complex forms (Figure 3).  
 
Figure 3 – Antigen-antibody precipitate formation indicating a positive test result. 
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More sophisticated methods, such as cross-over electrophoresis, use an electric 
field as an alternative to diffusion to drive antigens across an agar gel. As with the 
Ouchterlony method, a precipitate will form if a sufficient quantity of a target antigen is 
present.  
Immunochromatographic assays have gained popularity in recent years for their 
simplicity, specificity, cost, and speed
[19, 20]
. Commercial immunochromatographic assays 
are sold as single-use lateral flow strips that target specific proteins present in a given 
body fluid. The strips (Figure 4) contain a sample loading well, lateral flow membrane, 
and three antibodies. To run the test, a liquid extract from a questioned sample is 
introduced onto the conjugate pad where it mixes with colloidal gold labeled antibodies. 
Samples which contain the target protein form an antigen-antibody-colloidal gold 
complex that migrates by bulk fluid flow across the lateral flow membrane.  Immobilized 
antibodies, specific for the target protein, capture the antigen- antibody-colloidal gold 
complex as it migrates down the test strip. The aggregation of colloidal gold conjugated 
antibodies creates a visible band at the Test Line. Free antibodies not captured at the Test 
Line continue toward the control line where they are captured by immobilized antibodies 
targeted directly to the antibody portion of the antibody-colloidal gold conjugate. This 





Figure 4 - Lateral Flow Immunochromatographic Strip. A positive result is indicated by visible bands at both the 
Test Line and the Control Line.   
While sensitive and easy to use, antibodies have limitations which limit their 
probative value. The primary issue is that protein antigen-antibody binding is rarely 
100% specific; thus, false positive results are possible. This arises from several sources: 
first, proteins are known to have variability in structure due to genetic polymorphisms as 
well as differential post-translational modification
[21]
. Because immunoassays are based 
on binding a specific epitope of a target protein, any modification to this structure can 
result in a false negative result. Second, along with variability of the individual protein, it 
is possible for non-target molecules with a similar or identical epitope to be recognized 
by the antibody generating false positive results. Finally, it is possible for the target 
antigen to be at such a high concentration that the immobilized antibodies at the test line 
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are more likely to bind free antigen than the antigen-complexed mobile-phase antibodies. 
Referred to as the “hook effect”, this can produce false negatives or falsely indicate very 
low amounts of the target body fluid when, in fact, the exact opposite is true
[21]
. 
1.2.4 Microscopy Based Assays 
Microscopy is simply the use of a series of lenses to view objects which are too 
small to see with the naked eye. Applied to forensic serology, microscopy has primarily 
been used as a means of identifying sperm cells on sexual assault evidence. Sperm cells 
can be both detected and identified as being of human origin using visible light or 
fluorescence microscopy by a skilled analyst knowledgeable in the morphological 
characteristics of human sperm. Because spermatozoa are much smaller than the vaginal 
or other epithelial cells with which they are often comingled in a forensic context, they 
can be difficult to localize in the microscopic field. With visible light microscopy, 
detection is facilitated by the use of histological stains such as the combination of 
hematoxylin and eosin or nuclear-fast red and picroindigocarmine
[22, 23]
. The latter more 
commonly known as “Christmas tree’’ stain is particularly useful because it differentially 
stains spermatozoa and epithelial cells. Using this stain, the sperm head will be red with a 
pink tip, the mid section will be blue and the tail will be yellow-green. Epithelial cells by 
contrast will appear greenish to blue.  
The more recent introduction of fluorescence microscopy has greatly streamlined 
the process of identifying spermatozoa
[24, 25]
. The strategy takes advantage of the 
specificity of proprietary fluorochrome-conjugated antibodies targeted to a protein that is 
unique to the spermatozoa head. The approach, which requires a fluorescence microscope 
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fitted with appropriate excitation and emission filters, makes it possible to selectively and 
readily visualize human sperm heads even against a background crowded with epithelial 
cells, microbes and non-cellular debris such as fecal matter.  The spermatozoa heads 
appear as bright fluorescent ovoid bodies against a dark background.  
The major limitations with microscopy are the need for relatively intact spermatozoa 
and the laborious nature of visually scanning microscopic fields for the presence of 
relatively few spermatozoa where non-sperm cells and other debris often predominate. 
Spermatozoa may be difficult to separate from cotton and other clothing fibers since as 
they degrade they typically lose their characteristics tails and ovoid shape such that they 
become more difficult to distinguish in the presence of similarly-sized microbes such as 
yeast. While fluorescence microscopy circumvents many of these problems, it requires a 
greater investment in costly microscopes and, because it is antibody based, may fail to 
yield optimal results as spermatozoa degrade and antigenic target molecules become 
unrecognizable by the antibodies.  
 
1.3 Current Testing Methodologies 
Seminal fluid, saliva, and blood are some of the most commonly encountered forms 
of serological evidence in criminal investigations. While not as common, vaginal fluid, 
anal secretions, fecal matter, urine, sweat, tears and nasal secretions could also constitute 
potentially probative evidence depending on the context of the case. Unfortunately, the 
range of body fluids for which serological assays would be valuable exceeds the number 
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for which assays actually exist. Currently, there are no reliable tests for vaginal fluids, 
anal secretions, sweat, tears or nasal secretions. However, there are numerous assay 
options available for several body fluids with forensic relevance which offer a wide range 
of strengths and weaknesses.  
1.3.1 Semen and Seminal Fluid 
Semen is a mixture of spermatozoa (sperm cells) and seminal plasma. Seminal 
plasma is a mixture of secretions from six different glands/tissues of the male genital 
system. Semen is ejected as a heterogeneous mixture of these secretions during 
ejaculation.  The initial ejaculate (5% of the total volume) consists of secretions produced 
by the Cowper (bulbourethral) and Littre glands. The second portion of the ejaculate 
(15% to 30% of total volume) consists of secretions from the prostate gland.  The 
secretions of the ampulla and epididymis then provide a small contribution while the 
seminal vesicles account for the balance (approximately 60% of total volume)
[26-28]
. 
Spermatozoa (sperm cells) make up a small portion of whole semen (1% to 5% of the 
total ejaculate volume)
[29]
. Pre-ejaculation fluid is secreted almost exclusively by the 
Cowper’s gland and can contain traces of SAP and p30 but not semenogelin (Sg). The 
presence of sperm in pre-ejaculation fluid appears to be rare and may be due to carryover 
from a prior ejaculatory event. Because of the obvious association with sexual activity, 
seminal fluid and spermatozoa represent some of the most potentially probative evidence 
that can be collected as part of a sexual assault investigation.  
Chemical reaction-based tests are no longer commonly used for the detection of 
seminal fluid due to their lack of specificity and reproducibility. Historically, however, 
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the chemical reaction-based tests for seminal fluid were the Barberio and Florence crystal 
tests.   
Enzyme activity based tests such as the Brentamine test for seminal fluid target 
SAP activity, which is an abundant, but not unique, component of seminal fluid. SAP 
typically retains activity in a vaginal environment for approximately 48 hours post-coitus, 
but in an oral or rectal context, this period is typically shorter. A positive SAP result is 
indicted by a color change in the presence of a coupling agent and an indicator dye (e.g., 
α-naphthyl phosphate and Brentamine Fast Blue). The test may be performed as a spot 
test, commercially prepared test strips or as an overlay technique to localize possible 
seminal fluid stains.  Although SAP is a sensitive test, positive results cannot confirm the 
presence of seminal fluid. This is due to the fact that although SAP activity levels are 
elevated in seminal fluid, phosphatase activity in other fluids or materials can produce 
positive results. These include a number of non-seminal fluid associated substances such 
as vaginal fluid, fecal matter, plant material, spermicides and some feminine hygiene 
products.  
Historically, immunoelectrophoresis, Ouchterlony double diffusion and Enzyme-
Linked Immunosorbent Assays (ELISA) were employed to detect antibody binding. In 
recent years, these laborious and slow techniques have been supplanted by lateral flow 
immunochromatographic strip tests that are faster and commercially available at a 
relatively low cost. For seminal fluid detection, p30 and Sg are the primary targets of 
immunochromatographic test strips used in sexual assault investigations. The p30 protein 
is secreted by the prostate and is present in seminal fluid in a concentration range 
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between 70 to 5500 mg/mL with the majority of samples being between 820-1290 
mg/mL. Semenogelin (Sg) is produced by the seminal vesicles and serves as the substrate 
for PSA and is the predominant protein in seminal fluid. In living individuals, the ability 
to detect PSA and Sg tends to be lost within 24 hours in a vaginal context and even faster 
in an oral or rectal context. Although antibodies targeted to PSA and Sg are generally 
sensitive and highly specific for human proteins, positive results must still be interpreted 
with caution and cannot confirm the presence of seminal fluid. There are two reasons: 
first, while PSA and Sg are abundant proteins in seminal fluid, they can also be found in 
a variety other bodily fluids and tissues, although not typically at concentrations that 
overlap significantly with the concentration range seen in seminal fluid. In the case of 
p30, however, positive results may be obtained with post-ejaculate urine; urine from adult 






Figure 5 - Abacus Diagnostics ABAcard® p30 immunochromatographic test strips. TOP: Visible bands at the Test 
Line (T) and the Control Line (C) indicates the detection of prostate specific antigen in a semen sample. BOTTOM: 
Visible bands at the Test Line (T) and the Control Line (C) indicate the detection of prostate specific antigen in a pre-
coital vaginal fluid sample (i.e., in the absence of semen). Image courtesy of Jillian Fesolovich, NMS Labs, Willow 
Grove, PA. 
Similarly, positive results with Sg may be obtained with post-ejaculate urine. The 
second reason is that, by their very nature, antibodies are subject to cross-reactivity with 
non-target antigens that possess structurally similar epitopes but which may be 
completely unrelated to the intended target. 
Microscopy-based tests provide the most reliable means of indicating the presence 
of semen as they are based upon the direct identification of spermatozoa. On average, 
male ejaculate contains 3.5 mL of seminal fluid containing 10-50 million spermatozoa 
per mL.  Human spermatozoa have a distinct morphology allowing species differentiation 
and can be identified for a longer postcoital interval (approximately 72 hours) when 
compared to chemical or protein components of semen. There are a variety of histological 
stains used for light microscopy of spermatozoa. Using methylene blue and acid fuchsin 
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(Baecchi’s stain) the heads of the sperm stain red, while the midpieces and tails are blue. 
The use of hematoxylin and eosin (H&E stain) yields heads characterized by an intense 
blue-colored anterior spike and base-plate and a paler blue nucleus with a pink tail. Most 
commonly used is the aforementioned combination of nuclear-fast red and 
picroindigocarmine (Christmas tree stain) with which the heads are stained red and tails 
are yellow-green. The major drawback to light microscopy is the specificity of the dyes 
themselves. Regardless of the stain used, epithelial cells, microbes, bacteria and cotton 
fibers will also take up stain making the process of identifying the relatively small 
spermatozoa laborious and difficult. The use of fluorescence microscopy circumvents this 
drawback by allowing the selective visualization of spermatozoa through binding of 
commercially-available, sperm-specific antibodies conjugated to a fluorochrome. By 
combining the use of antibodies with microscopy, this approach also circumvents the 
possibility that antibody cross-reactivity might lead to an undetectable false positive 
result.   
When using microscopy in a forensic context, a failure to observe spermatozoa 
must be interpreted with caution. Some males have abnormally low sperm counts 
(oligospermia) or may not produce spermatozoa at all (aspermia). Spermatozoa will be 
absent in the seminal fluid of vasectomized males approximately 2-4 months following 
surgery. The presence of spermatozoa in seminal fluid can also vary with the age of the 
male, and can be impacted by a broad range of factors including disease, genetics, 
radiation exposure, environmental toxins, undescended testis, varicocele, trauma, diet, 
tobacco use and/or illicit drug consumption. 
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1.3.2 Vaginal Fluid 
Similarly to semen and its connection with sexual activity, the ability to detect 
vaginal fluid on evidentiary material has enormous potential to be probative as part of a 
sexual assault investigation. However, in contrast to current testing methods for semen, 
efforts to develop reliable tests for evidence of vaginal fluids have been largely 
unsuccessful.  
Over the years, there have been numerous attempts to reliably identify vaginal 
epithelial cells in evidentiary samples. While the use of histochemical stains to detect 
sperm cells
[23] 
is routine, staining to differentiate epithelial cells types (e.g., skin, buccal 
and vaginal cells) has not been as successful. In the 1960s, the iodine-based Lugol’s test 
held promise for identifying vaginal cells
[30, 31]
. This was based on studies suggesting that 
vaginal cells contained more glycogen than other epithelial cells. Unfortunately, Lugol- 
positive cells are also present in the male urethra
[32]





of penile swabs from males who had abstained from sex for several days and in the oral 
mucosa
[34]
. More recently, a methanol fixation protocol and Dane’s staining technique 
(stains targeted to pre-keratin, keratin and mucin) was able to differentiate pure samples 
of vaginal, buccal and skin cells
[35]
. This approach, however, was unable to distinguish 
between a pure buccal cell sample and a mixed preparation of vaginal and skin cells. 
Given that forensic samples often contain such cell mixtures, this essentially negates the 
potential forensic utility of this approach as even a moderately reliable means of 





Saliva is a fluid produced by the major (90%) and minor (10%) salivary glands. 
The fluid is made up of 99% water but also contains a complex mixture of low-
abundance proteins. Saliva provides lubrication, aids in digestion, maintains pH, assists 
with tooth enamel re-mineralization and plays a role in innate immune defense. The 
protein component of saliva is rich in the enzyme α-amylase which breaks down complex 
carbohydrates into smaller sugar molecules. As such, α-amylase activity or the ability to 
detect it through antibody binding serves as the basis of most serological saliva assays.  
Enzyme activity tests for α-amylase commonly use the starch-iodine radial 
diffusion test. Starch in the gel is incubated with suspected saliva samples.  Iodine is then 
added which stains starch a dark bluish-black. The passive radial diffusion of α-amylase 
into the gel and the subsequent breakdown of starch molecules produces an unstained 
“halo effect” around the test well that is characteristic of a positive result. There is a semi 
logarithmic correlation between the size of the halo and the amount of α-amylase loaded 
into the well
[36]
. Another approach is based on the use of degradable starch which 
contains a chemically-bound blue dye. Degradation of the starch due to α-amylase 
activity releases the blue dye to produce a color change that is visible to naked eye. The 
test may be performed as a spot test; using commercially prepared test strips or; as an 
overlay technique which may help to localize possible saliva stains on an article of 
clothing or other evidentiary material.  
As with other fluids, immunochromatographic tests have improved the 
presumptive detection of saliva via α-amylase specific antibodies. Similar to seminal 
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fluid assays, lateral flow immunochromatographic strip tests are employed and a positive 
test result is indicated by the appearance of visible lines at the “test” and “control” 
positions on the assay membrane.  
Regardless of whether the detection of α-amylase is based on enzyme activity or 
antibody binding, a positive result can only be considered presumptive.  The α-amylase 
protein has been well conserved in evolution, and as a result, enzyme activity assays will 
yield positive results regardless of whether the amylase is from bacteria, fungi, or 
domestic pets. Similarly, it is not possible on the basis of enzyme activity to distinguish 
between variants of α-amylase (i.e., salivary and pancreatic α-amylase). α-Amylase is 
also found in many body fluids other than saliva at levels that yield positive results with 
both enzyme activity and antibody-binding tests. These include breast milk, vaginal fluid, 
fecal matter, urine, blood and semen. Finally, cross-reactivity between antibodies and 
non-target antigens that possess structurally similar epitopes is also a possibility. 
1.3.4 Blood 
One of the most commonly encountered body fluids in criminal investigations is 
blood. Blood includes a cellular fraction consisting of erythrocytes, leukocytes and 
platelets (45%) suspended in a liquid fraction consisting of blood plasma (55%). Plasma 
contains 92% water along with a complex mixture of proteins, glucose, mineral ions, 
hormones as well as lipids. The metalloprotein hemoglobin is responsible for oxygen 
transport and is the major protein contained within erythrocytes. Because of its high 
abundance, the majority of blood detection strategies target this specific protein. 
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Among the many chemical reaction-based presumptive tests for blood are two crystal 
tests, the Takayama and aforementioned Teichmann tests, which rely on the heme group 
ferrous iron-catalyzed formation of crystals of heme derivatives. A positive result with 
the Takayama test is based on the formation of salmon-pink feathery crystals of pyridine 
hemochromogen resulting from the reaction of the ferriprotoporphyrin with pyridine. The 
Teichmann test positive result is indicated by the detection of brownish-yellow rhombic 
crystals of chlorohemin formed through the combination of a halogen with 
ferriprotoporphyrin.  While crystal tests have not been found to yield positive results with 
body fluids other than blood, they are only presumptive for human blood for two reasons. 
The first is that a positive result will be obtained with both human and non-human blood. 
The second reason is that crystal formation only reflects a chemical reaction with the 
ferriprotoporphyrin group of hemoglobin.  Thus false positives are technically possible 
with non-blood substances since iron porphyrin-containing hemoproteins such as 
cytochrome P450 and a number of other cytochromes occur frequently in biological 
systems
[37]
. As a practical consideration, however, these proteins are typically found in 
natural systems at concentrations well below the detection sensitivity of the crystal tests.  
A number of other chemical reaction-based assays widely employed are based on 
reactions involving the iron-containing heme group of hemoglobin. This protoporphyrin 
IX ring structure with its associated iron ion displays peroxidase-like activity that can be 
harnessed to produce chemoluminescence or colorimetric changes in any of several 
indicator dyes.  The Luminol test is most sensitive of these assays. Luminol and its 
contemporary derivatives are chemoluminescent substrates, the oxidation of which is 
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catalyzed by heme in the presence of hydrogen peroxide to form an unstable 
intermediate. Decay of this intermediate, liberates light
[38]
. Similarly, the aforementioned 
Kastle-Meyer (KM) and the Leucomalachite Green (LMG) tests rely on the peroxidase-
like activity of heme to catalyze the reduction of hydrogen peroxide. This reaction 
liberates oxygen which then oxidizes either phenolphthalein to produce a pink color in 
the case of the KM test or the triphenylmethane dye leucomalachite green to produce a 
blue/green color which indicates a positive LMG result. Some commercially available 
test strips employ filter paper that has been pre-treated with diisopropylbenzene 
dihydroperoxide and the indicator dye tetramethylbenzidine (i.e., Hemastix
®
). The 
peroxidase-like activity of the heme group catalyzes a change from yellow to green as a 
presumptive positive for the detection of blood. Positive results with these peroxidase 
reaction-based tests should be viewed as indicating peroxidase-like activity and by 
extension the presumed presence of blood.  False positive results have been obtained with 
non-blood hemoprotein containing substances such as potato and horseradish extract as 
well as chemical oxidizing agents such as bleach, rust, ferric sulphate and copper-salts 
(e.g., cupric sulphate which is an aquatic algaecide commonly used in aquaculture)
[39, 40]
.  
As with other body fluids, immunochromatographic tests have greatly improved the 
presumptive detection of blood. Hemoglobin has historically been targeted as the protein 
of choice for antibody-based tests with glycophorin-A being implemented more recently 
by the RSID™ Blood kit
[41]
.  Glycophorin-A is the primary membrane protein located in 
red blood cells and is involved with cell-cell binding interactions
[42]
. The specificity of 
the assay is such that it is even capable of distinguishing human from primate 
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glycophorin-A.  As with the commercially available antibody-based tests for seminal 
fluid and α-amylase, lateral flow immunochromatographic strip tests are employed; a 
positive test result is indicated by the appearance of visible lines at the “test” and 
“control” positions on the assay membrane. Although antibodies targeted specifically to 
human hemoglobin or glycophorin-A are generally sensitive and specific for human and 
often primate proteins, positive results should still be interpreted with caution. Antibody 
cross-reactivity to non-human blood is possible. For example, one antibody binding-
based assay which specifically targets human hemoglobin has also been found to yield a 
positive result with ferret blood
[43]
. In addition, the potential for binding to unrelated 
proteins with structurally similar epitopes is difficult or impossible to predict a priori and 
cannot be eliminated as a possibility. 
1.3.5 Menstrual Blood 
Menstrual blood is present between 3 to 7 days during an average 28-day female 
menstrual cycle. Menstrual blood has not typically been considered a critical fluid with 
regards to forensic serology, particularly in comparison to the identification of semen 
and/or vaginal fluid.  The reality, however, is that the ability to identify menstrual blood 
components also has the potential to provide critical evidence as part of a sexual assault 
investigation. 
Initial work on the identification of this fluid attempted to utilize the polymorphic 
isoenzyme Lactate Dehydrogenase (LDH)
[44]
. As with Hemoglobin, LDH quaternary 
structure consists of a tetramer of two subunits, M and H. Unlike Hemoglobin, LDH can 
exist as five separate isoforms; LDH-1 with 4H subunits, LDH-2 or 3H1M, LDH-3 or 
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2H2M, LDH-4 or 1H3M, and LDH-5 or 5M. Serological differentiation relies upon the 
specific localization of each isozyme. Peripheral blood contains LDH-1, LDH-2, and 
LDH-3 where menstrual blood also contains LDH-4 and LDH-5
[3]
.  Similar to other 
protein-based serological markers, LDH can be also be found in non-target tissues, 
thereby limiting its value as a specific test for menstrual blood
[45]
.   
1.3.6 Urine 
Urine contains a variety of inorganic ions including chloride, phosphate, and sulfate 
which are not specific to urine but which are found at concentrations that are significantly 
higher in urine than other body fluids
[37]
.  In addition, urine contains a variety of peptides 
and amines which can serve as presumptive indicators for the presence of urine including 
urea, uric acid, and creatinine.  A number of chemical reaction- and enzyme activity-
based tests have been developed to identify possible urine stains. Two that are in more 
common use are tests for urea and creatinine.  Both tests provide a presumptive 
indication of the presence of urine since both urea and creatinine are found at detectable 
concentrations in other bodily fluids including sweat and seminal fluid
[46]
.  
Tests for urea are based on the detection of exogenously added urease enzyme 
activity which breaks down urea to liberate ammonia and carbon dioxide. The production 
of ammonia is then detected by Nessler’s reagent (mercuric iodide in potassium iodide) 
which turns yellow or p-dimethylaminocinnamaldehyde (DMAC) which produces a 
strong red color. One of the first commercially available test strips based on this reaction 
employ paper impregnated with urease and bromothymol blue as a pH indicator to 
measure the formation of ammonia hydroxide. This same chemical system can be used to 
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locate suspected urine stains by spraying a combination of urease and bromothymol blue 




Tests for creatinine include the Jaffe and Salkowski tests. The former mixes a 
solution of picric acid in toluene or benzene with an extract of a suspected urine stain. A 
positive reaction is indicated by the formation of red creatinine picrate. The latter uses 
sodium nitroprusside so that a positive indication of creatinine is indicated by formation 
of a blue product upon heating.  Commercially available test strips based on the detection 
of creatinine employ a proprietary indicator system which produces a purplish-brown 
color in the presence of creatinine.  
Antibody-binding-based assays for urine currently provide the only specific means of 
identifying urine. A commercially available lateral flow immunochromatographic strip 
test is based on the use of antibodies that are targeted to the Tamm-Horsfall Protein 
(THP) (i.e., uromodulin) which is the most abundant protein present in urine. It is 
secreted into urine at a rate of 80-200 mg/day by the thick ascending limb of the loop of 
Henle
[48]
. As with other  immunochromatographic strip tests, a positive test result is 
indicated by the appearance of visible lines at the “test” and “control” positions on the 
assay membrane. A positive test result, however, should be considered presumptive for 
the identification of human urine. As currently formulated, the test does not display 
cross-reactivity with human saliva, semen, whole blood, vaginal fluid, or menstrual blood 
but it does show cross-reactivity with urine from non-human samples.   
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1.3.7 Fecal Matter 
Fecal material is most often identified by testing for the presence of urobilin which is 
formed as the terminal degradation product of heme in the enterohepatic urobilinogen 
cycle. Urobilin is responsible for the characteristic color of urine and fecal matter. In the 
large intestine, urobilinogen (a precursor of urobilin) is present at high levels and can be 
readily detected using the Edelman test which oxidizes the urobilinogen to urobilin by 
treatment with alcoholic mercuric chloride. This is followed by the addition of alcoholic 
zinc chloride to yield an urobilin-zinc salt compound which fluoresces a bright apple 
green under UV light. A positive result is not human specific and is only presumptive for 
fecal matter since urobilin is also present in urine, albeit at lower concentrations.   
Light microscopy can also be used for the identification of fecal matter. This 
approach requires a skilled analyst familiar with the appearance of various enteric 
microbes as well as undigested fibrous particles of food which may include both plant 
and animal products. Although many microbial species will be present in both human and 
non-human fecal matter, a careful analysis of partially decomposed food debris may 
provide an indication of whether the material is consistent with a human diet.  
 
1.4 Emerging Techniques 
While serological tests for blood, semen, saliva and urine have long existed
[19, 49-51]
, 
many of these are laborious, some pose health and safety risks, others consume 
significant amounts of a valuable evidentiary material, others fail to provide adequate 
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sensitivity or specificity. Additionally, there are some fluids (i.e. vaginal and menstrual 
fluids) which lack presumptive or confirmatory tests entirely. A number of promising 
methodologies have been in development to resolve the limitations of the current 
techniques. Emerging proteomic, transcriptomic, epigenomic and other technologies are 
being explored as a way to rapidly identify human body fluids with greater specificity 
and sensitivity than that of assays currently in use.  
1.4.1 mRNA/miRNA Biomarkers 
 Messenger ribonucleic acid (mRNA) acts an intermediary molecule for the transfer 
of genetic information stored in DNA to the cell’s functional units, i.e., proteins
[52]
. 
Significant research interest has been devoted to these molecules as a means of 
identifying bodily fluids on the basis of differential expression profiles
[53]
.  
Several research groups have been investigating the use of mRNA-based techniques 
for body fluid identification. In 2003, pioneering work identified markers for saliva by 
searching the Cancer Genome Anatomy Project for proteins expressed only in the 
salivary glands. Combining reverse transcription PCR, visualization through gel 
electrophoresis, and quantitation by RiboGreen

, several of these candidate markers, 
including histatin 3, statherin, and Proline-Rich Protein BstNI Subfamily (PRB1/2/3), 
were shown to be expressed in saliva but not blood or semen
[54]
.  
More recently, a comprehensive prototype method for identifying blood, saliva, 
seminal fluid, and menstrual fluid was successfully developed using reverse transcriptase 
PCR. This multiplex method paired mRNA genetic markers along with a housekeeping 
gene to normalize for differences in mRNA expression between different body fluids. 
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This allowed for more confident expression profiles to be developed for each bio fluid
[55]
. 
An in-depth study of RNA recovery under a variety of conditions also demonstrated that 
under optimal conditions mRNA remained stable and detectable in some casework-type 
samples even after 547 days
[56]
. 
 The use of mRNA biomarkers for body fluid identification has the advantage of 
enabling forensic practitioners to employ familiar sample preparation methods that are 
fundamental to any work involving nucleic acids. Methods for the co-extraction of DNA 
and RNA from the same stain have been developed
[57]
 so that both mRNA and STR 
profiles can be developed from the same extract thus facilitating both individualization 
and body fluid identification in a single step
[58]
.  
Micro RNAs (miRNA) are small, 21-25 base pair long, non-coding nucleotide RNA 
molecules which are involved in the regulation of gene expression
[59]
. Along with 
mRNA, these molecules have been explored as promising markers for the 
characterization of body fluids. An initial study on the forensic potential of these 
molecules, published in 2009, used a combination of database evaluation and empirical 
testing to identify miRNA candidates which showed differential expression among blood, 
semen, saliva, vaginal fluid, and menstrual fluid. The results of this work found that each 
body fluid (with the exception of semen) could be differentiated on the basis of a unique 
miRNA expression pattern. Further work to evaluate the reliability of miRNA 
biomarkers, examined twenty one different tissues (e.g., cervix, esophagus etc.) and 
found no expression patterns matching those of  the forensically relevant body fluids
[60]
. 
In a more recent study, however, in which a microarray strategy was used to identify 
29 
 
candidate miRNA markers for saliva, semen, vaginal and menstrual fluids and peripheral 
blood, miRNA biomarkers that differentiated peripheral blood and semen were identified. 
In this later study, the approach was not able to identify reliable markers for the detection 
of saliva, vaginal or menstrual fluids
[61]
.  
While this technology is in its infancy, the approach has the same key advantages as 
mRNA based-assays with respect to integration with the current forensic workflow for 
DNA. As an added advantage, the small size of miRNA molecules relative to mRNA 
makes them  potentially more robust for the analysis of aged or degraded samples
[62]
. 
1.4.2 Epigenetic Markers 
Epigenetics is the study of transmissible changes in DNA expression that are not 
related to modifications in the DNA sequence
[63]
. These changes are generally associated 
with DNA methylation-related gene silencing. DNA methylation typically targets 
cytosine residues and localizes at CpG islands in promoter regions upstream of protein 
coding genes
[64]
. What makes these sites significant is their capability for gene 
silencing
[65]
. Put simply, a gene with an unmethylated promoter region will freely 




The use of epigenetic biomarkers for body fluid identification, therefore, relies on 
detecting tissue-associated differences in DNA methylation patterns
[63, 66]
. As with RNA 
markers, this approach employs pattern analysis but has the advantage of making it 
possible to directly “query” the DNA in a sample to determine the tissue from which it 
originated. Initial studies of epigenetic markers demonstrated the potential utility of the 
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approach using semen, saliva and skin tissue
[67, 68]
. A commercially available assay uses 
methylation-specific PCR to target genetic loci which are differentially methylated 
between semen and non-semen samples. In stains containing semen, three semen specific 
methylated loci will preferentially amplify creating a strong signal which can be 
visualized on an electropherogram whereas non-semen samples will not amplify strongly 
at these loci thus generating a weaker signal
[69, 70]
. 
A more extensive study aimed at identifying methylation response ratios that 
could be used to differentiate between semen, blood, saliva and skin cells identified 38 
different loci which showed differential methylation patterns
[68]
. Of those, 15 were 
selected for inclusion in a multiplex assay which successfully differentiated target stains 
that were assayed as either pure or mixed samples. Tests with aged casework-type 
samples demonstrated that semen and blood could be clearly distinguished from each 
other in 20-month old samples. As with other nucleic acid-based assays, this 
methodology can also be readily incorporated into the standard DNA workflow.   
1.4.3 Raman Spectroscopy 
Non-destructive strategies for body fluid identification are particularly attractive 
to forensic practitioners for whom conventional methods of serological testing can be 
unacceptably consumptive of what are often minimal samples.  Raman spectroscopy is 
based on a spectroscopic technique which determines the identity of an unknown 
substance
[71]
 by measuring the inelastic scattering of light produced from the chemical 
constituents within the sample. Every unique “substance”, therefore should produce a 





. The technology is robust and sensitive such that little if any sample 
preparation is needed, and picogram quantities of a sample can be detected
[72]
.  
This technique has been applied to body fluids in order to identify unique 
“multidimensional spectroscopic signatures” for specific body fluids of interest. In an 
effort to accommodate sample heterogeneity, advanced statistical algorithms are also 
employed to search for the best match between an expected “spectroscopic signature” and 
that of a questioned sample. Encouraging results have been reported for the identification 
of single-source vaginal fluid, sweat, blood, and semen stains using this approach
[43] [73]
. 
Additional studies have suggested that Raman spectroscopy may be capable of 
differentiating menstrual fluid from peripheral blood
[48]
 as well as being capable of 
differentiating between human, canine, and feline blood samples
[64]
.  
Because of its reliance on statistical pattern fitting, however, additional studies 
will be needed to ensure that the pattern-matching algorithms can accommodate more 
challenging mixed stains as well as those containing contaminants or that are degraded,  
i.e., any forensic type sample that deviates substantially from the pristine reference 
“spectroscopic signature”.  
Because of its ability to analyze samples in situ, an added potential benefit of this 
technique would be the ability to screen evidentiary material at the crime scene, 
effectively eliminating the need in some cases to transport cumbersome items of evidence 





1.4.4 Proteomic Assays 
Among the most promising of the emerging strategies for body fluid identification 
are those made possible by advances in proteomics. The proteome is the final product of 
genome expression and comprises all the proteins present in a cell at a particular time
[74]
.  
In contrast to traditional approaches in molecular biology where a single or small subset 
of proteins are analyzed, proteomic techniques make it possible to identify and monitor 
hundreds to thousands of proteins in a single experiment
[75]
. It is now possible, for 
example, to map entire proteomes using 2-D gel electrophoresis or multidimensional 
HPLC based techniques coupled to mass spectrometry to identify potentially useful 
biomarkers. Once identified, targeted-ion mass spectrometry can be used to facilitate the 
detection and quantitation of low abundance protein biomarkers of interest
[76]
. This has 
resulted in a wealth of new opportunities to develop protein-based assays for medical and 
forensic purposes. 
The application of proteomics to the analysis of challenging samples in forensic 
serology has been the focus of research and development activities of multiple research 
groups
[77]
. By comparing the proteomes of different body fluids, researchers seek to 
discover protein biomarkers that are unique to a given body fluid and thus could serve as 
the basis for the development of confirmatory tests for the identification of such 
forensically relevant body fluids as saliva, seminal fluid, peripheral blood, vaginal and 
menstrual fluids, and urine.  
One research group with the New York Office of the Chief Medical Examiner has 
reported the successful development of a multiplex assay for blood, saliva, and semen on 
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a MALDI-TOF/TOF tandem mass spectrometer
[77, 78]
. Using protein biomarkers 
identified through database mining as well as empirical research results, several front-end 
sample preparation protocols were evaluated. These include 2-dimensional fractionation 
by combining isoelectric-focusing and reverse-phase liquid chromatography (IEF-LC-
MALDI); 1-dimensional fractionation by reverse-phase liquid chromatography (LC-
MALDI) and; direct spotting of unfractionated samples followed by MALDI-TOF/TOF 
analysis. These approaches made it possible to successfully detect several body fluid 
protein biomarkers including cystatin-SA and α-amylase 1 as markers of saliva; 
semenogelin I/II and kallikrein 4 as markers of semen; and hemoglobin subunit α and β 
as markers of blood.  
A major strength of the MALDI-TOF/TOF platform is the potential speed of analysis. 
Using the direct spotting method, a 96-well plate of samples can be processed in a matter 
of minutes. As with all mass spectrometry strategies, however, there is a relationship 
between the amount of pre-fractionation and the sensitivity of the assay. The trade-off is 
that fractionation steps are consumptive in terms of time and cost but achieve superior 
sensitivity. For example, the direct spotting approach was only able to detect 
semenogelin-1 and 2 in 0.1nl of semen, whereas the LC-MALDI approach detected 
several additional biomarkers in the seminal fluid panel. This relationship also carried 
over to the analysis of mixtures by MALDI-TOF/TOF. The more rigorous sample pre-
fractionation achieved by the IEF-LC-MALDI strategy made it possible to detect salivary 
α-amylase in a 10:1 mixture of semen to saliva while the LC-MALDI and direct spotting 
approaches were not able to detect the minor saliva component.  Overall, however, these 
34 
 
approaches made it possible to characterize single and mixed body fluid stains in the 




1.5 Proteins as Serological Candidates  
One of the significant advantages of a protein biomarker approach is the tremendous 
diversity of potential targets that are made possible due to post-translational modification 
in different tissues. As a result, a single protein may be differentially modified by one’s 
metabolism in two different body fluids, making it possible to develop highly specific 
assays in cases where epigenomic patterns or mRNA expression profiles might not differ. 
Another key advantage is the stability of many proteins under conditions that lead to the 
degradation of other molecules.  Proteins are among the most long-lasting of all 
biological molecules having been routinely isolated from even ancient biological 
material
[80, 81]
. In a more forensically applicable study, a 99.5% decrease in mRNA levels 
was observed in post-mortem brain tissue while protein levels remained relatively 
constant
[82]
.  Still, as is the case with all biological molecules, proteins do fragment and 
degrade over time.  Assays based on the use of protein biomarkers, however, can be 
readily adapted to detect fragmented proteins. Thus, even partially degraded target 









Proteomics is a large scale study of expressed proteins. Because of recent 
advancements in instrumentation and techniques, the field of proteomics has expanded 
such that research scientists have the ability to rapidly and reliably profile entire 
proteomes of nearly any tissue or fluid. The primary objective of most proteomic-based 
research projects has been to develop novel diagnostic tests for the clinical setting. These 
assays are based on the use of proteins as diagnostic or prognostic markers of disease 
states such that they serve as tools for the personalization of medical treatments
[84]
. While 
the identification of disease biomarkers is not the goal of a proteomics project focused on 
forensic serology, the same principals, methodologies, and instrumentation can be 
utilized in order to identify proteins that can act as biomarkers for the identification of a 
specific biological fluid. These methodologies follow a well established proteomics 
pipeline that begins with a discovery phase to experimentally derive a panel of candidate 
biomarkers followed by a validation phase to confirm their specificity across a larger 
sample population. 
1.6.1 Proteomics Front End Technologies 
One of the primary challenges of proteomics discovery research is the enormous 
number of different proteins that are present within most biological fluids.  Human 
plasma, for example, is estimated to contain several thousand different proteins. 
Additionally, the difference in concentration between the most and least abundant 
proteins can vary across ten orders of magnitude
[85]
. As a consequence, high-abundance 
proteins (e.g., serum albumin or immunoglobulins in blood) which are not highly specific 
for a single body fluid can easily mask the detection of less abundant proteins that are 
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more “diagnostically relevant” for forensic applications. To circumvent this, proteomes 
are fractionated to reduce complexity of analysis.  
As stated above, the primary goal of proteomics discovery research is to identify 
protein biomarkers. In a medical diagnostics setting, biomarkers should be differentially 
expressed between two samples – typically one from a patient with a disease state of 
interest and the other from a healthy individual. Adapted to forensic serology, useful 
biomarkers should be uniquely expressed in a target body fluid. Regardless of whether a 
protein is being used for a clinical or forensic application both rely on the combination of 
qualitative and quantitative assessments of a proteome. In this vein, researchers have 
employed gel-based methods, metabolic and chemical labeling methods, label free 
methodologies, as well as targeted quantitative methods in order to identify promising 
biomarkers.  
1.6.1.1 Gel-Based Methods 
Traditionally, proteome analysis has relied on two-dimensional polyacrylamide 
gel electrophoresis coupled with mass spectrometry. These methods have been successful 
in separating highly complex mixtures where protein spots in gels are compared, picked, 
and subsequently identified by mass spectrometry. However, these techniques have been 
shown to be highly variable from gel to gel making it difficult to distinguish between 
actual protein variability versus gel-to-gel experimental variation
[86]
. More recent 
improvements to this traditional approach have utilized two-dimensional difference gel 
electrophoresis (2D-DIGE). In this technique, two or more samples are differentially 
labeled with fluorescent tags, pooled, and run on a single gel. The proteins in each sample 
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are then differentially detectable by their fluorescent tags.  Protein spots that are 
differentially expressed between samples are subsequently characterized through mass 
spectrometry
[87]
.  While these techniques have improved the ability to detect differentially 
expressed proteins, there still are limitations that impede the accurate analysis of proteins 
with very high or low pI values, proteins with large transmembrane domains as well as 
limitations to proteins with extremely large or small molecular masses
[88, 89]
. 
1.6.1.2 Labeling-Based Methods 
Metabolic and chemical labeling strategies offer a different approach than in-gel 
methods. Stable Isotope Labeling with Amino acids in Cell culture (SILAC) is one 
option. In this method, cells are grown in cultures with differentially-labeled amino acids. 
One culture media will contain normal amino acids and the other will have heavy isotope 
labels, e.g. C-13 vs. C-12 or N-15 vs. N-14. The amino acids in culture will be 
incorporated into the protein. When run on the mass spectrometer, peptides will behave 
identically but will have a measurable mass shift associated with their unique isotopic 
makeup, allowing quantitation and detection of differential expression between two 
states
[90]
. This strategy has been successfully used in many cell culture based systems. 
For example. Nirmalan et al. successfully measured proteomic changes in the parasite 
Plasmodium falciparum with regard to its protein expression during development as well 
as responses to anti-malaria drugs
[91]
. However, a drawback in this approach is the 
requirement for the incorporation of labeled amino acids in cell culture.  This leaves 
many human/clinical samples (e.g., serum and tissues) incompatible with the assay.  
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Chemical labeling strategies exist as well. Two well known methods of chemical 
labeling are Isotope-Coded Affinity Tag or the ICAT system and Isotope Tagging for 
Relative and Absolute Quantitation or the ITRAQ system. Both methods use a chemical 
label that is incorporated into the protein. In the ICAT system a heavy or light label plus 
an affinity tag is incorporated into cysteine SH groups. The biotin affinity tag is used to 
isolate the ICAT peptides through affinity chromatography so that quantitative 
differences can be measured
[92]
.  ITRAQ uses a different system with the tag attaching to 
the N-terminal of digested peptides. The tagging molecule consists of three groups, a 
reporter group, an isobaric tag, and a reactive group that will link to the peptides. 
Differentially labeled peptides behave identically but have different reporter ions that 
liberated during collision-induced dissociation. Quantitative information is achieved by 
examining reporter ion abundances 
[93]
. Numerous challenges, however, are present in 
these workflows. ICAT, for instance, relies on cysteines to be present. Without the 
presence of the appropriate amino acid, the affinity isolation process fails resulting in 
missed tryptic peptides, which may be diagnostically useful for quantification. Another 
issue relevant to both methods is the addition of labels downstream in the methodology. 
This can be compromised by potential errors in the efficiency of any process before the 
addition of tags such as fractionation, depletion, or digestion
[94]
. In addition, these 
methods are typically expensive, rely on proprietary software, and aside from ITRAQ, 







1.6.1.3 Label-Free Methods 
Two major label-free methodologies exist. Both methods follow the same process 
for sample preparation, digestion, chromatographic fractionation, and analysis on a 
tandem mass spectrometer. Data are quantified either through spectral peak intensities or 
spectral counting after identification by database search tools
[95]
. Using spectral peak 
intensities, extracted ion chromatograms for each peptide are integrated and peak areas 
are used for quantitative comparisons. The spectral counting method compares the 
number of spectra identified for each peptide in an analytical run. Label-free methods 
have the advantage of eliminating laborious and potentially expensive labeling steps; the 
capability of running any sample type, without limitation on how many samples can be 
compared. Conversely, these techniques rely heavily on reproducible chromatography 




1.6.1.4 Targeted Proteomics 
   The final methodology, targeted proteomics, utilizes a triple quadrupole (QQQ) 
mass spectrometer operating in Multiple Reaction Monitoring (MRM) mode
[97]
. This 
method employs tandem quadrupole mass analyzers in order to isolate specific precursor 
and product ions. Quantitation is achieved through incorporation of synthetic peptides 
labeled with stable isotopes.  Both the synthetic peptides and the native digested peptide 
will behave identically in the instrumentation. Calculating the ratio between standard and 
native peptide allows quantitation of the peptides
[98]
 . This method has become popular 
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1.6.1.5 High-performance Liquid Chromatography 
Dependable and sensitive proteomics experiments are directly linked to separation 
technologies used to simplify samples before analysis
[100]
 . One additional technique that 
has gained popularity is multidimensional high-performance liquid chromatography (2D-
HPLC). This method has left gel-based methods behind in favor of precise HPLC-based 
separations. One specific instrument, the ProteoSep™ 2D-HPLC system (Eprogen, 
Downers Grove, IL; formerly the Beckman Coulter ProteomeLab™ PF2D), employs 
chromatofocusing and reverse-phase chromatography to fractionate the proteome.  
 
Figure 6 - Eprogen ProteoSep™ multidimensional high-performance liquid chromatography system. System uses 
two dimensions of separation (chromatofocusing and reverse-phase chromatography) to separate entire 
proteomes from a single injection.   
Using the ProteoSep™ system as seen in Figure 6, a chromatofocusing column 
first separates proteins based off their isoelectric point. More specifically, proteins, which 
are carrying a negative net charge, are loaded into a column at pH of 10 followed a 
gradient to pH 4. As the pH decreases, proteins will begin to elute off the column into a 
series of first dimension fractions on a 96-well fraction collector. Specifically, proteins 
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elute at their isoelectric point (i.e., the pH at which the protein net charge is zero).  
Reverse-phase chromatography is then performed on each of the pH fractions from the 
first dimension. In this step, a stationary phase with octadecyl carbon chains, or C18, and 
mobile-phase gradient (organic solvent) elute proteins based on their hydrophobicity. 
Proteins are initially bound to the hydrophobic stationary phase until a sufficient 
concentration of organic solvent disrupts the interaction between the protein and the 
stationary C18 particles
[101]
. As proteins elute from the reverse-phase column they are 
collected in a series of fractions across eight 96-well plates. During the reverse-phase 
runs, a 214 nm UV detector monitors the eluent for the presence of proteins as they are 
released from the column. Reverse-phase runs are then digitally combined to generate a 
conceptual proteome map (Figure 7) in which all the proteins successfully fractionated 
by the system are represented by pH (x-axis) / hydrophobicity (y-axis) / quantity (z-axis) 
coordinates. The multidimensional maps can then be compared using suitable software 
programs to identify differential protein expression across multiple samples. Based on the 
user’s scientific question, individual reverse-phase fractions can be recovered and tandem 





Figure 7 - Example of the ProteoSep™ pH/hydrophobicity/quantity map (i.e., proteome map) obtained using a body 
fluid sample. Proteins, which are represented as colored bands across the image, are separated based on pH on the 
x-axis followed by hydrophobicity on the y-axis. Relative protein quantity is indicated by the color (red=high; 
blue=low). 
 
1.6.2 Liquid Chromatography Tandem Mass Spectrometry for Proteomics 
The most powerful tools in proteomics research are the mass spectrometry 
systems which allow scientists to identify, characterize, and quantitate proteins in 
complex biological matrices. These systems incorporate high-performance liquid 
chromatography to fractionate samples, an ion source to generate charged gas-phase 
molecules, and a mass spectrometer to analyze the resulting ions. Once the data have 
been acquired, software tools are employed to identify individual proteins by comparing 





1.6.2.1 Reverse-Phase High-Performance Liquid Chromatography 
Chromatography is a general term for a variety of techniques which are used to 
separate mixtures. All chromatographic techniques utilize a mobile phase as well as a 
stationary phase. A mixture is dissolved in the mobile phase and is then passed through a 
stationary phase. Every compound in a mixture will have a higher or lower affinity for 
the mobile and stationary phases, thus allowing complex mixtures to be separated.  
The most popular chromatographic technique for protein analysis is reverse-phase 
high-performance liquid chromatography (HPLC). This technique uses a pumping system 
to deliver a gradient over a stationary phase. The mobile phase consists of a blended 
aqueous and organic buffer where the stationary phase consists of porous silica particles 
coated with carbon chains. 
During separation, a protein mixture is loaded onto the stationary phase under 
high aqueous (i.e., polar) conditions causing hydrophobic moieties on the 
protein/peptides to bind the non-polar solid-phase particles. A linear gradient with an 
increasing percentage of organic solvent is applied to the stationary phase causing the 
mobile phase to become increasingly non-polar – conditions under which hydrophilic 
proteins adsorb to the stationary phase poorly whereas hydrophobic proteins adhere 
strongly. As a result, hydrophilic proteins elute quickly where a higher percentage of 
organic solvent will be required to elute hydrophobic proteins from the column (Figure 





Figure 8 – Acetonitrile (buffer B) gradient used to elute peptides (orange and red peaks) using reverse-phase HPLC.  
1.6.2.2 Electrospray ionization 
Many modes of ionization exist for generating charged particles for analysis via 
mass spectrometry. Currently, peptide and protein analysis is restricted to ‘soft’ 
ionization techniques via Electrospray Ionization (ESI) or Matrix-Associated Laser 
Desorption Ionization (MALDI). The restriction to ESI and MALDI is due to the need to 
avoid fragmentation in the source from “harsh” ionization methods such as chemical or 
electron ionization. 
When coupling an HPLC system to a mass spectrometer, an electrospray 
ionization source is commonly used as it allows molecules to become ionized directly 




Figure 9 - Electrospray ionization source. Peptides eluting into the source are charged, dried, and travel into the 
mass spectrometer inlet. 
In this process, the volatile organic solvent and acidic eluent (i.e., acetonitrile with 
an acid modifier such as formic acid) from the HPLC is forced through a capillary under 
a high voltage potential (i.e., ≥2000 Volts) between the spray needle and entrance to the 
mass spectrometer. This process generates positively charged droplets containing solvent, 
acid and analyte which will travel together towards the negatively charged MS inlet. 
Heated nitrogen drying gas (approximately 300°C) aids in evaporation of the solvent. As 
the solvent evaporates, the repulsive forces increase due to the excess charge contained in 
the droplets
[102]
.  The repulsive force eventually becomes strong enough that a Coulomb 
fission occurs splitting the initial droplet into a number of smaller droplets. Repeated 
evaporation and fission events lead to protonated gas-phase molecules which enter the 
mass spectrometer
[103]
.    
Proteome analysis by LC-MS/MS represents one of the most difficult analytical 
challenges when trying to identify biomarkers in complex biological matrices. Sample 
quantities are typically limited and individual proteins in a matrix are generally low in 
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abundance. To circumvent these problems, nanoscale liquid chromatography is typically 
employed to increase the sensitivity of the LC-MS platform. 
As the method implies, nanoscale liquid chromatography is simply a scaled-down 
version of the standard electrospray technique where column inner diameters and flow 
rates are significantly reduced. As a comparison, a standard HPLC column with a 4.6 mm 
inner diameter and a 150 mm length would have a column volume of approximately 2.5 
mL. By contrast, a nanoscale column with a .075 mm inner diameter and a 150 mm 
length would have a column volume of only 700 nL.  This ultimately leads to a much 
more concentrated sample on the column. In addition to the concentration advantage in 
nanoflow systems, low flow (400 nL/min vs. 400 µL/min) nanoscale electrospray 
generates smaller charged droplets compared to standard HPLC   
1.6.2.3 Mass Spectrometry 
Modern mass spectrometers consist one or more mass analyzers as well as a 
detector to record ion abundance
[104]
. More specifically, mass spectrometers measure 
compounds using mass-to-charge (m/z) ratios - the molecular mass divided by compound 
charge. For example, a peptide sequence Serine-Glycine-Alanine-Valine-Methionine-
Lysine (Figure 10) under acidic LC conditions will protonate and enter the mass 
spectrometer with a +2 charge, one charge at each basic functional group. The m/z ratio 
for this compound would be computed by determining the mass of the compound 591 Da, 
adding two protons, and dividing by a charge state of 2 to give the following formula 





Figure 10 – Peptide with the sequence Serine-Glycine-Alanine-Valine-Methionine-Lysine. The m/z ratio for this 
doubly charged compound would be 296.5 m/z. 
Various mass spectrometers are capable of performing proteomics experiments. 
Instruments are differentiated from each other by the mass analyzer(s) integrated into the 
system. Some of the most common mass analyzers are the quadrupole, ion trap, and time-
of-flight tube
[104, 105]
. Modern proteomics instruments are capable of multiple steps of 
mass measurements. This process, also called tandem mass spectrometry, can generate a 
mass spectrum of both the intact ionized peptide (MS) as well as its fragmentation spectra 
(MS/MS). Some instruments such as an ion trap can perform MS and MS/MS using the 
same mass analyzer whereas other instruments require multiple analyzers working in 
tandem to achieve the same result.  
Ion Trap Mass Spectrometers (Figure 11) utilize alternating electric fields to trap and 
eject ions. Using this system, peptides are trapped and subsequently ejected from an 
oscillating electric field produced by static direct and alternating radio frequency (RF) 
currents
[106]
. More specifically, a multi-stage tandem-in-time process is carried out where 
ions are first stored or “trapped” in orbitals specific to their m/z ratios. The RF amplitude 
is then increased which ejects peptides from the trap to a detector. Acquisition software 
examines the MS spectra and selects specific precursor ions for fragmentation. Ions not 
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selected for fragmentation are ejected from a new batch of ions in the trap. An increased 
RF signal is then applied at a specific resonance frequency to induce fragmentation of the 
isolated compound. Product ions are then ejected in the same manner as the initial MS 
scan, with the spectra representing product ions generated during fragmentation
[102]
.  





allows for a compound to be fragmented and the resulting 
fragments further isolated in the ion trap. This feature allows ion traps to provide greater 





Figure 11 Top – Schematic of an ion trap mass spectrometer. Red line indicates path of ions which are trapped in an 
electric field in the ion trap prior to ejection and detection. Bottom – MS/MS spectra generation through ion 
isolation, fragmentation, and ejection from the ion trap. In this example, the target ion (blue) is isolated in the ion 





Quadrupole Time-of-Flight (QTOF) is a hybrid mass spectrometer which combines 
quadrupole and time of flight mass analyzers (Figure 12). Like the ion trap, these 
instruments are capable of acquiring tandem MS data but with the added functionality 
from the quadrupole mass filter and accurate mass TOF analyzer. In standard data-
dependent acquisition mode, the instrument generates a survey scan of all eluting 
peptides (MS scan). Acquisition software then selects specific precursor ions from the 
MS scan and the quadrupole filters for only that specific m/z.  The selected precursor ion 
is then fragmented in the collision cell and the product ions are accelerated and resolved 
in the TOF for detection. The precursor isolation, fragmentation, separation, and 
detection process produces the MS/MS fragmentation spectra for each peptide. 
The advantages to the Q-TOF are twofold. First, the quadruple mass analyzer 
allows the system to isolate ions with specific m/z ratios allowing targeted acquisition. 
Additionally, the system can achieve high mass accuracy (typically <5 ppm) coupled 
with high resolving power.  Together, these factors give the QTOF the advantage of 
being able to isolate and more accurately measure and resolve peptides when compared 









Figure 12 - Bottom – Schematic of a Quadrupole Time-of-Flight mass spectrometer. Red line indicates ion path 
which enters the instrument in the inlet, is isolated in the quadrupole mass filter (Q1), fragmented (q2), and 
resolved on the TOF before detection. Bottom – MS/MS spectra generation through ion isolation in quadrupole 
one (Q1), fragmentation in the collision cell (q2), followed by separation by the TOF mass analyzer.  In this 
example, the target ion (blue) is isolated in the quadrupole, undergoes fragmentation in the collision cell, and the 
subsequent fragments (green, purple, red) are resolved in the TOF analyzer before detection to generate a spectra. 
Triple quadrupole mass spectrometers (QQQ) have been described as the gold standard 
of modern quantitative analysis
[110]
. This class of instrument (Figure 13) is made up of 
two quadrupole mass filters as well as a collision cell between them. The gold standard 
classification is due to the sensitivity, selectivity, and ease of operation of these 
51 
 
instruments due to the ability to perform Selective Ion Monitoring (SRM) and Multiple 
Reaction Monitoring (MRM) experiments. In MRM mode, two separate selection steps 
are performed. First, quadrupole one (Q1) isolates a select precursor ion, precursor ions 
are selected and fragmented in the collision cell q2, and then specific product ions are 
selected in quadrupole three (Q3) and subsequently detected. While this instrument has 
much lower mass accuracy/resolution compared to the QTOF, the QQQ mass 
spectrometers in MRM mode achieve a greatly enhanced signal-to-noise ratio which 
ensures that target ions are detected with improved sensitivity and confidence even with 















Figure 13 - Schematic of a triple quadrupole mass spectrometer. Red indicates the ion path starting from the inlet, 
isolation in quadrupole 1 (Q1), fragmentation in the collision cell (q2), and fragment isolation in (Q3) prior to 
detection.  Bottom – MS/MS spectra generation through MRM mode with peptide isolation in quadrupole 1 (Q1), 
fragmentation in the collision cell (q2), product ion isolation in quadrupole 2 (Q3).  In this example the instrument 
the target ion (blue) is isolated in the first quadrupole, undergoes fragmentation in the collision cell, then a specific 
fragment is isolated in quadrupole 3 (purple) before detection and spectra generation. 
 
1.7 Research Objectives  
In the current research study, proteome mapping and sensitive protein detection 
technologies have been applied to six forensically significant body fluids (i.e., semen, 
saliva, urine, peripheral blood, vaginal and menstrual fluids) with the overarching goal of 
developing a multiplex body fluid assay on a mass spectrometry platform. To do this, a 
standard proteomic workflow was employed encompassing a biomarker discovery and 
verification phase followed by the development of a prototype assay for implementation 
in the environment of a standard caseworking laboratory.  
53 
 
The discovery phase of the research was designed to generate a panel of candidate 
protein biomarkers which were unique to the six target body fluids. Front-end 
fractionation was performed with the ProteoSep system in order to generate 2D-HPLC 
proteome maps. These were then analyzed using a novel, in house software package 
designed to flag potentially unique biomarkers. Unique, but unknown, proteins 
represented by specific pH/hydrophobicity/quantity coordinates were then identified by 
tandem mass spectrometry. This generated a database of candidate high-specificity 
protein biomarkers. 
The biomarker verification phase was designed to evaluate the reliability and 
specificity of the candidate biomarkers. A multiplex, targeted, Q-TOF assay was 
designed to analyze samples of each body fluid collected from fifty unrelated individuals 
for each fluid. The results were evaluated for consistency of biomarker expression as well 
as specificity for the intended target body fluid. A small series of casework-type samples 
were also tested to evaluate the performance of the assay with casework-type samples.     
The prototype validation phase examined the viability of a mass spectrometry-
based serological assay for use in a higher-throughput caseworking laboratory. The most 
promising targets from the verification phase were then used to develop a rapid multiple 
reaction monitoring assay on a triple quadrupole mass spectrometer. Additionally, a 







The general hypothesis being tested by this dissertation research is that a mass 
spectrometry based proteomics assay will provide an accurate and robust method for the 
simultaneous identification of semen, saliva, urine, peripheral blood, vaginal and 
menstrual fluids for use with evidentiary samples in a criminalistics lab. Furthermore, it 
is predicted that the assay will improve upon current methodologies by providing true 
confirmatory results for all the target fluids in a single multiplex assay. The specific core 
hypotheses of this dissertation research are therefore: 
(1) Proteomic fractionation in combination with tandem mass spectrometry is capable 
of generating a database of body-fluid specific proteins for the identification of 
biological stains. 
(2) A mass spectrometry-based assay can successfully designed to simultaneously 
screen samples from a larger sample population for six forensically relevant body 
fluids. 
(3) Mass spectrometry is sufficiently robust for processing casework samples in a 
production lab environment. 
(4)  Mass spectrometry is compatible with existing DNA workflows as well as with 
the demands of a testing laboratory. 
 
1.9 Dissertation Structure 
Each chapter of the current dissertation contains a brief introduction, description 
of the experimental methods employed, an overview of the results obtained, as well as a 
discussion of the research findings. Chapter 2 focuses on the discovery of the panels of 
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candidate high-specificity biomarkers for each body fluid which were identified using 
three protein identification approaches. The focus of chapter 3 is on the development and 
testing of a multiplex assay on a Q-TOF which was designed to screen for six biological 
fluids simultaneously. Chapter 4 assesses the feasibility implementing a mass 
spectrometry-based body fluid assay in a casework lab environment. Chapter 4 will also 
include the results of experiments which examine the compatibility of the sample 


































The objective of this phase of the dissertation research was to develop a database 
of candidate biomarkers specific to individual biological fluids which includes saliva, 
semen, urine, peripheral blood, vaginal menstrual fluids. In order to ensure that at least 
two to three high-specificity biomarkers were successfully validated for each body fluid, 
a minimum of five to ten candidate biomarkers were to be identified for each fluid of 
interest. This was based on the expectation that some of the identified as promising 
candidate biomarkers would eventually be found to be expressed at unacceptably high 
levels in non-target tissues or would not be reliably detectible in the general population.    
Traditionally, proteomics-based discovery research begins with whole proteome 
fractionation by 2D gel electrophoresis and manual excision/purification of proteins of 
potential interest for subsequent identification by mass spectrometry
[112]
. While these 
methods have a long history of successful use, they are not without limitations. For 
example, it is difficult to resolve proteins that are lipophilic, very large (>150 kDa), very 
small (<5 kDa) or less abundant. Also, poor reproducibility between gels often 
necessitates that numerous gels be run to obtain data sets that can be reliably compared 
with each other to identify proteins of interest
[113]
.  
More recently, multidimensional liquid chromatography platforms have been 
introduced to overcome some of the more significant limitations of traditional gel-based 
approaches
[114]
. The use of liquid-phase separation avoids many of the solubility 
problems associated with gels. Second, as a result of improved solubility liquid-phase 
separation ensures that a more complete proteomic profile of each body fluid can be 
generated because a greater range of proteins are fractionated and recovered. Third, less 
58 
 
abundant proteins in complex mixtures are more readily screened as potential markers of 
specific body fluids because there was a higher efficiency of recovery (>95%) of eluted 
proteins in liquid fractions and more total protein (up to 5 mg) can be injected initially 
onto the HPLC column without the band distortion that occurs with 2DGE. 
While the limitations of 2DGE have been well documented, it is also likely that 
yet to be characterized limitations exist in the liquid chromatography based fractionation 
technique as well. To account for this possibility and to ensure a comprehensive view of 
the proteomes of each of the six target fluids, multiple separation approaches were 
employed to characterize each proteome. These included 1D fractionation, 2D 
fractionation, as well as a “whole” proteome analyses. Thus, a series of experiments were 
performed in order to populate a database of candidate body fluid-specific protein 
biomarkers. ProteoSep 2D-HPLC fractionation and tandem mass spectrometry served 
as the core technologies to fulfill these goals. First, a combination of chromatofocusing 
and reverse-phase fractionation (i.e., 2D liquid-phase separation) was used to generate 
global proteome maps followed by cluster analysis and mass spectrometry analysis. Next, 
pH fractionation alone (i.e., 1D liquid-phase separation) was performed followed by mass 
spectrometry analysis. Finally, a whole proteome approach using unfractionated samples 




Figure 14 - Three analytical strategies were employed for biomarker identification. These included non fractionated 
analysis of whole body fluids, analysis of 1D chromatofocusing fractions as well as cluster analysis of 2D 
chromatofocusing/reverse phase fractions. 
 
2.1 Materials and Methods 
All research conducted under this project was reviewed, approved by the 
University of Denver Institutional Review Board (IRB) for research involving human 
subjects and conducted in full compliance with U.S. federal policy for the protection of 
human subjects.  In total, 10 subjects (five males and five females) were recruited from 
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the undergraduate population at the University of Denver. Female donors were 
compensated $80 and males $20 for their participation in the research study. All research 
volunteers agreed and signed a letter of informed consent acknowledging they have 
received, read, and understood the protocols involved in the collection of samples. 
Additionally, all donated samples were given a random alphanumeric label to ensure 
confidentiality. Finally, males were instructed to refrain from ejaculation for 24 hours 
prior to sample collection and all donors were instructed to refrain from sexual 
intercourse for 5 days prior to the collection of urine, and vaginal fluids and menstrual 
blood for females.  
2.1.1 Sample Collection and Preparation 
An overview of the workflow performed from sample collection through 
biomarker identification is provided in Figure 15. Saliva, seminal fluid, urine, vaginal 
fluid, and menstrual blood were self collected where peripheral blood samples were 
collected at the University of Denver health clinic. After collection, saliva, seminal fluid, 
urine, vaginal fluid samples were desalted, concentrated, quaantified for total protein and 
stored at -80°C prior to 2D, 1D, or unfractionated analysis. All blood based samples 
underwent additional preparation steps via high abundant protein immunodepletion. 







Figure 15 - Overview of Biomarker discovery phase from sample collection to protein identification. Briefly, 
samples were collected, cellular debris was removed, followed by concentration and buffer exchange. Blood 
samples were processed through an immunodepletion column to remove high abundant proteins. Samples were 
then quantified for total protein, fractionated on the Pf2D system prior to mass spec analysis. 
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2.1.1.1 Saliva  
Saliva samples were self-collected in the laboratory setting using Salivette™ 
saliva collection sponges (Sarstedt, Newton NC). Each donor was directed to thoroughly 
rinse their mouth with sterile water to remove residual food particles. After five minutes 
to allow secretion of saliva, the donor was instructed to place a Salivette™ saliva 
collection sponge into their mouth and to gently chew and roll the sponge around in their 
mouth for approximately three and a half minutes. The sponge was then placed into a 
sterile plastic conical tube. This process was then repeated five additional times to ensure 
that sufficient quantities of saliva were collected for proteome mapping.  
Salivette™ sponges were centrifuged at 1500 x g for 2 minutes at 4°C to recover 
saliva. Individual Salivette™ sponge fractions were then pooled for each donor for a total 
volume between 5 and 10 mL. Pooled samples were centrifuged again at 10,000 x g for 
20 minutes at 4°C to pellet cells and insoluble material. The supernatant was filtered 
through a 0.45 µm filter to remove remaining debris prior to concentration. Each sample 
was then concentrated at 4000 x g for 30 minutes at 4°C using an Amicon Ultra-15 
(EMD Millipore, Billerica, MA) with a 5K nominal molecular weight cut off (NMWCO) 
centrifugal filter unit to concentrate the sample to a final volume of 2.5 mL. 
2.1.1.2 Seminal Fluid 
Semen samples were self-collected by male donors in the privacy of their home. 
Donors were directed to refrain from sexual activity for a minimum of 24 hours and then 
to collect a 3-6 mL sample of seminal fluid by masturbation. The subject was instructed 
to directly deposit the fluid into a sterile plastic collection cup provided by the laboratory 
and then to refrigerate the sample until it could be transported to the lab within one hour. 
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The freshly collected semen was then incubated at room temperature for 30 
minutes to allow it to liquefy. Liquefied samples were then transferred to a 15 mL conical 
vial and diluted with a 1/3 volume of phosphate buffered saline. The sample was then 
centrifuged at 10,000 x g for 20 minutes at 4°C to pellet spermatozoa. The protein-rich 
supernatant was then passed through 0.45 µm filter to ensure cellular removal. 
2.1.1.3 Urine 
Urine samples were self-collected by donors in the privacy of their home. Donors 
were instructed to deposit a morning urine sample (>50mL) into a sterile collection cup 
provided by the laboratory. Protein concentration varied substantially between 
individuals thus >20 mL was typically used to ensure that a sufficient quantity of protein 
was recovered for accurate proteome mapping.  
Freshly collected urine was centrifuged at 10,000 x g for 20 minutes at 4°C and 
passed through a .45 µm filter to ensure cellular removal. Two 15 mL volumes of urine 
were then concentrated at 4000 x g for 30 minutes at 4°C using an Amicon Ultra-15 with 
a 5K NMWCO centrifugal filter units to a final total sample volume of 2.5 mL. 
2.1.1.4 Vaginal Fluid 
Vaginal fluid samples were self-collected by female donors in the privacy of their 
home. Donors were instructed to insert a commercially available 100% cotton tampon 
and were encouraged to use lubricant to minimize the risk of tissue abrasion and/or 
microbial infections. The tampon was left in place for the period of approximately 10 
minutes, gently removed and placed in a 15mL conical tube. Donors were directed to 
refrigerate the sample until it could be transported to the lab within one hour. 
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Tampons were saturated with PBS and allowed to sit at room temperature for 30 
minutes with occasional vortexing to elute proteins. The tampon was then placed in a 50 
cc syringe to force out the fluids and eluted proteins. The liquid was transferred to 50 mL 
conical vials and centrifuge at 10,000 x g for 20 minutes at 4°C. The resulting 
supernatant was passed through a 0.45 µm filter to ensure cellular removal prior to 
concentration. The sample was then concentrated using an Amicon Ultra-15 with a 5K 
NMWCO centrifugal filter units at 4000 x g for 30 minutes at 4°C to a final total sample 
volume of 2.5 mL. 
2.1.1.5 Peripheral Blood 
Donors were escorted to the Student Health Center where a 15mL sample of 
whole blood was obtained by a certified nurse using venipuncture. The blood was drawn 
into a sterile vacuum tube containing an anticoagulant (EDTA) and gel barrier to 
facilitate separation of the blood serum from cellular material.  
EDTA gel barrier tubes were spun at 1500 x g for 10 minutes to separate the 
blood serum. The isolated serum was then passed through a 0.45 um filter unit to ensure 
cellular removal from the sample. 
2.1.1.6 Menstrual Fluid 
Menstrual fluid was self-collected by female donors the privacy of their home. 
The collection protocol employed an FDA-approved over-the-counter latex-free, 
DivaCup™ (Diva International, Kitchener, Ontario) hypoallergenic cup for the collection 
of menstrual flow. The cup was then gently removed and the contents were poured into a 
sterile 50mL conical tube and refrigerated until delivered to lab within one hour. 
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Fresh menstrual fluid was transferred to a 15 mL conical vial and diluted with 1/3 
total volume of phosphate buffered saline. The sample was homogenized by vortexing 
and added to an EDTA gel barrier blood collection tube which was then allowed to 
incubate for 15 minutes at room temperature. Tubes were then spun at 1500 x g for 10 
minutes at 4°C to separate the fluid/serum component. Menstrual fluid/serum was then 
passed through a 0.45 µm filter unit to ensure cellular removal from the sample. 
2.1.1.7 Hemoglobin Removal from Menstrual Blood 
HemogloBind™ (Biotech Support Group, Monmouth Junction, NJ) was used to 
remove hemoglobin from lysed erythrocytes commonly encountered in menstrual fluid 
samples. Effective hemoglobin removal was achieved by the addition of 500 µL of 
HemogloBind™ to 250 µL of menstrual fluid/serum. The solution was vortexed and then 
gently mixed for 15 minutes. The sample was then centrifuged at 9000 x g for 2 minutes 
at room temperature. The supernatant containing hemoglobin-free menstrual serum was 
recovered.    
2.1.1.8 Protein Partitioning System (PPS): Immunodepletion 
Both menstrual fluid and peripheral blood were depleted of twelve non-specific 
high-abundance serum proteins which had the potential to mask the detection of lower-
abundance proteins with greater body fluid specificity. These included albumin, IgG, 
IgA, IgM, fibrinogen, transferrin, HDL, haptoglobin, α1-antitrypsin, α1-acid glycoprotein 
and α2-macroglobin. For protein partitioning, 250 µL of sample was diluted with 375 µL 
of dilution buffer (10 mM Tris-HCL, 150 mM NaCl, pH 7.4). The partitioning column 
was first equilibrated for 30 minutes at a flow rate of 2 mL/min with dilution buffer. 
Proteins were loaded onto the column in a dilution buffer at a flow rate of 2 mL/min. 
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Unbound proteins in the flow through were collected in 50 mL conical tubes using a FC/I 
Module (Beckman-Coulter, Brea, CA). Bound high abundance proteins were then eluted 
with stripping buffer (100 mM glycine, pH 2.5) at a flow rate of 2 mL/min. Lastly, the 
column was equilibrated with dilution buffer at a flow rate of 2 mL/min This process was 
repeated with 7 total runs for each sample. Flow through from each individual sample 
was pooled and concentrated with an Amicon Ultra-15 with a 5K NMWCO centrifugal 
filter units at 4000 x g for 30 minutes at 4°C to concentrate samples to 1 mL total 
volume. ProteoSep™ (proprietary) start buffer was added for a total volume of 4 mL and 
concentrated again to exchange buffer contents. ProteoSep™ start buffer was added again 
to a final volume of 2 mL. 
2.1.1.9 Buffer exchange 
Non-blood containing samples which had not been treated by the PPS 
immunodepletion column required a buffer exchange prior to injection into the 
ProteoSep™ system to equilibrate samples to the chromatofocusing starting pH. This was 
achieved through use PD-10 Desalting Columns (GE Healthcare, Buckinghamshire, UK) 
which were equilibrated with 25 mL of ProteoSep™ start buffer. A 2.5 mL protein 
sample was added to the PD-10 column and the flow through was discarded. The 
column-bound proteins were then eluted by the addition of 3.5 mL of ProteoSep™ start 
buffer to the column in a clean conical tube. 
2.1.1.10 Protein Quantitation by Micro BCA™ kit 
The total protein content of the cell-free extract of each body fluid sample was 
quantitated by visible light spectrophotometry using the Micro BCA™ kit (Pierce 
Biotechnology, Rockford, IL) based on comparison to a standard curve generated for 
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Bovine Serum Albumin (BSA). A total of eight serial dilutions of BSA were prepared 
with concentrations ranging from 0.5 µg/mL to 200 µg/mL. The working stock reagent 
for the assay was prepared by combining 25 parts of proprietary “BCA Reagent A”, 25 
parts of proprietary “BCA Reagent B” and 1 part of proprietary “BCA Reagent C”. In a 
1.5 mL microcentrifuge tube 150 µl of working stock reagent was added to 150 µL of 
sample or standard. Tubes were vortexed, spun briefly, and allowed to incubate in a 
Thermomixer
®
 (Eppendorf, Hauppauge, NY) at 37ºC for 2 hours. Samples were then 
allowed to cool to room temperature for 10 minutes and read on a visible 
spectrophotometer at 562 nm. The BSA standard curve was used to generate a linear 
equation from which the protein concentrations of the unknown samples were 
determined.  
2.1.2 ProteoSep™ 2D-HPLC Fractionation 
Fractionation using the ProteoSep™ 2D-HPLC system involved a two-step 
fractionation process – High-Performance Chromatofocusing (HPCF) followed by High-
Performance Reverse-Phase (HPRP) chromatography. An HPCF column was used to 
fractionate protein mixtures based on the isoelectric points of the liquid-phase proteins. 
An in-line pH meter, linked to the instrument’s automated fraction collector, controlled 
the output of the eluent to a 96-well plate from pH 8.5 to pH 4.0 in 0.1 pH increments. 
The first dimension HPCF column was equilibrated with 30 column volumes of 
ProteoSep™ start buffer at pH 8.5 at a flow rate of 0.2 mL/min for 130 minutes. 
Following equilibration, 5 mg of protein was injected into the HPCF module followed by 
20 minutes of ProteoSep™ start buffer at a flow rate of 0.2 mL/min. At 20 minutes, 
eluent buffer (pH 4) was run at a flow rate of 0.2 mL/min for 115 minutes to create a pH 
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gradient after which 1 M NaCl was run as a high ionic strength salt wash. During the 
gradient phase, eluted fractions were collected at 0.1 pH intervals and stored in a chilled 
96 deep-well autosampler plate. These first-dimension fractions were used both for direct 
analysis by mass spectrometry and for further second-dimension HPRP fractionation. 
For liquid phase second-dimension fractionation, each fraction collected from the 
first dimension module was automatically and sequentially injected into an HPRP column 
where proteins were separated on the basis of their hydrophobicity. This second-
dimension HPRP column was initially flushed with 5 column volumes of 0.08% 
trifluroacetic acid (TFA) in acetonitrile followed by 10 column volumes of 0.1% TFA in 
H2O running at 0.75 mL/min. Sample proteins were bound with 2 min of 0.1% TFA in 
water at a flow rate of 0.75 mL/min. At 2 minutes, a 0-100% gradient of 0.08% TFA in 
acetonitrile was run over a 30-minute interval creating a 3.33% change in solvent 
concentration/minute. At 0.5 minute intervals, fractions were collected with an FC-204 
fraction collector (Gilson, Middleton, WI) into a series of 96 deep-well plates. The 
collected fractions which contained intact proteins (approximately 400 fractions) were 
stored in a locked -70°C freezer until required for further characterization.  
2.1.3 Protein Identification by Mass Spectrometry 
First-dimension protein fractions, second-dimension protein fractions and 
unfractionated total protein extracts from each body fluid of interest were analyzed by 
mass spectrometry to generate a comprehensive series of proteomes for each body fluid. 
In preparation for mass spectrometry, first-dimension fractions were concentrated and 
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desalted and second-dimension fractions and 30 µg of unfractionated total protein were 
both lyophilized.  
2.1.3.1 pH Fraction Desalting  
Direct analysis of ProteoSep™ pH fractions (i.e., first dimension fractions) by 
mass spectrometry required that samples be desalted using Spin-X UF 500 concentrators 
(Corning, Lowell, MA) with a 5000 Da Molecular Weight Cut Off (MWCO). For each 
sample, 500 µL of sample was added to the filter unit and spun at 10,000 x g until the 
filtrate had passed through the column. Three 500 µL volumes of 50 mM ammonium 
bicarbonate were then passed through the column to remove residual salts. The retained 
supernatant was then recovered and brought up to a total of 500 µL and quantified for 
total protein using the Thermo Scientific Micro BCA assay described previously.  
2.1.3.2 Trypsin digestion 
First- and second-dimension protein fractions were reconstituted in 40 µL of 100 
mM Tris-HCl pH 8.5 while unfractionated proteins were reconstituted in 40ul of 8M urea 
in 100 mM Tris-HCl pH 8.5. Each of the reconstituted protein extracts was mixed with 
1.2 µL of 100 mM Tris(2-carboxyethyl)phosphine (TCEP) as a reducing agent. The 
resuspended proteins were then shaken for 20 minutes at room temperature. After 
incubation, 0.88 µL of 500 mM Iodoacetamide (IAA) was added and the samples were 
shaken in the dark for an additional 15 minutes to alkylate the proteins. The alkylated 




 resuspended proteins from first dimension fractions were mixed with 1.25 
µg of trypsin and incubated for 16 hours at 37°C. 
 resuspended proteins from second dimension fractions were mixed with 
1.25 µg of trypsin and incubated for 8 hours at 37°C after which the  
samples were sonicated and digested with a second equal volume of 
trypsin for an additional 8-10 hours at 37°C.  
 resuspended proteins from unfractionated body fluid extracts were mixed 
with 120 µl of 100 mM Tris-HCl to dilute the urea in the sample to 2M 
after which the sample was mixed with 1 µg of trypsin and incubated for 
14-16 hours at 37°C. 
The digested proteins from the ProteoSep™ first- and second-dimension fractions 
were then vacuum dried and re-suspended in 3% acetonitrile and 0.1% formic acid for 
subsequent analysis by mass spectrometry.  Due to the urea present in the unfractionated 
protein samples, an additional post-digest cleanup and desalting step was necessary.  
2.1.3.3 Post Trypsin Peptide Cleanup and Desalting 
Pierce C-18 spin columns (Pierce Biotechnology, Rockford, IL) were used to 
cleanup and concentrate digested peptides from the unfractionated body fluid samples. 
Each spin column was placed in a 1.5 mL microcentrifuge tube and activated by adding 
200 µL of 50% acetonitrile followed by centrifugation at 1500 x g for 1 minute at room 
temperature. This was repeated one additional time. The column resin was equilibrated 
with 200 µL of 5% acetonitrile and 0.5% triflouroacetic acid and spun at 1500 x g for 1 
minute at room temperature. This step was repeated one additional time. Digested 
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samples were then loaded onto column and spun at 1500 x g for 1 minute at room 
temperature. The flow through was collected and passed through the column again at 
1500 x g for 1 minute at room temperature. The column was washed with 200 µL of 5% 
acetronitrile and 0.5% triflouroacetic acid and spun at 1500 x g for 1 minute at 
temperature. This process was repeated three additional times after which the digested 
peptides were eluted by adding 20 µL of 70% acetonitrile followed by centrifugation at 
1500 x g for 1 minute at room temperature. This was repeated one additional time. The 
recovered peptides were then lyophilized in a vacuum centrifuge and resuspended in 3% 
acetonitrile and .1% formic acid for analysis by LC-MS/MS. 
2.1.3.4 MS/MS Acquisition 
For the analysis of first- and second-dimension ProteoSep™ fractions by mass 
spectrometry an Agilent 6300 series ion trap mass spectrometer (Agilent Technologies, 
Santa Clara, CA) was used while for the analysis of unfractionated proteins an Agilent 
6510 series Q-TOF mass spectrometer was used. These were all coupled to a 1200 series 
HPLC-Chip/MS system (Protein ID chip specifications: 150mm 300 Å C18 chip for first-
dimension fractions and unfractionated protein samples; Protein ID “short chip” 
specifications 43mm 300 Å C18 chip for second dimension fractions).  
Columns were equilibrated in 0.1% Formic acid in water. For first-dimension 
fractions and unfractionated proteins, 1 µL of protein digest (equivalent to 1 µg of 
digested protein) per injection was used. For second-dimension fractions 0.1 µl to 1.5µl 
of protein digest (variable protein content) per injection was used. A 0-45% of 0.1% 
formic acid in acetonitrile gradient was performed over 40 minutes followed by a 6 
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minute column re-equilibration (first-dimension fractions), 11-minutes followed by a 4 
minute column re-equilibration (second-dimension fractions) or 44 minutes followed by a 
6 minute column re-equilibration (unfractionated proteins). 
2.1.3.5 Data Analysis 
Data analysis was performed using Spectrum Mill software suite by Agilent 
Technologies. Data were searched against the Swiss-Prot database. Search parameters 
included setting the species selection to “Human”; designating a missed cleavage 
allowance of 3; fixed modifications included carbamidomethylation and variable search 
modifications included methionine oxidation and deamidation. The search criteria 
employed with data from the Agilent 6300 series ion trap allowed for a 2.5 Da precursor 
and a 0.7 Da product ion mass tolerance with a minimum matched peak intensity of 60%. 
On the 6510 series Q-TOF, the search criteria allowed a 20 ppm precursor and 50 ppm 
product ion mass tolerances with a minimum matched peak intensity of 60%.   
 
2.2 Results and Discussion 
In total, over 1000 proteins were identified in the course of the biomarker 
discovery experiments. This included candidate proteins identified by: (1) Analysis of 
peaks from the ProteoSep™ which were identified as unique using an in-house software 
package; (2) Analysis of protein rich pH fractions and; (3) Analysis of unfractionated 
body fluid samples. Table 2.1 summarizes all candidate biomarkers identified under these 























Semenogelin-1 P04279 √ √ √ 
Semenogelin-2 Q02383 √ √ √ 
Prolactin-inducible protein P12273 √ √ 
 
Prostate-specific antigen P07288 √ √ √ 








Histatin-1 P15515 √ 
 
√ 














Cornulin Q9UBG3 √ √ √ 
IgGFc-binding protein Q9Y6R7 
  
√ 






















Vimentin P08670 √ 
  
Urine 















Complement C3  P01024 √ √ √ 
Hemoglobin subunit beta P68871 
 
√ √ 




2.2.1 Biomarker Identification: ProteoSep™ 2D Fractionation 
Five individuals were recruited to donate samples of each body fluid being 
analyzed. This redundancy was intended to help to discriminate between proteins that are 
consistently expressed in a specific body fluid versus those that might reflect inter-
individual variability in protein expression - and thus not be suitable as biomarkers. Five 
individuals reflected an additional effort to obtain the maximum amount of proteomic 
information within a reasonable budget and timeframe. Additionally, while mapping 
proteomes from a larger number of study participants would provide a stronger 
assessment of protein expression among different humans, the primary objective of this 
stage of the search was to identify candidate biomarkers of body fluids that could be 
subsequently validated for use across a larger population. 
Samples were prepared as summarized in Figure 15. Saliva, seminal fluid, urine, 
and vaginal fluid were prepared in a similar manner. In all cases, samples were 
centrifuged at high speed to remove cellular material followed by concentration and 
buffer exchange with ProteoSep™ loading buffer.  
Menstrual and peripheral blood needed to be treated separately primarily due to 
the complexity of the blood proteome – and the presence of abundant non-specific 
proteins. Peripheral blood was collected in an EDTA gel barrier tube in order to generate 
blood serum devoid of cells and clotting factors. Menstrual blood, however, was typically 
contaminated with hematosed erythrocytes. As hemoglobin comprises 32-36% of all the 
proteins found in red blood cells, the serum from menstrual blood samples containedlarge 
75 
 
quantities of hemoglobin which acted to mask the detection of less abundant menstrual 
fluid-specific proteins. For this reason, hemoglobin was removed from collected serum 
samples prior to proteome fractionation through the use of HemogloBind™. 
Because the dynamic range of protein concentration in serum spans more than ten 
orders of magnitude, the presence of these high-abundance proteins (e.g. albumin, IgG, 
transferrin) makes it difficult to identify proteins that are abundant but which are more 
likely to be specific markers of each body fluid
[115]
. To circumvent this potential problem, 
commercially available IgY-12 Proteome Partitioning columns were employed. These 
antibody-based columns made it possible to remove twelve highly abundant proteins 
(albumin, IgG, transferrin, fibrinogen, IgA, α-2-Macroglobin, IgM, α-1-acid antitrypsin, 
haptoglobin, α-1-acid glycoprotein, apolipoprotein A-I and A-II) from human blood 
serum. This yielded an enriched pool of the less abundant but more body fluid-specific 
blood proteins in the flow-through fraction. 
Each body fluid sample was quantified using the Micro BCA kit as described 
above and a standardized 3 mg of total protein was loaded onto the ProteoSep™ system. 
In total, thirty proteome maps were generated. In each of these maps, data from the 
chromatofocusing column (X axis) was combined with data from the reverse-phase 
column (Y axis) to yield a .dat file containing  X, Y, and Z (height) values which can be 
processed and visualized with the ProteoVue™ software suite. Examples of the 2D 
pH/hydrophobicity/quantity maps for peripheral blood, urine, semen and saliva are shown 
in Figure 16. The intensity and color of the bands represent the abundance of the protein 
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detected. Red, orange and yellow bands represent more abundant proteins while green 
and blue represent less abundant proteins. 
 
Figure 16 - Examples of the 2D pH (x-axis)/hydrophobicity (y-axis) maps (i.e., proteome maps) obtained from five 
different body fluid samples (peripheral blood, urine, semen, saliva, and menstrual fluid/blood). Differences in the 




2.2.1.1 Proteome Map Comparison 
Rigorous pairwise comparisons among the 2D-fractionated pH / hydrophobicity / 
protein expression “proteome maps” for each body fluid were made as part of the effort 
to identify potential high-specificity biomarkers. Initially, the commercial DeltaVue™ 
software suite which was integrated into the ProteoSep™ System was used for comparing 
proteome maps. The software requires a .dat file input to generate color-coded 
“differential display” maps in which differences between the proteomic profiles of any 
two samples (Figure 17) are highlighted. 
 
Figure 17 - DeltaVue™ difference profile (center panel) comparing the urine proteomic map (center left panel in 
red) with the saliva proteome map (center right panel in green). Loss of resolution of lower abundance proteins 
and the inability to normalize protein position for subtle retention time differences and pH variances between 





Following several comparisons, however, the limitations of the software became 
apparent. The software was designed for traditional biomedical-based proteomics projects 
where diseased samples are compared to healthy samples. As an example of the more 
typical workflow in a disease diagnostics context, tissue samples from multiple 
individuals with a given biological state of interest (e.g., healthy vs. diseased hepatic 
tissues) would be run on the ProteoSep™. In that case, two nearly identical proteomes 
would be compared to identify quantitative differences in protein expression. By contrast, 
using the ProteoSep™ for comparisons of six highly dissimilar biological matrixes 
introduced an unanticipated level of complexity – specifically the need to accurately align 
and compare very dissimilar proteomic maps.  Doing such comparisons using the 
standard DeltaVue™ software would require hundreds of one-to-one comparisons 
between different proteomes.  
Given the inherent limitations of the instrument’s DeltaVue™ software, it was 
necessary to develop an in-house software suite to facilitate the rigorous and 
simultaneous comparison of multiple proteome maps at once. To this end, a series of data 
optimization procedures were developed and combined with a data mining algorithm to 
identify body fluid-specific peak clusters (i.e., x-/y-/z-axis coordinates representing the 
HPCF pH fraction, HPRP retention time and expression level, respectively of individual 
proteins) within the ProteoSep™ proteome maps. Those ProteoSep™ fractions 
containing proteins corresponding to the peaks flagged by the software as unique to the 
proteome of a specific body fluid were then recovered and the protein(s) represented by 
the peak(s) of interest were identified using tandem mass spectrometry. 
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2.2.1.2 Dataset Optimization 
As stated above, each proteome map is stored as a .dat file which is produced by 
the ProteoSep™ System. Each proteomic map file consisted of >450,000 data points in a 
45 x 10,501 data point matrix. A large portion of these data points, however, represent 
“uninformative” background noise created when no proteins are eluting from the system 
or represent what is essentially “uninformative” space between peaks during the reverse-
phase separation (Figure 18).  
 
Figure 18 – Histogram of peak height distribution generated by the ProteoSep™ system. The majority of the stored 
data exists as background/non-protein regions. This can be seen as the majority of data center around 0, which 
represents background signal in the instrument. 
Due to the enormous quantity of data points generated for each proteome map, 
coupled with the fact that the majority of the data exists as background signal, a protein 
peak identification algorithm was implemented to transform each proteome map into a 
simplified dataset containing only the coordinates of peak locations (Figure 19). The 










positive to negative (or the point where a derivative changes signs) represents the 
coordinates on the proteome map where a protein peak is likely to exist. Using this 
technique virtually all of the underlying noise and uninformative data can be eliminated 
while increasing the resolution of the signal itself. 
 
Figure 19 - Application of a protein peak identification algorithm to second-dimension raw hydrophobicity data 
(top) generated from a single first-dimension ProteoSep™ fraction. Protein peaks are called based on the point at 
which the slope of the trace changes from positive to negative or the point where a derivative changes signs 
(middle). Once identified, called protein peaks are used to create a normalized representative dataset from which > 
99.9% of the underlying noise and “uninformative” data has been eliminated (bottom). 
2.2.1.3 Data Mining of Optimized Proteome Maps 
It was also necessary to create a reliable means of comparing different proteomes 
while taking into consideration the subtle differences between sample runs (x/y axis) and  
interindividual (z axis) differences in protein expression levels. For this task, a data 
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mining algorithm was implemented to combine individual proteome maps for the same 
body fluid into a single consensus proteome map. Data mining for this purpose was 
defined as grouping like objects together. This “clustered/consensus map” was then used 
to facilitate comparisons among different body fluids. The specific algorithm that was 
implemented is known as the k-means clustering - an algorithm that organizes a dataset 
into k subsets. The algorithm involves a four step procedure. First, a location is assigned 
for each of the subset centers k (centroids); second, each data point is assigned to its 
nearest center; third, the optimal position of each center is calculated based off a distance 
measure to each point assigned to it and; fourth, steps 2 and 3 are repeated until the 
centers are “stable” with each center representing the set of individual protein points from 
multiple proteome maps from the same body fluid. The overall product of this procedure 
was a set of points split into k partitions, meaning that all of the peaks representing a 
given protein across multiple samples of the same body fluid from different individuals 
were grouped together in three dimensional space and were represented by a single 
central “consensus point”. The clustered “Consensus” proteome maps for each of the 
body fluids of interest were then overlaid with each other and cluster centers were 
compared between each fluid. Any cluster center which appeared in a single fluid and did 
not overlap with a cluster center in any other fluid was flagged as the map position of a 







2.2.1.4 Recovery and Analysis of ProteoSep™ 2D Fractions 
The translation of identified proteome map coordinates by Protein Miner™ into 
actual candidate protein biomarkers was a relatively straight forward process. The first 
step of this workflow began with the retrieval of ProteoSep™ second dimension fractions 
containing potentially unique proteins. A fractional analysis software package from the 
University of Michigan was used to rapidly locate a specific protein fraction that had 
been eluted from the ProteoSep™ second dimension HPRP column. By placing the 
cursor over a desired peak from the second dimension chromatogram, the software 
identifies the specific deep-well plate location of the protein fraction containing the peak 
of interest (Figure 20). 
 
Figure 20 – Fraction analysis software acquired from the University of Michigan. Cursor placement reveals the exact 
96 deep-well plate and well number where the proteins in a peak of interest are expected to be found. 
The proteins contained in these fractions were prepared as stated in section 2.1.3. 
Briefly, the protein(s) contained in a fraction of interest were denatured and digested to 
form peptide fragments using the enzyme trypsin. Mass spectrometry was performed on 
an Agilent 6300 series ion trap mass spectrometer coupled with a nanoflow-LC 1200 
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series HPLC-Chip/MS system. Because of the molecular simplicity of each ProteoSep™ 
second-dimension fraction (i.e., only 1-3 proteins/fraction are expected to be eluted), it 
was possible to use a short 43mm analytical column with only an 11-minute gradient was 
to obtain accurate protein identifications. 
Database identification of specific proteins was performed using Agilent’s 
Spectrum Mill search engine as described previously. Figure 21 shows an overview of 
the workflow and search results for a cluster of peaks representing potentially unique 
protein biomarkers in saliva sample #SLSA. Using the peak selection software the peak 
of interest was localized to HPCF pH fraction 30/HPRP fraction C10 which correlated to 
well F6 of 96 deep-well plate P1. After recovery of the liquid-phase fraction from this 
well, digestion, MS/MS analysis and database search of the resulting data, the protein 
statherin was identified as a potential biomarker of human saliva. This result was 
encouraging as statherin had also been independently identified as a possible saliva 
marker by gene expression database searches and by forensic researchers working on the 
development of mRNA biomarkers for saliva
[54, 116]
. Similarly, the identification of 
semenogelin-1 and -2 as markers of seminal fluid
[117]
 and periplakin as marker of vaginal 
secretions were consistent with what has been reported by biomedical researchers
[118]
. 
The accuracy with which the proteomic approach was able to identify these markers was 
seen as boding well for the likely specificity of numerous other candidate biomarkers that 






Figure 21 – Protein identification workflow. Briefly, proteins flagged as unique are recovered, digested and 
analyzed on an ion trap mass spectrometer. Acquired data is then processed using Agilent’s Spectrum Mill search 
engine to determine the identity of the unknown proteins in the fraction. 
This strategy of cluster analysis, unique peak selection, ProteoSep™ 2D fraction 
recovery, and biomarker identification through tandem mass spectrometry was repeated 
for each body fluid of interest in order to populate a database of candidate biomarkers.  
Where available, the potential utility (i.e., tissue specificity) of the candidate biomarkers 
was bolstered based on searches of independent proteome database projects and 
published reports in the professional proteomic literature. These included: semenogelin-
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I/II, prolactin inducible protein, prostate specific antigen, and prostatic acid phosphatase 
as markers of seminal fluid; histatin-1, salivary acidic proline rich phosphoprotein 1/2, 
and statherin as markers of saliva; cornulin, involucrin, periplakin, and vimentin as 
markers of vaginal fluid; osteopontin as a candidate urine biomarker; and α-1-antitrypsin, 
complement C3, hemoglobin subunit β, and hemopexin as markers of peripheral blood. 
Unfortunately, no high-specificity menstrual fluid markers were identified using this 
approach. Analysis of each candidate protein based on information in Swiss-Prot 
/uniprot/ncbi as well as published biomedical literature made it possible to arrive at a 
reasonably specific listing of candidate biomarkers. Biomarker candidates will be 
described further in relation to their biological function and tissue specificity in a later 
section.   
While this particular approach provided promising results, the original goal of 
generating five to ten candidate biomarkers for each fluid was not met. Additionally, no 
viable menstrual fluid proteins were identified using the ProteoSep™ mapping strategy. 
The fundamental assumption employed in this approach is that clusters flagged by the 
software would contain unique proteins – that is to say, a peak cluster found only in 
saliva should contain a saliva-specific protein. The reality, however, was that not all 
unique peak clusters were found to contain viable biomarkers. Figure 22 illustrates a 
search result from the analysis of a vaginal fluid fraction that was flagged as containing a 
unique protein. The search results of the acquired MS/MS data identified several serpin 





, all of which are known to be ubiquitously expressed in a range of human 
tissues.  
 
Figure 22 – Spectrum Mill results from the analysis of a ProteoSep™ 2D fraction flagged as containing a peak cluster 
unique to vaginal fluid. The identified proteins, however, are known to be ubiquitously expressed in non-target 
tissues.  
These results established that unique clusters of peaks may not necessarily contain 
body fluid-specific proteins. Conversely, not all clusters with similar (or even identical) 
map coordinates between two fluids may contain the same proteins. To circumvent this 
limitation of the cluster analysis approach, two alternative proteome strategies were 
employed to identify additional biomarker candidates. 
2.2.2 Biomarker Identification: ProteoSep™ 1D Fractionation 
As stated above, corresponding map coordinates and peak clusters from two 
separate fluids may not necessarily indicate that the peaks represent the same protein. As 
a result proteins with potential utility as high-specificity biomarkers may be missed using 
a 2D cluster analysis based approach.  To test this, protein-rich ProteoSep™ first-
dimension pH fractions for each body fluid were desalted, quantified, and run on a longer 
gradient in an effort to identify additional biomarkers which may have been missed by 
the initial cluster analysis. Figure 23 shows a portion of a vaginal fluid proteome map 
corresponding to first-dimension pH fractions 20 through 27 which were selected for 




Figure 23 – Proteome map of a vaginal fluid sample showing protein-rich ProteoSep™ first-dimension pH fractions 
20-27 which were recovered from the HPCF eluent deep-well plate for MS/MS analysis. 
Analysis of the ProteoSep™ first-dimension pH fractions resulted in the addition 
of several candidate biomarkers for each body fluid and successfully identified the first 
candidate biomarker for menstrual fluid (calpastatin). Analysis of seminal fluid detected 
all previously identified biomarkers and identified one additional candidate protein, 
epididymal secretory protein E1. Cystatin-SA was identified as an additional candidate 
biomarker for saliva. Vaginal fluid analysis was also successful in identifying several 
new candidate biomarkers including Ly6/PLAUR domain-containing protein 3 and 
neutrophil gelatinase-associated lipocalin. Finally, uromodulin was added to the 
candidate list for urine.  
These results confirmed the hypothesis that a single pass approach to biomarker 
discovery based on a cluster analysis of ProteoSep™ 2D proteome mapping results may 
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not provide a sufficient resolution of the proteome to ensure the identification of all 
possible body fluid specific proteins. This alternative approach achieved greater protein 
resolution and as a result added six new candidate biomarkers while confirming the 
identification of many other biomarkers (e.g. semenogelin-I/II). The confirmation 
provided by this approach provided support to the view that those candidate protein 
biomarkers that were identified by cluster analysis are reliable and reproducibly 
detectable.  
2.2.3 Biomarker Identification: Unfractionated Body Fluids 
Given the success achieved by direct analysis of the ProteoSep™ first-dimension 
pH fractions, an additional series of experiments were performed in which unfractionated 
body fluids were analyzed by tandem mass spectrometry. It is well known that not all 
proteins are compatible with all separation approaches. Thus, this second alternative 
strategy represented an effort to obtain an even more comprehensive dataset of the 
proteins expressed in each body fluid of interest. Additionally, data from unfractionated 
body fluid extracts would offer a “real world” assessment of the biomarker detection 
characteristics as no laborious fractionation or enrichment steps are involved – an 
important issue that may impact the ultimate feasibility of implementing mass 
spectrometry-based assays in a forensic caseworking environment.  
 To reduce the potential impact of interindividual variability in protein expression, 
three samples of each body fluid were prepared as described under sections 2.1.1 
“Sample Collection and Preparation” and 2.1.3 “Protein Identification by Mass 
Spectrometry”. However, neither menstrual fluid nor peripheral blood samples were 
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passed through an immunodepletion column nor was any effort made to remove 
hemoglobin for these experiments.  
The results obtained by MS/MS analysis of these samples further supplemented 
the candidate database for saliva as well as vaginal fluid while reconfirming the apparent 
tissue specificity of several candidate markers that had been previously identified by 
cluster analysis and first-dimension pH fraction strategies. The analysis of unfractionated 
body fluid protein extracts resulted in the addition of cystatin-D, histatin-1, as well as 
submaxillary gland androgen-regulated protein 3B as candidate biomarker list for saliva.  
Immunoglobulin G Fc-binding protein, matrix metalloproteinase-9, mucin 5B, as well as 
suprabasin were identified as high-specificity biomarker candidates of vaginal fluid.  
2.2.4 Candidate Biomarker Review 
A comprehensive list of candidate biomarkers (Table 1) was compiled after the 
completion of the biomarker discovery phase of this research. This list was propagated 
through a combination of empirical comparative proteomic data as well as an inspection 
of public proteome database annotations a review of the proteomic and biomedical 
literature. A description of the candidate biomarkers that comprised the initial assay 
panels for each body fluid of interest are provided in detail in the following sections. A 
more thorough investigation and validation of the tissue specificity (and thus ultimate 
utility) of these candidate markers was also performed and is described in Chapter 3. 
2.2.4.1 Seminal Fluid  
Seminal fluid showed highly consistent results between all three experimental 
methods; only epididymal secretory protein E1 and prolactin-inducible protein were not 
consistently expressed across all experiments. Epididymal secretory protein E1 was first 
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identified as a major secretary protein in the epididymis
[121]
. The protein is involved in 
the transportation of cholesterol from lysosomes and is proposed to have a role in sperm 
formation
[122, 123]
. This protein was not identified in the ProteoSep™ 2D fractions but was 
found in the comparative proteomic analyses of ProteoSep™ 1D pH fractions as well as 
unfractionated samples.   
Semenogelin-I/II are the most abundant proteins in seminal plasma and are 
responsible for the gel-like matrix of human semen. Both isoforms act as substrates for 
prostate specific antigen (p30), where upon lysis, sperm are able to move freely through 
the seminal matrix
[124, 125]
. Both protein variants were identified by all three biomarker 
discovery methods.
 
Prolactin-inducible protein is a small 17 kDa glycoprotein located in saliva, sweat 
glands, but with very high expression in seminal fluid
[126]
. Depending on the expression 
levels in saliva, this protein may not be suitable for differentiating these two fluids. The 
protein has numerous biological functions including protection of spermatozoa from 
damage by endogenous IgG antibodies
[127]
. Prolactin-inducible protein was detected in 
the comparative proteomic analyses of ProteoSep™ 2D fractions as well as the 
ProteoSep™ 1D pH fractions but was not detected in analyses of unfractionated samples. 
Prostate-Specific Antigen (also known as PSA or p30) is a serine protease 
produced by epithelial cells located in the prostate
[128]
. The primary function of prostate-
specific antigen is to cleave semenogelin-I/II thus creating a soluble, liquid medium, for 
spermatozoa movement
[129]
. Prostate-specific antigen has been well studied as an 
indicator for prostate cancer when serum levels reach approximately 4-10 ng/mL
[130, 131]
.  
While this protein is not absolutely seminal fluid-specific, the detection limits of most 
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assays make it difficult to detect it in whole blood
[132]
. As a result, this protein may have 
utility, in combination with other biomarkers, for the detection of seminal fluid. As with 
semenogelin, PSA/p30 was reproducibly detected in by three biomarker discovery 
strategies. 
Prostatic Acid Phosphatase (also known as Seminal Acid Phosphatase or SAP) is 
a glycoprotein secreted by the epithelial cells of the prostate gland which is capable of 
hydrolyzing phosphate groups from substrate molecules 
[133]
.  SAP is another seminal 
fluid protein which has seen utility as a clinical marker for prostate cancer
[134, 135]
. While 
largely replaced by PSA/p30 for screening purposes, the combination of low expression 
in non-target tissues and assay detection limits makes this protein useful as a potential 
marker of seminal fluid. 
All of the proposed protein biomarkers of seminal fluid have been well 
characterized in proteomic experiments and have been reported in numerous independent 





Salivary biomarkers were more variable in their detection across the three 
experiments. Cystatin D and cystatin SA originate from the submandibular and 
sublingual glands and act as protease inhibitors in saliva
[138]
. Both of these proteins are 
salivary specific with no expression in the seminal vesicles, prostate, ovaries or other 
tissues
[139]
. Cystatin D was only detected in analyses of unfractionated protein samples 
whereas cystatin SA was detectable in analyses of both unfractionated protein samples 
and the ProteoSep™ 1D pH fractions.  
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Histatin-1 originates from the submandibular and sublingual glands and is 
associated with the regulation of salivary calcium
[140, 141]
. Histatin-1 was identified in the 
ProteoSep™ 2D fractions as well as the unfractionated protein samples. Salivary acidic 
proline-rich phosphoprotein is secreted into saliva where it also acts to regulates calcium 
phosphate salts providing a protective / reparative environment for dental enamel
[142, 143]
. 
This protein was identified only in comparisons of the ProteoSep™ 2D fractions. 
Statherin, also secreted into saliva, has a similar function to that of salivary acidic 
proline-rich phosphoprotein 1/2. Statherin inhibits potentially harmful calcium phosphate 
precipitation in saliva
[144, 145]
. Statherin was detected in both the comparative proteomic 
analyses of ProteoSep™ 2D fractions and unfractionated protein samples.  
All the proposed biomarkers of saliva have also been well characterized in 
numerous proteomics studies thereby increasing the likelihood that these will prove to be 
reliable biomarkers for saliva
[146, 147]
.  
2.2.4.3 Vaginal Secretions 
Vaginal fluid was among the most difficult body fluids to analyze as the proteins 
associated with the fluid appear to be less consistent across multiple experiments and are 
less rigorously documented in the literature in terms of tissue localization and biological 
function. Involucrin is a structural protein contained within squamous epithelial cells
[148] 
that was detected only in vaginal fluid samples by all three biomarker discovery 
strategies.  Similar to involucrin, cornulin is also expressed in squamous where it plays a 
role in epithelial cell differentiation.  It may also play a role in mucosal-epithelial 
immune response. The protein has been characterized in the cervix and in esophageal 
tissues
[149, 150]
. This being said, it was not detected in any saliva samples in the current 
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study. This protein is one of only two candidate biomarkers of vaginal fluids that was 
identified by all three comparative proteomic approaches.  
IgGFc-binding protein is involved with the mucosal layers of epithelial cells, it 
has been found in the colon and placenta, and is thought to aid in immunity
[151]
.  IgGFc-
binding protein was only detected in analyses of unfractionated protein samples.  
Ly6/PLAUR domain-containing protein 3 is involved in the regulation between 
extracellular structural support scaffolding and epithelial cell layers
[152]
. Ly6/PLAUR 
domain-containing protein 3 was identified in the comparative proteomic analyses of 
both ProteoSep™ 1D pH fractions and unfractionated protein samples.  
Matrix metalloproteinases are a family of proteins which break down and remodel 
components of the extracellular matrix
[153]
. Matrix metalloproteinase-9 was found only in 
unfractionated protein samples of vaginal fluids. Although this protein has been reported 
in serum and blood plasma, its expression levels appear to be below the detection limits 
of most assays making it a potentially viable candidate biomarker for use in conjunction 
with other candidate proteins
[154, 155]
. 
Mucin-5B is a member of a class of large highly glycosylated proteins which 
form elastic matrices on mucosal surfaces
[156]
. Mucin 5B is reportedly expressed in the 
mucosal glands of the uterine endocervix as well as the airway epithelium
[157-159]
. In the 
current study mucin-5B was found to be a very abundant protein in vaginal fluid but may 
also detected in saliva samples. Nevertheless, it may have utility as a vaginal marker if 
the protein is undetectable in the saliva samples. Mucin-5B was only reliably detected in 
the comparisons of unfractionated protein samples.  
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Neutrophil gelatinase-associated lipocalin belongs to the lipocalin family of 
transport proteins which have been associated with innate immunity though iron 
sequestration
[160]
. As such, this protein can be found in tissues prone to exposure to 
bacterial and other microorganisms including the respiratory tract, salivary glands, uterus, 
and prostate
[160, 161]
. Neutrophil gelatinase-associated lipocalin was detected in analyses 
of ProteoSep™ 1D pH fractions and unfractionated protein samples.  
Periplakin is a protein component of the cornified envelope in human skin
[162]
 and 
was identified in comparative analyses of both the ProteoSep™ 1D pH fractions and 
unfractionated protein samples. Suprabasin is expressed in keratinocytes and plays a role 
in epidermal differentiation. It has been reported to be expressed in the uterus as well as 
the esophagus
[163]
. Suprabasin was only identified in analyses of unfractionated protein 
samples. Vimentin which acts as the major intermediate filament in mesenchymal stem 
cells
[164]
, was identified only through cluster analysis of the ProteoSep™ 2D fractions.  
Vaginal fluid was the most difficult body fluid to analyze with respect to 
specificity and thus the potential utility of candidate biomarkers. The presence of these 
markers as being consistently identified in a series of vaginal proteomics projects was 
reviewed in the professional literature. Table 2 presents a compiled list of eight vaginal 
fluid proteomics research reports and lists the study in which the candidate biomarker 







Table 2 –  Meta-Analysis of Biomarkers from Eight Vaginal Fluid Proteomics Studies
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Table adapted from Tang
[170]
. 
Each of the candidate protein biomarkers of vaginal fluids selected for forensic 
validation was also identified in at least two independent projects with several being 
identified in three to six of the eight published studies. Because the candidate biomarkers 
form the current study are consistent with what has been independently reported by other 
biomedical researchers, it is believed that these proteins have significant potential utility 
as reliable biomarkers. However, it is also appreciated that due to the limited literature 
available on some of these biomarkers, more rigorous forensic validation studies may 







Two prospective urine biomarkers were identified in the course of the current 
research. The protein osteopontin provides protection from kidney stone formation 
through the inhibition of calcium crystal formation
[173]
. Osteopontin can also be found in 
plasma with connections varying from autoimmune disorders to tumor progression 
[174, 
175]
. Osteopontin was identified by all three comparative proteomics strategies. 
Uromodulin, also known as Tamm-Horsfall urinary glycoprotein, is the most 
abundant protein found in human urine
[176]
.  It has been proposed that uromodulin is 
involved in preservation of water and electrolyte levels as well as being linked to 
infection prevention
[176, 177]
. Uromodulin is also involved as an extracellular protein in 
bone matrix formation
[178]
.Uromodulin was detectable in analyses of both ProteoSep™ 
1D pH fractions and unfractionated protein samples. Both of these proteins are 




2.2.4.5 Menstrual Blood 
Only a single menstrual blood-specific biomarker was identified, that being  
calpastatin, which was initially flagged through comparative analysis of the ProteoSep™ 
1D pH fractions. Calpastatin, is another cysteine protease inhibitor. More specifically, 
this protein is thought to be involved in the regulation of a subset of cellular apoptotic 
events
[181]
 and to play a role in tissue preservation and muscle degradation through 
proteolysis inhibition
[182]
. To date, no menstrual blood proteomics projects have been 
published. The failure to readily detect this marker in unfractionated menstrual fluid 
samples does raise some concern. It is possible that the protein may not be universally 
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expressed which would explain the absence in the other samples analyzed. It is also a 
possibility that removing the immunodepletion step as part of sample processing has 
placed the protein below the detection limits of even modern mass spectrometers. 
However, there were multiple vaginal-specific candidate biomarkers detected in 
menstrual blood as might be anticipated. Table 3 summarizes the prevalence of these 
proteins in menstrual blood. Because vaginal fluid will be a component of any vaginal 
sourced sample, these data suggest that it may be possible to generically differentiate a 
sample as being of potential vaginal origin. However, there would be no way to 
confidently identify a sample as menstrual fluid versus a mixture of peripheral blood and 
vaginal fluid. 













Cornulin Q9UBG3   
√ 
IgGFc-binding protein Q9Y6R7    
Involucrin P07476    
Ly6/PLAUR domain-containing 
protein 3 O95274    
Matrix metalloproteinase-9 P14780    
Mucin-5B Q9HC84    
Neutrophil gelatinase-
associated lipocalin P80188  
√ √ 
 
Periplakin O60437    
Suprabasin Q6UWP8    
Vimentin P08670   
√ 
 
2.2.4.6 Peripheral Blood 
Four peripheral blood biomarkers were selected during the course of the 
biomarker discovery phase of the current study. α-1-antitrypsin is a non-specific serine 
protease inhibitor found in human plasma. This protein’s primary role is as an inhibitor of 
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neutrophil elastase thus protecting tissues from proteolytic damage
[183, 184]
.  α-1-
antitrypsin was identified in the comparative proteomic analyses of both the ProteoSep™ 
1D pH fractions and unfractionated protein samples. 
Complement C3 is a serum protein implicated in the complement cascade of the 
immune system. More specifically, complement C3 is involved with innate immunity and 
aids antibodies as well as phagocytes in response to pathogen infection
[185, 186]
.  
Complement C3 was identified by all three comparative proteomics methods. 
Hemoglobin subunit beta - The metalloprotein hemoglobin is responsible for 
oxygen transport and is the major protein contained within erythrocytes. Hemoglobin 
exists as a tetramer containing two beta chains and two alpha chains
[187]
. Hemoglobin 
subunit beta was not flagged as a potential biomarker in the cluster analysis of the 
ProteoSep™ 2D fractionation experiments – attesting to the efficient removal of 
hemoglobin during sample processing.  This protein was, however, detected as a potential 
biomarker in analyses of the protein rich ProteoSep™ 1D pH fractions and the 
unfractionated protein samples from which hemoglobin was not removed.  
Hemopexin is produced in the liver and found in plasma. This protein is 
responsible for trapping free heme in plasma as well as iron recycling in the liver
[188, 189]
.  
As with complement C3, this protein was identified by all three biomarker discovery 
strategies.   
These selected blood proteins have all been well characterized and all appear to 







Proteomics-based methodologies can routinely identify hundreds to thousands of 
proteins in a biological system
[191]
. The overall objective of these types of studies are to 
identify candidate protein biomarkers for use as diagnostic tools – be it for a clinical 
diagnosis or, in the case of the current study, for use as a diagnostic marker for a specific 
body fluid in forensic casework.  
 In the current study, over one thousand proteins were identified utilizing three 
approaches: 1) cluster analysis of proteomic maps developed from ProteoSep™ 2D 
fractionation and peak analysis by mass spectrometry; 2) comparative proteomic analysis 
of protein-rich ProteoSep™ 1D pH fractions and analysis following mass spectrometry 
and; 3) comparative proteomic analysis of unfractionated body fluids following mass 
spectrometry. After careful review of the data, a database containing thirty body fluid-
specific protein biomarkers was compiled. These include candidate biomarkers for the 
identification of semen, saliva, urine, peripheral blood, vaginal/menstrual fluids.  
While these results are highly encouraging, it is important to stress that these 
protein biomarkers were identified by mapping the protein profiles of just five individuals 
per bodily fluid and thus these proteins can only be considered candidate biomarkers. For 
example, the possibility cannot be ignored that some candidate biomarkers might be 
secreted into non-target fluids, particularly with the less well-documented proteins 
associated with vaginal fluid. In fact, the published literature and proteomic data from the 
current study, itself, clearly suggest that few of the candidate biomarkers will be 
absolutely specific for a single body fluid. Because of this, a larger-scale study must be 
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completed in order to more rigorously confirm the degree to which these candidate 
protein biomarkers can be interpreted as sufficiently specific to a given body fluid as to 






























The traditional proteomics research and development pipeline is characterized by 
a methodical discovery phase to identify putative biomarkers followed by a high-
throughput verification phase to assess the diagnostic potential of the biomarker 
candidates. Historically, verification in the clinical setting has been performed using 
immunoassays in order to generate accurate and reproducible quantitative measurements 
of specific proteins of interest
[192, 193]
.  While the use of immunoassays is well established 
approach, a disconnect exists in the translation from biomarker candidates to clinical 
utility. This exists primarily due to the lack of commercially-available 
antibodies/reagents as well as the prohibitive cost of de novo immunoassay development. 
This problem is compounded by the fact that typical proteomics discovery projects may 
identify as few as ten or as many as fifty candidate proteins with potential clinical 
utility
[76, 194]
. Recent advances in targeted mass spectrometry offer an alternative 
approach to traditional antibody-based testing. Using ion-scanning techniques on 
quadrupole mass spectrometers, it has become possible to identify, as well as quantify, 
hundreds of protein biomarkers in a single analysis without the added cost of 
immunoassay design and characterization
[195, 196]
.  
In developing a verification platform for a body fluid-specific serological assay, it 
must be emphasized that, with any antibody-based assay, the results are “presumptive by 
definition”. This is because the potential for antibody cross-reactivity with non-target 
molecules is difficult to predict a priori and can never be completely eliminated
[197]
. 
Thus, for a biomarker verification assay, a targeted mass spectrometry-based platform 
offers a lower cost, a shorter development time, as well as the inherent accuracy of 
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detection by mass spectrometry rather than indirect identification based on an 
intermolecular binding event.  
For the verification outlined in this phase of the dissertation research, a 
quadrupole time-of-flight system will be employed to carry out the analyses. This 
instrument utilizes target ion “inclusion lists” that are generated based on the candidate 
biomarkers being verified. Each of these target ions are diagnostic tryptic peptides of our 
candidate biomarkers which the first quadrupole isolates. The isolated ions are then 
fragmented into smaller peptides in the following collision cell. These fragments then 
enter a TOF mass analyzer which yields highly accurate product ion spectra which is 
uniqe to each peptide 
[198, 199]
. The bottom line is that the Q-TOF assay allows 
unprocessed biological stains to be directly injected and even low-abundance biomarkers 
can be reliably detected in a background of hundreds to thousands of higher-abundance 
proteins. The core objective for this phase of the current research was to verify the body 
fluid specificity and the consistency of expression in the general population of the 
previously identified candidate protein biomarkers. This was performed utilizing a 
Quadrupole Time-of-Flight instrument.  
 
3.1 Materials and Methods 
All research conducted under this project was reviewed, approved by the 
University of Denver Institutional Review Board (IRB) for research involving human 
subjects and conducted in full compliance with U.S. Federal Policy for the Protection of 
Human Subjects.  In total, 100 subjects (50 males and 50 females) were recruited from 
the undergraduate population at the University of Denver. Female donors were 
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compensated $80 and males $20 for their participation in the research study. All research 
volunteers agreed and signed a letter of informed consent acknowledging they have 
received, read, and understood the protocols involved in the collection of samples. 
Additionally, all donated samples were given a random alphanumeric label to ensure 
confidentiality. Finally, males were instructed to refrain from ejaculation for 24 hours 
prior to sample collection and all donors were instructed to refrain from sexual 
intercourse for 5 days prior to the collection of urine, and vaginal fluids and menstrual 
blood for females. 
3.1.1 Sample Collection and Preparation 
An overview of the workflow performed from sample collection through biomarker 
identification is provided in Figure 24. Saliva, seminal fluid, urine, vaginal fluid, 
peripheral, and menstrual blood were self collected whereas peripheral blood samples 
were collected by laboratory staff. After collection saliva, seminal fluid, urine, vaginal 
fluid, peripheral, and menstrual blood samples were centrifuged to remove cellular 
material and quantified for total protein. Urine was processed further via a methanol 
precipitation cleanup step. Samples were divided into 10-15 equal volume aliquots and 






Figure 24 – Biomarker verification workflow from sample collection to biomarker identification.  Briefly, samples 
were collected and cellular debris removed via centrifugation and filtration. Samples were quantified for total 
protein and analyzed by mass spectrometry. 
3.1.1.1 Saliva 
Saliva was self-collected as described in section 2.1.1.1 with slight modification. 
Samples were stored as aliquots after the 0.45 µm filtration step and no concentration by 
Amicon Ultra-15 centrifugal filtration was performed. 
3.1.1.2 Seminal Fluid 






Urine was collected as described in section 2.1.1.2 with the following 
modifications. After the urine had been collected, it was centrifuged at 10,000 x g for 10 
minutes at 4°C and then passed through a 0.45 µm filter to ensure cellular removal. The 
protein component of the urine was then precipitated from a 300 µL aliquot of the urine 
by the addition of 3 volumes (900 µL) of cold methanol and incubation for 10 min at -
20ºC. The precipitated proteins were pelleted by centrifugation at 12.000 x g for 10 min 
at 4ºC after which the supernatant was discarded. One volume (300 µL) of -20ºC acetone 
was added to the pellet and the tube was allowed to stand for 10 minutes at min at 4ºC. 
The sample was then centrifuged at 12.000 x g for 10 min at 4ºC to repellet the protein 
precipitate. The supernatant was discarded and 100 µL of 25 mM ammonium bicarbonate 
was added and the tube was incubated at 37 ºC with gentle shaking for 10 minutes to 
resolublize the protein pellet. 
3.1.1.4 Vaginal Fluid 
Vaginal fluid collection employed an FDA-approved, over-the-counter, single-use 
latex-free, hypoallergenic cup SoftCup™ (Evofem, San Diego, CA). Donors were 
instructed to insert the SoftCup™ for one hour and then deposit the cup into a 50 mL 
sterile collection container.  Donors were directed to refrigerate the sample until it could 
be transported to the lab within one hour. Upon receipt, 2-3 mL of phosphate buffered 
saline was added to the SoftCup™ to rehydrate and recover vaginal fluids from the sides 
of the device. The recovered liquid was transferred to two or more 1.65 mL 
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microcentrifuge tubes which were centrifuged at 10,000 x g for 10 minutes at 4°C. The 
supernatant was then passed through a 0.45 µm filter to ensure cellular removal. 
3.1.1.5 Peripheral Blood 
Small volumes of peripheral blood were collected using the Unistik
®
 3 single use 
safety lancets (Owen Mumford, Marietta, GA) and the StatSampler EDTA collection vial 
(Statspin Technologies, Norwood, MA). Donors were instructed to wash their hands with 
disinfectant soap for two minutes under warm water. The donor’s finger was then cleaned 
with an alcohol swab and punctured using the lancet on the side of the volunteer’s ring 
finger to minimize discomfort. Blood was expressed and collected from the volunteer 
using the capillary tube from the StatSampler
®
 collection kits. Once the capillary tube 
was full (200 µL) the volunteer was given a Band-Aid
®
 to cover the puncture site. The 
StatSampler
®
 capillary tube was then expelled into a gel barrier microcentrifuge tube and 
spun for 2 minutes at 1500 x g to recover the serum. Blood sera from StatSampler
®
 
collection kits were spun at 10,000 x g for 20 minutes at 4°C and passed through a 0.45 
µm filter to ensure cellular removal. 
3.1.1.6 Menstrual Fluid 
Menstrual fluid/blood was self-collected by study participants in the privacy of 
their homes. The collection protocol employed an FDA-approved, over-the-counter, 
latex-free, hypoallergenic DivaCup™ for the collection of menstrual flow. The donor was 
directed to insert the cup into the vagina during menses for a period of approximately one 
hour. The cup was then gently removed and the contents were poured into a sterile 50mL 
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conical tube. The donor was instructed to refrigerate the collected sample until delivered 
to the lab within one hour. 
Menstrual blood was delivered in a sterile 50mL collection container. The blood 
was then transferred to a pink-cap 5 mL EDTA blood collection tube. The blood was 
rinsed with 2-3 mL of PBS and returned to a pink-cap EDTA blood tube. If necessary, 
due to the volume of material received, samples were divided between additional pink-
cap EDTA blood tubes. Samples were allowed to stand for 5 minutes at room 
temperature and then centrifuged at 1500 x g for 10 minutes at room temperature to 
separate the menstrual serum from cells and debris. The menstrual serum was transferred 
to a fresh tube and centrifuged at 10,000 x g for 10 minutes at 4°C after which the 
supernatant was passed through a 0.45 µm filter to ensure cellular removal. 
3.1.1.7 Protein Quantitation with Pierce Micro BCA kit 
Protein Quantitation was performed as described in section 2.1.1.10 
3.1.2 Body Fluid Identification 
3.1.2.1 Trypsin Digestion and Peptide Cleanup 
Trypsin digest and C-18 cleanup was performed as described in sections 2.1.3.2 
and 2.1.3.3. 
3.1.2.2 Q-TOF MS/MS Acquisition  
Mass spectrometry was performed on an Agilent Technologies HPLC-chip/MS 
system coupled to an Agilent 6510 Quadrupole Mass Spectrometer. The HPLC chip 
column used was a 150 mm 300 Å C18 analytical with a 160 nL enrichment column. 
Columns were equilibrated in 0.1% formic acid in water. A total of 500 ng of protein was 
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injected onto the column with the following run conditions: Buffer A (0.1% formic acid 
in water) and Buffer B (90% Acetonitile, 10% water, 0.1% formic acid). An initial 44-
minute run employed a gradient of 3-36% Buffer B over 38 minutes. This was followed 
by 80% Buffer B from 40-44 min and then a 5-minute post-run equilibration with 3% 
Buffer A. 
3.1.2.3 Q-TOF Data Analysis 
Data analysis was performed as described in 2.1.3.5 
3.1.3 Preparation of Casework Samples 
3.1.3.1 Stains on Swabs and Substrates 
Casework-type single body fluid samples were created by pipetting 50 µL of a 
desired body fluid, prepared as described in section 3.2.1, onto either standard cotton 
swabs or variable substrates (e.g. cotton, denim, leather ). Swabs and substrates were 
allowed to air dry in a biosafety hood for 40-60 minutes. Once dried, the cotton was 
removed from the swab or a cutting was removed from a substrate with a scalpel and 
placed into a 1.65 mL microcentrifuge tube. Proteins were extracted by adding 300 µL 
phosphate buffered saline to the swab and shaken at 37°C for 10 minutes. After 
incubation, the swab was placed into a spin basket and centrifuged for 30 seconds at 
13,000 x g to recover all fluid. Samples were then quantified using Micro BCA protocol 





3.1.3.2 Stains on Swabs with Contaminants 
Biological fluids on casework type samples encountered in the lab may often be 
mixed with contaminants from the environment and/or chemicals used in the processing 
of the crime scene. In order to prepare samples to test the impact of these additives, 
swabs were prepared as described in section 3.1.3.1 with minor adjustment. Prior to 
addition of the body fluid of interest, swabs were dipped in various environmental 
contaminants (e.g., bleach, Bluestar®, and spermicidal lubricant). The body fluid of 
interest was then applied to the swab and allowed to dry.  
3.1.3.3 Mixed Stains on Swabs     
Casework-type samples encountered in the lab may often contain mixtures of 
more than one biological fluid. In order to generate samples to evaluate the ability to 
detect target biomarkers representing more than one type of stain, swabs were prepared 
similarly to section 3.1.3.1 with minor adjustment. For volume-based mixtures, two equal 
volumes of a body fluid of interest (25 µL each) were added to a swab which was then 
dried.  
 
3.2 Results and Discussion 
In order to validate the consistency of detection and target body fluid specificity 
of the candidate biomarkers identified during the discovery phase of the current research, 
fifty single-source samples of saliva, vaginal fluid, seminal fluid, urine, peripheral blood, 
and menstrual fluid/blood were collected and run on a Q-TOF mass spectrometer 
operating in targeted MS/MS mode. Additionally, a variety of casework-type samples 
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were prepared for standard and sensitivity analyses which included dried biological stains 
on cotton swabs, a variety of commonly encountered substrates, stains mixed with typical 
chemical contaminants encountered in a forensic context, mixtures of different body 
fluids.     
3.2.1 Sample Collection and Analysis 
Fifty single-source samples were collected from donors for analysis by targeted 
mass spectrometry. These were collected and quantified as previously described. In order 
to appropriately represent the conditions under which samples will be analyzed in the 
context of a caseworking laboratory, no prefractionation or other exceptional 
pretreatments were employed at this stage. For example, menstrual blood was not treated 
with HemogloBind™ to remove hemoglobin. Additionally, neither menstrual fluids nor 
peripheral blood were passed through an immunodepletion column to remove abundant 
and thus potentially interfering proteins. In order to assess the utility of the candidate 
biomarkers for use with more challenging type of evidentiary material, a variety of 
casework-type samples prepared as described above were also analyzed during this phase 
of the research. 
3.2.2 Assay Method Development 
While targeted mass spectrometry based assays are highly reproducible and robust 
significant method development is required to design the analytical method. Due to the 
complexity of an analytical method which can process six biological matrixes 
simultaneously, the assay development activities were divided into a series of smaller 
objectives. These included: protein biomarker selection, target peptide selection, single-




Figure 25 – Method development workflow from peptide selection through multiplex assay design. 
By carefully reviewing the data generated during the initial biomarker discovery 
phase of the project, three to five of the most promising candidate protein biomarkers 
were selected for the inclusion in the multiplex assay for each body fluid of interest. Once 
the proteins were selected, optimal tryptic peptides for the detection of each protein were 
identified by mass spectrometry. Additionally, the analytical run parameters were 
optimized and a single-fluid multiplex assay was developed for evaluation. Finally, 
successfully-developed assays for each individual body fluid were merged and again 
evaluated for performance prior to analysis of the fifty individual fluids. 
3.2.2.1 Protein Selection 
The discovery phase of the current research identified numerous candidate 
biomarkers with potential utility for body fluid differentiation. From these candidates, the 
most discriminating and reliable protein targets must be identified for integration into the 
targeted Q-TOF assay. The optimal proteins are those that were identified using multiple 
biomarker discovery approaches and whose tissue specificity was also supported by a 
review of the proteomic and biomedical literature.  
In general, candidate seminal fluid biomarkers were identified consistently by all 
three comparative proteomic strategies. Only two proteins were not – epididymal 
secretory protein E1 was not identified as a potential biomarker by cluster analysis of the 
proteomic maps from the ProteoSep™ 2D fractions and prolactin inducible protein was 
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not identified in the comparative analysis of mass spectrometry data from unfractionated 
protein samples. All of the candidate biomarkers except for prolactin inducible protein 
were included in the development of the targeted assay for seminal fluid. The decision 
not to included prolactin inducible protein was that it has been reproducibly identified in 




The selection of saliva biomarkers was slightly more difficult as no biomarker 
was detected by all three comparative proteomic approaches employed in the current 
study. In this case, more weight was given to proteins identified through analysis of 
unfractionated protein samples as it was felt that this would better ensure that the selected 
proteins were abundant enough to be reliably detected. Included as candidate biomarkers 
for the saliva assay, therefore, were statherin, histatin-1 and cystatin-SA which were all 
identified by two of the comparative proteomics approaches, where cystatin D and 
submaxillary gland androgen regulated protein were only identified by the comparative 
analysis of data from the unfractionated protein samples. Salivary acidic proline-rich 
phosphoprotein 1/2 was omitted due to the fact that it was only detectable as being 
potentially unique by the cluster analysis of the ProteoSep™ 2D fractions.  
The selection of the most promising vaginal fluid proteins was also challenging as 
only one candidate biomarker, cornulin, was identified as unique by more than one 
comparative proteomics strategy. Additionally, according to a thorough literature review, 
the vaginal candidates appeared to have the least overall specificity. For example, 
cornulin, involucrin, Ly6/PLAUR domain-containing protein 3, periplakin and 
suprabasin were all reported to be associated with the epithelium. Thus, it can be assumed 
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that similar tissues may contain these proteins as well. Therefore, it is very possible that 
other non-keratinized tissues such as the mouth, esophagus, male reproductive tract, as 
well as the intestines may contain these proteins. As an example, cornulin has been linked 
to cancer involving esophageal tissues
[202]
. Table 4 provides a summary of the findings 
from four independent studies where candidate biomarkers of vaginal fluids were 
identified in salivary proteomic studies.   
Table 4 – Salivary Proteomic Studies where Candidate Biomarkers of Vaginal Fluid were Identified.  
Body Fluid Protein 
Accession 
Number 
Study 1[203] Study 2[204] Study 3[205] Study 4[206] 
Vaginal 
Secretions 
Cornulin Q9UBG3     
IgGFc-binding protein Q9Y6R7     




containing protein 3 O95274     
Matrix 
metalloproteinase-9 P14780   
√ 
 
Mucin-5B Q9HC84 √ √ √  
Neutrophil gelatinase-
associated lipocalin P80188    
√ 
 
Periplakin O60437   
√ 
 
Suprabasin Q6UWP8     




Based on the results presented in Table 4, several of the proposed biomarkers of 
vaginal fluids have also been identified in saliva proteome projects. These results must be 
taken into consideration when designing the final targeted Q-TOF assay. However, it 
should be noted that none of these markers were identified in any saliva samples analyzed 
during this dissertation research.  Based on these findings, cornulin, IgGFc-binding 
protein, Ly6/PLAUR domain-containing protein 3, as well as suprabasin were selected 
for inclusion in the targeted Q-TOF assay for vaginal fluid. Additionally, matrix 
metalloproteinase-9, mucin-5B, as well as neutrophil gelatinase-associated lipocalin were 
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added to the assay. While these markers have been identified in saliva, all four studies 
utilized extensive two dimensional fractionation strategies to detect proteins with very 
low expression levels. Thus, while several of these proteins may be expressed in both 
fluids, the quantity of protein that can be found may in one tissue versus another may still 
make it possible to discerng saliva from vaginal fluid. Neither vimentin nor involucrin 
nor periplaklin were detected in comparisons of proteomic data from unfractionated body 
fluid samples. Accordingly, they were removed from consideration for the targeted assay 
development.  
Urine biomarkers, osteopontin as well as uromodulin, were both selected for 
integration into the targeted assay. Both markers appear highly specific to urine and both 
proteins were identified in nearly all the biomarker discovery strategies employed.  
Calpastatin was the only protein identified as a potential biomarker of menstrual 
fluid. Unfortunately, this protein was only detected in the comparative analysis of 
proteins from the ProteoSep™ 1D pH fractions.  Because of the potential value of 
identifying a reliable biomarker of menstrual fluid, an attempt was made to locate the 
protein manually in the dataset generated by the Q-TOF analyses of the unfractionated 
protein samples described in Chapter 2. Using the results from the ProteoSep™ 1D pH 
fraction where the protein was originally identified, two peptides 
GTVPDDAVEALADSLGK and LAAAISEVVSQTPASTTQAGAPP were used in an 
attempt to manually identify the protein in the raw data from the analysis of the 
unfractionated protein samples. By using the exact masses of these tryptic peptides, the 
extracted ion chromatograms (EIC) for the calpastatin peptides and a reference peptide 




Figure 26 –Extracted ion chromatogram for Calpastatin (top) and Hemopexin (bottom). Hemopexin was reliably 
detectable in the menstrual blood sample whereas the Calpastatin peptide could not be manually located. 
At 19.5 minutes, a clear peak exists for hemopexin (which was also confirmed via 
a database search) whereas the data region that should contain the calpastatin peptides 
only revealed only noise. This result, which was observed reproducibly across all 
menstrual samples analyzed, suggests that the protein is either not present in the samples 
or that omitting the preparation steps (i.e., HemogloBind™ and immunodepletion) may 
have made the protein undetectable in the assay. Although calpastatin may not be a 
reliable marker for menstrual blood, some of the vaginal-fluid associated biomarkers 
were also identified in menstrual blood samples. Therefore, the best option currently 
available may be to use these as indicators of the vaginal origin of an unknown sample.  
Similar to seminal fluid, peripheral blood was relatively straightforward as all the 
candidate biomarkers were reliably identified by each of the comparative proteomic 
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assays.  Accordingly, complement C3, hemoglobin subunit beta, as well as hemopexin 
were included in the development of the targeted assay. 
3.2.2.2 Peptide Selection 
The next step in assay development was the selection of optimal tryptic peptides 
for targeting as representative/diagnostic peptides for each of the candidate biomarker 
proteins. Ideal peptides were those which: (1) were detected consistently across multiple 
experiments, with additional weight given to peptides identified in the unfractionated 
experiments; (2) had no post-translational modifications that would alter the mass-charge 
ratio; (3) were of high abundance so as to facilitate robust detection; (4) are human 
specific in their primary amino acid sequence.  
Following the above criteria, each protein was examined in order to select two to 
three diagnostic peptides. In some cases, this was a relatively straightforward process. 
The presence of statherin, for instance, is based on the detection and identification of only 
one peptide. While two to three diagnostic peptides per protein are typically optimal for 
targeted assays, this single peptide (shown in red below) represents approximately 50% 
of the entire sequence of the statherin protein (MKFLVFAFILALMVSMIGADSSEEK 
FLRRIGRFGYGYGPYQPVPEQPLYPQPYQPQYQQYTF) and it has been consistently 
identified in samples from multiple individuals.  
The selection of optimal peptides for other biomarker proteins, such as cystatin-
SA, was relatively straightforward as there were only a select few peptide sequences that 
were consistently detected in the Q-TOF analysis of the unfractionated protein samples. 
Table 5 shows the results obtained from three independent analyses of unfractionated 
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salivary protein samples. The cystatin-SA derived peptides 
SQPNLDTCAFHEQPELQKK, QLCSFQIYEVPWEDR, and IIEGGIYDADLNDER 
were consistently detected in all three runs and thus represent optimal diagnostic peptides 
for their parent protein. 
Table 5 – Cystatin SA identification Results for Three QTOF Injections of Unfractionated Saliva Proteins. 
Sample Peptide Modifications 
Spectrum 




IIEGGIYDADLNDER   2.30E+05 18.91 79.6 2 846.906 11.9 
QLCSFQIYEVPWEDR C:Carbamidomethylation 1.74E+05 16.73 92.5 2 985.458 19.8 
QLCSFQIYEVPWEDR C:Carbamidomethylation 1.57E+05 16.47 85.2 3 657.309 19.8 
SQPNLDTCAFHEQPELQKK C:Carbamidomethylation 1.07E+07 15.69 74.7 4 568.282 10 




IIEGGIYDADLNDER   2.61E+05 23.06 91 2 846.91 11.7 
QLCSFQIYEVPWEDR C:Carbamidomethylation 1.28E+05 13.88 74.6 2 985.456 19.7 
QLCSFQIYEVPWEDR C:Carbamidomethylation 1.28E+05 14.56 74.6 2 985.456 19.8 




ALHFVISEYNK   1.09E+06 9.14 65.2  3 440.901 18.1 
IIEGGIYDADLNDER   5.17E+05 12.78 70.7  2 846.905 11.8 
QLCSFQIYEVPWEDR C:Carbamidomethylation 3.65E+05 16.45 86.5  3 657.307 19.8 
SQPNLDTCAFHEQPELQKK C:Carbamidomethylation 5.12E+06 8.82 50.8  3 757.364 10 
SQPNLDTCAFHEQPELQKK C:Carbamidomethylation 5.51E+06 10.96 55.3  3 757.364 10 
 
In other cases, peptide selection was more complicated due to the sheer number of 
potential targets that were identified. Large and highly abundant proteins such as 
semenogelin and hemoglobin produced more than 30 viable peptide targets. In these 






3.2.2.3 Q-TOF Method Development 
With proteins and peptides selected, an optimal analytical gradient needed to be 
designed for the multiplex assay. Once an optimal gradient was chosen, replicates for 
each body fluid were then run in order to identify the exact retention time at which each 
target peptide eluted into the mass spectrometer. Using the mass-to-charge ratio and 
retention time data, a Q-TOF inclusion list was generated that made it possible to 
selectively target each peptide for each biomarker for each body fluid of interest.  
The original Q-TOF analysis of unfractionated protein samples employed a 44-
minute analytical run. While this method was successful in identifying numerous 
biomarker candidates for each body fluid that was analyzed, it was postulated that the 
chromatographic separation could be improved to spread out the elution time of the 
peptides into the mass spectrometer. Using the original method as a starting point four 
similar gradients were tested as well as a shorter 22-minute method. (Table 6).  
Table 6 – Four Analytical Gradients Tested. 
Gradient 1 Gradient 2 Gradient 3 Gradient 4 
Original 40 minute Short 22 minute Modified 40 minute Modified 40 minute 
Time % Organic Time % Organic Time % Organic Time % Organic 
0 3 0 3 0 3 0 3 
1 10 1 10 1 6     
33 45 20 45 33 38 33 38 
35 80 20.1 80 35 80 35 80 
40 80 23 80 40 80 40 80 
40.1 3 23.1 3 40.1 3 40.1 3 
 
In an attempt to speed sample throughput, a 22-minute gradient (gradient 2) was 
built and tested against all target fluids. For most fluids, this offered a substantial increase 
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in speed with no chromatographic or detection issues when identifying the target 
proteins. However, problems arose with saliva using the faster throughput methods. The 
saliva proteome consists of a considerable number (~50% of the total protein content) of 
small, hydrophilic, low molecular weight proteins
[207]
. Using reverse-phase conditions 
hydrophilic peptides are retained weakly whereas hydrophobic peptides are retained 
strongly and elute later in the run. This translated into column overloading issues (Figure 
27) in which the majority of the salivary peptides overloaded the column and the mass 
spectrometer at the front end of the run.  
 
Figure 27 – An irresolvable MS scan reflective of column overloading by small, hydrophilic, low molecular weight 
salivary proteins on a fast 22-minute gradient.  
 Poor chromatograph and column overloading result in poor peak shapes, non-
reproducible retention times, as well as ion suppression. Because of this overloading 
issue, the original 40-minute gradient was revisited and optimized.  Figure 28 represents 
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three gradients tested for replicate saliva injections. Gradient 1 is the original one used 
for the unfractionated experiments. It is clear that from approximately 25 minutes to 40 
minutes very few peptides are eluting into the mass spectrometer essentially “wasting” 
instrument run time. To address this, two additional methods were created and tested to 
improve the overall chromatography. From the results, gradient 3 (Center, Figure 28) 
was selected as the optimal method because the overloading issues were alleviated with 
the greatest peptide distribution of any of the methods tested.   
 
Figure 28 – Three 40-minute gradients tested for chromatography optimization. Gradient 1 (top) is the original used 
for the unfractionated experiments where Gradient 3 (center) and Gradient 4 (bottom) represent modifications of 
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this gradient.  Gradient 3 (center) was selected due to optimal peptide distribution across the chromatographic 
separation. 
With a gradient selected, two samples from each fluid were run in order to 
identify the exact retention time in which each peptide eluted into the system. Once 
located, peptide m/z, retention time, as well as charge was used to compile an inclusion 
list for each body fluid – a table which the instrument uses to target specific “diagnostic” 
peptide targets (Tables 7A-E). For each body fluid, the inclusion list describes the 
candidate proteins being assayed, their corresponding target peptides, retention times, and 
exact mass-to-charge ratios. The target ion inclusion lists for each “singleplex” body fluid 
assay were then tested before being combined into the final multiplex assay. This process 
resulted in the development of the final multiplex assay illustrated in Figure 29.    
Table 7A – Peripheral Blood Peptide Inclusion List 
Protein 
Biomarker 






LLVVYPWTQR 637.8732 2 20.8 
VVAGVANALAHKYH 483.9403 3 12.4 
GTFATLSELHCDK 739.8534 2 14.4 
Complement 
C3 
TMQALPYSTVGNSNNYLHLSVLR 860.1049 3 23.43 
VYAYYNLEESCTR 834.3748 2 14.77 
VFLDCCNYITELR 851.9012 2 21.4 
Hemopexin 
NFPSPVDAAFR 610.8107 2 18.3 






Table 7B – Saliva Peptide Inclusion List 
Protein 
Biomarker 





IIEGGIYDADLNDER 846.9146 2 17.5 
SQPNLDTCAFHEQPELQKK 757.3652 3 14.5 
QLCSFQIYEVPWEDR 985.4583 2 26.3 
Cystatin D 
SQPNLDNCPFNDQPK 887.3956 2 13.8 





GPYPPGPLAPPQPFGPGFVPPPPPPPYGPGR 776.1541 4 28.8 
IPPPPPAPYGPGIFPPPPPQP 710.7205 3 25.25 
Statherin FGYGYGPYQPVPEQPLYPQPYQPQYQQYTF 1215.8982 3 28.4 
Histatin-1 EFPFYGDYGSNYLYDN 982.4056 2 26.27 
 
 
Table 7C – Seminal Fluid Peptide Inclusion List 
Protein 
Biomarker 





KQGGSQSSYVLQTEELVANK 722.7071 3 18.5 
DIFTTQDELLVYNK 842.9264 2 23.45 
Semenogelin 2 
DVSQSSISFQIEK 734.3714 2 18.31  
DIFTTQDELLVYN 842.9264 2 24.1 
PSA 
VMDLPTQEPALGTTCYASGWGSIEPEEFLTPK 1175.5551 3 30.5 
AVCGGVLVHPQWVLTAAHCIR 586.8051 4 24.2 
LSEPAELTDAVK 636.8399 2 16.75 
Prostatic Acid 
Phosphatase 
ELSELSLLSLYGIHK 567.9866 3 28.5 
FQELESETLKSEEFQK   16.3 
SPIDTFPTDPIK 665.8475 2 19.35 
Glycodelin 
VHITSLLPTPEDNLEIVLHR 574.8187 4 27.3 




AVVHGILMGVPVPFPIPEPDGCK 810.7632 3 32.2 







Table 7D – Urine Peptide Inclusion List 
Protein 
Biomarker 






GDSVVYGLR  927.9524 2 13 
QLYNKYPDAVATWLNPDPSQK 816.7445 3 23.8 
AIPVAQDLNAPSDWDSR 927.9533 2 20.5 
Uromodulin 
 
VLNLGPITR 491.8078 2 18.2 
STEYGEGYACDTDLR 868.8572 2 13.1 
DGPCGTVLTR  538.2658 2 10.21 
 
Table 7E – Vaginal Fluid / Menstrual Fluid Peptide Inclusion List 
Protein 
Biomarker 






GYQVCPVLADIECR 840.3965 2 22.4 
AQAQPGVPLGELGQVVECSLDFGLVCR 967.1501 3 36.51 
AAGGAVCEQPLGLECR 844.3968 2 14.8 
Cornulin 
ISPQIQLSGQTEQTQK 893.4706 2 13.4 
TLSESAEGACGSQESGSLHSGASQELGEGQR 1036.125 3 21.35 
IgGFc-binding 
protein 
APGWDPLCWDECR 831.3529 2 25.3 
SLAAYTAACQAAGVAVKPWR 697.6999 3 22.2 




DGVTGPGFTLSGSCCQGSR 971.925 2 16.02 
GLDLHGLLAFIQLQQCAQDR 766.0686 3 32.2 









SYPGLTSYLVR 628.3402 2 21.2 
TFVPGCQPGEFTLGNIK 622.3172 3 22.6 
Suprabasin 
ALDGINSGITHAGR 461.2476 3 12.4 



































































































































































































































































































































































































Analysis of a representative urine sample is shown in Figure 30.  
Chromatography and database search results revealed the identification of the two 
targeted biomarkers for urine (osteopontin and uromodulin) with no non-urine associated 
proteins detected.   
Results obtained with samples of the other five body fluids also proved to be of 
high quality and specificity (Figures 31-35). Specifically, the analysis of a representative 
seminal fluid sample resulted in the detection of semenogelin I/II, prostate specific 
antigen, epididymal secretory protein E1, and prostatic acid phosphatase. No non-seminal 
fluid associated proteins were detected (Figure 31).  
The multiplex assay of a representative saliva sample produced results that 
revealed the presence of mucin 5B, cystatin SA, cystatin D, submaxillary gland androgen 
regulated protein, statherin and histatin-1.  Here again, no unexpected non-saliva 
associated protein was detected (Figure 32). It should be noted that while mucin 5B was 
proposed to be a vaginal-associated protein.  
Analysis of a vaginal fluid sample revealed the presence of the targeted markers 
cornulin, IgGFc-binding protein, Ly6/PLAUR containing protein 3, neutrophil 
gelatinase-associated lipocalin, suprabasin, and matrix metallo-proteinase-9. No 
unanticipated non-vaginal associated proteins were detected (Figure 33). As noted above, 
mucin 5B is a vaginal secretion- associated protein; but was identified in saliva as well. 
Similarly, cornulin, also appears in menstrual blood.  
The multiplex assay of a representative menstrual blood sample resulted in the 
detection of the target ions for complement C3, hemoglobin subunit beta, hemopexin, and 
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cornulin (Figure 34). Because menstrual blood contains peripheral blood as a major 
component, it was anticipated that all of the peripheral blood markers would also appear 
in this sample. In addition to the peripheral blood proteins, cornulin was also detected in 
this sample. This biomarker was initially employed as a prospective vaginal fluid-specific 
marker. It is not clear whether its detection in menstrual blood is the result of mixing 
between the menstrual blood and vaginal fluid during collection or if cornulin is also a 
component of menstrual blood. In either event, the ability to detect cornulin in these cases 
has potential utility for identifying vaginal sourced samples.  
Finally, the analysis of a representative peripheral blood sample resulted in the 
unambiguous detection of complement C3, hemoglobin subunit beta and hemopexin 
(Figure 35).  Aside from the expected occurrence of these proteins in menstrual blood, 




Figure 30 - TOP - Raw Q-TOF multiplex data indication of a urine hit.  BOTTOM – Database search results indicate 
high-confidence confirmatory identification: Human urine. All targeted urine biomarkers were detected. No 
biomarkers indicative of other body fluids were detected 
 
Figure 31 TOP – Raw Q-TOF multiplex data indication of a seminal fluid hit.  BOTTOM – Database search results 
indicate high-confidence confirmatory identification: Human seminal fluid. All targeted seminal fluid biomarkers 




Figure 32 - TOP - Raw Q-TOF multiplex data indication of a saliva hit.  BOTTOM – Database search results indicate 
high-confidence confirmatory identification: Human saliva. All targeted saliva biomarkers were detected. No 
biomarkers indicative of other body fluids were detected. 
 
 
Figure 33 - TOP - Raw Q-TOF multiplex data indication of a vaginal fluid hit.  BOTTOM – Database search results 
indicate high-confidence confirmatory identification: Human vaginal fluid. Targeted vaginal fluid biomarkers were 




Figure 34 - TOP - Raw Q-TOF multiplex data indicating a possible menstrual blood hit.  BOTTOM – Database search 
results indicate high-confidence confirmatory identification: Human blood biomarkers and a moderate-specificity 
vaginal fluid biomarker. No biomarkers indicative of other body fluids were detected. Taken together, these results 
may indicate the presence of menstrual blood or a mixture of peripheral blood and vaginal fluid. 
 
Figure 35 - TOP - Raw Q-TOF multiplex data indication of a blood hit.  BOTTOM – Database search results indicate 
high-confidence confirmatory identification: Human blood. All targeted blood biomarkers were detected. No 
biomarkers indicative of other body fluids were detected. 
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3.2.3 Single-Source Population Study 
The applicability of the candidate biomarkers requires thorough verification for 
stain specificity across a larger population sample. To assess this, multiplexed Q-TOF 
analyses of single-source body fluid samples from a sample population of fifty human 
research participants were used. This made it possible to assess the frequency at which 
target biomarkers may be detected in both target and non-target body fluids.  The results 























Table 8 - Results of the targeted ion Q-TOF 6-body fluid multiplex assay. Targeted biomarkers are listed 
across the top of the figure and the body fluids tested are listed along the right side of the figure.  
Green cells indicate protein biomarkers that display high-specificity for their target body fluid and 
which were detected in all samples tested. Yellow cells indicate protein biomarkers that were detected 
in less than 100% of their target body fluid samples. Red cells indicate cases where a specific biomarker 




3.2.3.1 Seminal Fluid 
Seminal fluid biomarkers semenogelin I/II, epididymal secretory protein E1, 
prostatic acid phosphatase and prostate specific antigen were consistently detected in all 
semen samples. These markers were undetectable in non-target body fluids with a few 
exceptions. Semenogelin I/II, epididymal secretory protein E1, prostatic acid phosphatase 
and prostate specific antigen were observed in 20-80% of male urine samples and 
epididymal secretory protein E1 was observed in 4% of female urine samples.  
Seminal fluid donors were instructed to refrain from ejaculation for 24 hours prior 
to urine collection, although compliance was based only on self-reporting. It is possible 
that some seminal fluid proteins may persist in the male urinary/reproductive tract. This 
may be due to leakage from the reproductive system or residual proteins from a prior or 
nocturnal ejaculation. The seminal fluid proteins employed as biomarkers in the current 
study have also been observed in other urinary proteomics studies involving male 
subjects
[208]
. Even though these proteins have been detected in non-target body fluids, Sg 
I/II, SAP and PSA/p30 were only identified in male-derived samples. Interestingly, no 
urine-specific markers were detected in any seminal fluid sample. This leads to the 
conclusion that at a minimum, these seminal fluid biomarkers may have utility in tracing 
source of the stain to the male genitourinary tract.  
The candidate seminal fluid biomarker Epididymal secretory protein E1, however, 
was detected in female urine at nearly the same rate as in male urine samples. It was not 
possible based on the assays performed to determine if this represented an endogenous 
component of vaginal fluid or urine, or if the detected protein represented residual protein 
from a prior sexual encounter though this seems less likely. As with male participants, 
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females were instructed to refrain from sexual intercourse for 5 days prior to the 
collection of urine, vaginal fluids and menstrual blood. As a result of these findings, 
epididymal secretory protein E1 cannot be considered specific to seminal fluid or even 
males. Accordingly, it was eliminated as a marker of seminal fluid.  
3.2.3.2 Saliva 
Saliva candidate biomarkers consisted of cystatin SA, cystatin D, submaxillary 
gland androgen-regulated protein, histatin-1, and statherin. Of these markers, several 
showed a high degree of target fluid specificity and consistency of detection across the 
expanded donor population. Submaxillary gland androgen-regulated protein was detected 
in 100% of saliva samples; cystatin SA and statherin were identified in ≥90% of the 
samples and; Cystatin D was identified in 76% of samples and processed on the Q-TOF.  
Improvements in assay sensitivity (e.g. use of a QQQ platform) may allow for more 
consistent detection of cystatin SA, cystatin D, as well as statherin. In contrast to these 
results, histatin 1 was only detectable in 30% of samples assayed. Based on the low 
identification rate achieved for histatin 1 in the samples tested, the decision was made to 
remove it from further consideration as a reliable biomarker of saliva. 
3.2.3.3 Urine 
Urine candidate biomarkers uromodulin and osteopontin were detected in all male 
and female urine samples. These two proteins were not detected in any samples of non-
target body fluids. Uromodulin and osteopontin appeared to be well-suited, reliable and  




3.2.3.4 Vaginal fluid 
Vaginal fluid biomarker candidates included cornulin, IgGFc-binding protein, 
neutrophil gelatinase-associated lipocalin, Ly6/PLAUR containing protein 3, suprabasin, 
and matrix metalloproteinase-9. Of these, cornulin, neutrophil gelatinase-associated 
lipocalin and Ly6/PLAUR containing protein 3 were detected in 100% of samples 
assayed. IgGFc-binding protein was detected in 68% of samples, matrix metallo-
proteinase-9 in 20% of samples, and suprabasin was detected in 22% of samples analyzed 
on the Q-TOF. Other than the anticipated non-target identification of cornulin, neutrophil 
gelatinase-associated lipocalin and Ly6/PLAUR containing protein 3 in samples of 
menstrual blood.  
Of these markers, mucin5B was detected consistently in other non-targets body 
fluids analyzed (i.e., saliva and menstrual blood).  It was initially hypothesized that 
mucin 5B would be specific to vaginal fluid. However, it was also detected in 20% of 
menstrual blood samples as well as 4% of male/female urine samples. From these results 
it is unlikely that mucin 5B will offer any discriminatory power with regard to body fluid 
identification.  
3.2.3.5 Menstrual Blood 
As discussed in the method development section, there were no reliable markers 
which could definitively differentiate menstrual fluid/blood from vaginal fluid. It was 
hypothesized that vaginal fluid markers may allow the differentiation of menstrual blood 
from other fluids – with differentiation from peripheral blood being particularly 
important. However, cornulin, neutrophil gelatinase-associated lipocalin and 
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Ly6/PLAUR containing protein 3, were only found in 30%, 6%, and 4% of menstrual 
blood samples assayed, respectively. This may be due to the complexity of the blood 
proteome and sensitivity limits of the Q-TOF method. Accordingly, these markers should 
be reevaluated for their potential utility from the perspective that a more sensitive assay 
may allow reliable detection of these proteins. That being said, it must be emphasized   
that without a 100% specific menstrual blood protein biomarker, it is impossible to 
differentiate between menstrual blood vs. a mixture of peripheral blood and vaginal fluid. 
3.2.3.6 Peripheral Blood 
Biomarker candidates for peripheral blood included hemoglobin subunit beta, 
complement C3, and hemopexin. Hemoglobin and complement C3 were detectable in all 
peripheral blood samples while hemopexin was identified in 96% of analyzed samples.  
These markers, however, were also detectable in several non-target body fluids 
including menstrual fluid/blood, vaginal fluid, female urine and saliva. It was expected 
that these candidates would be detected in menstrual fluid as peripheral blood is a major 
component of this fluid. Hemoglobin subunit beta, complement C3, and hemopexin were 
detected in 100%, 54% and 76% of menstrual blood samples. The lower rate of detection 
of some of these proteins in menstrual fluid is thought to be due to matrix suppression by 
proteins derived from cellular/endometrial tissues. Blood detection in vaginal fluid, 
female urine, and saliva may be due to trace amounts of these proteins in these fluids due 
to small abrasions from normal activities such as the use of dental floss, or feminine 
hygiene products. Additionally, hemoglobin, complement C3, and hemopexin have been 
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documented in some salivary, vaginal fluid, and urinary proteomics projects aside from 
the findings presented here
[146, 209]
.  
3.2.4 Casework-Type Samples  
Laboratory samples from the completed population study were used to identify those 
biomarkers which demonstrated the highest degree of consistency and target fluid 
specificity. While these laboratory samples facilitated the selection of the most promising 
biomarkers for further validation, they did not assess the use of a mass spectrometry 
platform for the processing of samples under conditions typically encountered in a 
forensic lab. In order to address this gap, a series of studies were performed to evaluate 
the reliability of biomarker detection in a forensic context. More specifically, samples 
were assayed to determine whether or not the selected biomarkers could be recovered 
from a variety of substrates such as cotton, leather or denim and items typically 
associated with sexual assaults and then accurately identified. Samples were also 
prepared to determine the extent to which body fluids exposed to a variety of 
environmental and chemical contaminants could be accurately identified. Finally, 
mixtures containing two to three different body fluids were prepared and assayed to test 
the overall reliability of the multiplex assay to reliably detect multiple biomarkers in a 
single-pass assay.  In all, 37 casework-type samples were analyzed in order to gain an 
initial assessment of the applicability of the method for use by forensic practitioners 
(Tables 9 and 10). These samples were divided into five specific categories including 
single source body fluids extracted from swabs, substrate extractions, volume-based 
mixtures, and contaminant extractions.  
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3.2.4.1 Single Source Swabs 
For each body fluid of interest, a 50 µL aliquot of untreated sample was applied to 
a cotton swab which was then allowed to dry in accordance with standard practices 
employed by caseworking laboratories. Prior to testing, the dried sample was re-
suspended in phosphate buffered saline. Summarized results can be seen in Table 9. 
Saliva, semen, vaginal fluid, peripheral blood and urine spotted onto cotton swabs were 
accurately identified by one or more body fluid specific proteins. Unfortunately, no 
vaginal-specific proteins were identified in the menstrual blood swab assayed. Inclusion 
of vaginal proteins in the menstrual blood sample could support an interpretation that the 
source of the sample had been in contact with the vaginal canal, but without an 
identification of any of these proteins it was impossible to differentiate menstrual blood 
from peripheral blood. Finally, aside from the anticipated epididymal secretory protein 
E1 which was detected in urine, no unexpected proteins were identified in any of these 
body fluids.  
3.2.4.2 Single Source Substrate Studies 
For each body fluid of interest, 50 µL of sample was added to a variety of 
commonly encountered substrates which were then allowed to dry in accordance with 
standard practices employed by caseworking laboratories. Prior to testing, the dried 
sample was re-suspended in phosphate buffered saline. Summarized results can be seen 
in Table 9. As was seen with single-source samples spotted on cotton swabs, saliva, 
semen, vaginal fluid, peripheral blood and urine were accurately identified although 
menstrual blood could not be differentiated from peripheral blood.  
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As expected, epididymal secretory protein E1 was detected in the urine sample 
that was tested. In addition to epididymal secretory protein E1, Ly6/PLAUR containing 
protein 3 was also detectable in all three saliva samples (i.e., cigarette butt, mouth of 
bottle, and swab of saliva stained finger). Based on prior work this protein had been 
considered a vaginal fluid-specific biomarker. Upon further research, it was found that 
Ly6/PLAUR containing protein 3 has also been identified in the squamous esophageal 
epithelium – though specifically in relation to esophageal cancer
[210]
. The detection of 
this protein in a non-target body fluid at this stage of the research is likely due to the 
modified collection protocols for the casework samples. In the population study, saliva 
was collected using an absorbent cotton sponge that was placed next to the salivary ducts. 
It is thought that this process produces a pure and cell-free saliva solution. To more 
realistically simulate what would be seen in an actual forensic context, saliva samples 
were deposited directly from the mouth into a 50 mL collection tube before application 
onto the cotton swab and other substrates. This modified method deposited a greater 
amount of cellular material and protein from the oral cavity which may account for the 
detectible presence of Ly6/PLAUR containing protein 3. This unexpected result 
highlights the importance of conducting studies on casework-type samples.  
3.2.4.3 Volume Mixtures 
Six, two-component mixtures of human body fluids were run on the multiplex 
assay to evaluate potential matrix interference between the proteins of different body 
fluids. Summarized results can be seen in Table 10. In all but one case (i.e., a mixture of 
equivalent volumes of saliva and peripheral blood), at least one biomarker for each body 
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fluid present in the mixture was detected. This loss of detection is likely due to the 
quantitative difference in protein content between saliva and peripheral blood when 
mixed in equal volumes. The total protein content of saliva is approximately 1.3 mg/mL 
while the protein concentration in peripheral blood is approximately 120 mg/mL. 
Applying 25 µl of saliva to the swab results in ~32 µg of total saliva protein on the swab 
compared to ~3,000 µg of total blood protein onto the swab. Based on these values it is 
likely that there is not enough saliva protein to reliably detect it against the background of 
more abundant blood proteins.  
3.2.4.4 Contaminant Studies 
A series of single-source body fluid samples were also assayed for the influence 
of chemical additives and/or inhibitors on biomarker detection. These chemical additives 
included spermicidal lubricant commonly found on condoms and sexual assault swabs; 
BlueStar
®
 which is commonly employed in screens for blood, soil and chewing tobacco 
juice which contain potent inhibitors of some enzymes; coffee which is encountered in 
some beverage adulteration cases and; chewing gum. Summarized results can be seen in 
Table 10. Of the inhibitors assayed, only chewing tobacco juice appeared to prevent the 
identification of saliva. This was not entirely unexpected given that tobacco juice is also 
known to act as a potent inhibitor of DNA typing chemistries due to its action on Taq 
polymerase. Aside from saliva which has a low overall protein content, no interference of 





Table 9 - Results of the Q-TOF multiplex assays using casework-type samples. Targeted biomarkers are 
listed across the top of the figure and the description of the type of body fluid and substrate are 
provided along the right side of the figure.  Green cells indicate protein biomarkers that were detected. 
Red cells indicate protein biomarkers that were not detected.  (VF: vaginal fluid; MB: menstrual blood; 






Table 10 - Results of the Q-TOF multiplex assays using casework-type mixed-source samples and 
samples containing mixtures. Green cells indicate protein biomarkers that were detected. Red cells 
indicate protein biomarkers that were not detected. (VF: vaginal fluid; MB: menstrual blood; PB: 





The second phase in the proteomics pipeline was to assess the biological applicability 
of candidate biomarkers to their intended use. In the case of the current research, the two 
major objectives were to assess whether the candidates were specific to their target body 
fluid as well as to determine whether the biomarkers could be reliably and consistently 
detected in a larger population of donors.  In addition, because the overall goal of this 
project is to replace traditional/non-specific forensic serological tests with a confirmatory 
multiplex assay, it was also necessary to assess the viability of a mass spec-based assay 
for processing forensic-type samples.  
To assess the specificity and consistency of the initial biomarker candidates, twenty 
one of the most promising protein markers identified during the discovery phase were 
selected for inclusion in a multiplex validation assay. These markers consisted of six 
seminal fluid candidates, two urine candidates, six saliva candidate biomarkers, seven 
vaginal/menstrual fluid candidates as well as three peripheral blood candidate 
biomarkers. Using these proteins, a 44-minute targeted ion assay was designed and tested 
with single-source laboratory samples collected from fifty human donors. Results from 
this study identified several biomarkers which were both target-fluid specific and which 
were consistently detected in all donor samples. In these studies, several candidate 
markers which were non-specific for the target body fluid or were inconsistently detected 
in an expanded population of human donors were also identified and subsequently 
eliminated from further consideration as forensic biomarkers. In addition to the 
population study, a series of casework-type samples were also processed in order to 
evaluate the performance of the prototype targeted-ion Q-TOF method for use in a 
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caseworking laboratory. Of these casework-type samples, detection of the target 
biomarkers made it possible to correctly identify the body fluid components in all but a 
select few challenging samples.   
Overall, this series of experiments was able to successfully assess the specificity, 
consistency, and applicability of a mass spectrometry-based forensic assay for body fluid 
identification.   However, even with these successes, a number of serious limitations to 
the instrument’s performance were recognized that may act as barriers to adoption by 
practitioners in forensic testing laboratories. Most significantly, the instrument is not 
optimally engineered for multiplex assays
[211]
 and at a top speed of 44-minutes/sample 
and one sample/run it is not well suited to the higher throughput needs of most forensic 
laboratories. With this limitation of speed in mind, a different mass spectrometry-based 
platform may be a superior choice to meet the throughput requirements of a typical 
caseworking lab. Triple quadrupole mass spectrometers performing multiple reaction 
monitoring (QQQ-MRM) have become the “workhorse” instrument for high-throughput 
clinical and toxicological screening. This is due to advantages in sensitivity, selectivity, 
easier operation and lower cost of these instruments compared to Q-TOFs. In addition, 
QQQ instruments offer faster analytical gradients which can match the needs of a 
caseworking/production lab. Therefore, the next step in the dissertation research was to 
develop a QQQ multiplex assay incorporating the optimal biomarkers identified in the 

























The current dissertation research has followed the traditional proteomics research 
and development pipeline beginning with the discovery of candidate biomarkers for body 
fluid identification through verification of the candidate biomarker specificity and 
reliability. The biomarker discovery phase resulted in the generation and characterization 
of a panel of over thirty candidate biomarkers for the identification of biological stains. 
During the biomarker verification phase, a novel Q-TOF assay was designed to verify the 
specificity of the most promising biomarker candidates across a larger population of 
human donors. The Q-TOF verification phase was able to successfully confirm the 
specificity of many of protein biomarkers while also flagging several proteins which 
displayed a detectible presence in non-target biological fluids; thus eliminating them as 
high-specificity biomarkers. Additionally, the viability of a mass spectrometry-based 
serological assay for adoption was successfully assessed using casework-type samples. 
The data from the first two phases of this research and development effort produced a 
panel of body fluid-specific biomarkers which can be reliably detected using mass 
spectrometry. The next step in the research and development process, with an emphasis 
on “real-world” application, was a full developmental validation to assess the reliability, 
reproducibility, accuracy, sensitivity and limitations of a mass spectrometry-based assay 
for human stain identification. The overarching goal of this final stage of development 
being the implementation of an MS-based serological assay for forensic laboratory use. 
While the Q-TOF assay was successfully able to confidently identify a biological 
stain, the instrument is not well suited for multiplex assays or the throughput required by 
a caseworking laboratory. Due to these critical limitations, a developmental validation 
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study using this instrument would be inadvisable for a laboratory implementation 
perspective. However, in recent years triple quadrupole mass spectrometers performing 
multiple reaction monitoring (QQQ-MRM) have been considered to be the new  
“workhorse” instrument for proteomics validation assays, clinical laboratory testing, and 
confirmatory testing of illicit substances in toxicology laboratories. This is due to their 
greater sensitivity, greater selectivity, easier operation, and lower cost of operation and 
ownership compared to the Q-TOF.   
The use of the QQQ-MRM platform provides analysts with much greater 
confidence in the accuracy of the results obtained for a given stain. This is because each 
individual body fluid is identified based on the presence of multiple biomarker proteins 
(e.g. statherin and cystatin-SA for saliva). The presence of each biomarker protein itself 
is based on the detection of multiple diagnostic ions (i.e. precursor ions) that are derived 
from the original biomarker protein by trypsin digestion. The presence/identity of each 
precursor ion is then independently reconfirmed by detection of its breakdown products 
(i.e. product ions). The two-fold filtration mechanism in these interments leads to a much 
more sensitive assay when targeting specific analytes. Additionally, this internal 
confirmation and reconfirmation of targets stands in sharp contrast to existing 
commercial forensic assays where identification is typically based on the indirect 
detection of a single binding event between an antibody and its presumed target protein.  
The following chapter will focus on the development and testing of a QQQ-MRM 
prototype assay for the identification of seminal fluid, saliva, and vaginal fluid (i.e., a 
“sexual assault” targeted assay) in laboratory- and casework-type samples. Additionally, 
a workflow was developed in order to simultaneously process evidentiary material for 
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STR-based DNA analysis (for stain individualization) coupled with an MS-based 
serological identification.  
 
4.1 Materials and Methods 
All research conducted under this project was reviewed, approved by the 
University of Denver Institutional Review Board (IRB) for research involving human 
subjects and conducted in full compliance with U.S. Federal Policy for the Protection of 
Human Subjects.  In total, 100 subjects (50 males and 50 females) were recruited from 
the undergraduate population at the University of Denver. Female donors were 
compensated $80 and males $20 for their participation in the research study. All research 
volunteers agreed and signed a letter of informed consent acknowledging they have 
received, read, and understood the protocols involved in the collection of samples. 
Additionally, all donated samples were given a random alphanumeric label to ensure 
confidentiality. Finally, males were instructed to refrain from ejaculation for 24 hours 
prior to sample collection and all donors were instructed to refrain from sexual 
intercourse for 5 days prior to the collection of urine, and vaginal fluids and menstrual 
blood for females. 
4.1.1 Sample Collection and Preparation 
An overview of the workflow performed from sample collection through biomarker 
identification is provided in Figure 36.  Saliva, seminal fluid, and vaginal fluid, were self 
collected by study participants. After collection, samples were centrifuged and filtered to 
remove cellular material and quantified for total protein. Samples were divided into 10-




Figure 36 - Overview of QQQ Prototype phase from sample collection to protein identification. Briefly, samples 
were collected and cellular debris removed via centrifugation and filtration. Samples were quantified for total 
protein and analyzed by mass spectrometry. 
4.1.2 Body Fluid Identification 
4.1.2.1 Trypsin Digestion and Peptide Cleanup 
Trypsin digests and C-18 cleanup was performed as described in sections 2.1.3.2 
and 2.1.3.3. 
4.1.2.2 QQQ MS/MS Acquisition 
Mass spectrometry was performed on an Agilent Technologies 6410 triple 
quadrupole mass spectrometer. The method employed a 150 x 1.0 mm 3.5um 300SB-C18 
analytical column with 12.5 x 2.1mm 5µM SB-C8 enrichment column. Solvent A 
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contained H20 with 0.1% formic acid and Solvent B contained a 90:10 mixture of 
acetonitrile:H20 with 0.1% formic acid. Samples were initially loaded on an enrichment 
column at a flow rate of 0.2 mL/min with flow through going to waste. At 1 minute, the 
column was switched to analysis mode with Buffers A and B passing through both the 
enrichment and analytical columns with a gradient of 5-35% Buffer B over 15 minutes. 
This was followed by 80% Buffer B from 15.01 minutes to 16 minutes and 100% Buffer 
B from 16.01 minutes to 17.01 minutes. A 5-minute post-gradient run was performed to 
re-equilibrate the column.    
4.1.2.3 QQQ Data Analysis 
Data analysis was performed using Agilent MassHunter QQQ Quantitative 
software as well as the Skyline targeted proteomics environment.  
4.1.3 Preparation and Analysis of Casework-Type Samples 
All casework-type samples were prepared as described in section 3.1.3 and 
analyzed using the methods described in section 4.1.2. 
4.1.4 Combined DNA Typing and Serological Analysis 
Mixtures and swabs were prepared as described previously with the following 
minor modification. After the cellular centrifugation step, the supernatant was removed 
and processed for protein analysis. The cellular pellet (i.e., DNA-rich material) was 





4.1.4.1 DNA extraction on BioRobot EZ1 
Genomic DNA was extracted by paramagnetic isolation using the using the 
manufacturer’s recommended protocol for the EZ1 DNA Tissue kit (Qiagen, Valencia, 
CA). Briefly, 190 µL of proprietary Buffer G2 and 10 µL of Protinase K (activity = 600 
mAU/ml) were added to the pelleted material and incubated for 15 minutes at 56°C with 
constant shaking in and in an Eppendorf
®
 Thermomixer to lyse the cellular material. 
Insoluble material, was then pelleted by centrifugation at 300 x g for 1 minute at room 
temperature. The DNA-containing supernatant was then transferred to a new 2 ml sample 
tube and processed for DNA extraction and purification on the BioRobot EZ1 using the 
EZ1 DNA Tissue Card. 
4.1.4.2 DNA Quantitation with Quantifiler™ Duo 
Quantifiler™ Duo (Life Technologies/ Applied Biosystems, Foster City, CA) 
primer mix (4.2 μL/sample) and PCR reaction mix (5 µL/sample) were combined to form 
a DNA quantification master mix. In addition, eight control DNA standards were 
prepared at a concentration of 50, 16.7, 5.56, 1.85, 0.62, 0.21, 0.068 and 0.023 ng/µL. For 
each quantification reaction, 0.8 µL of DNA sample or DNA control standard was mixed 
with 9.2 µL of master mix in the wells of a standard optical 96-well plate.  Wells were 
sealed with optical film and analyzed on a Life Technologies/ Applied Biosystems Prism 
7900HT Sequence Detection System. DNA quantities were determined using the 
integrated SDS v2.1.1 software.  
4.1.4.3 DNA Profiling with Identifiler™ Plus 
Identifiler™ Plus (Life Technologies/ Applied Biosystems, Foster City, CA) 
master mix (4 µL/sample) and Identifiler™ Plus primer mix (2 µL/sample) were 
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combined to form an master reaction mix for human DNA profiling by Short Tandem 
Repeats (STR) loci genotyping. For each amplification reaction, 6 µL of master mix was 
added to a 0.2 mL PCR tube followed by 4 µL of DNA extract at a concentration of 0.1 
ng/µL. The thermal cycling conditions are shown in Table 11. All amplification reactions 
were accompanied by negative and reagent blank controls. Amplified products were 
electrokinetically injected for 5 sec and fractionated on an Prism
TM
 310 Genetic Analyzer 
using the GS STR POP4 (1 mL) G5 filter set module. The electrophoresis run time of 24 
min allowed detection the 500 base pair size peak of the GS500 internal lane sizing 
standard. Data Collection Software v3.1 and Genemapper ID v3.2 (Applied Biosystems, 
Foster City, CA) were used for data collection and analysis.  



































4.2 Results and Discussion 
4.2.1 Method Development 
The first objective of this phase of the current research was to identify the optimal 
diagnostic ions to develop an “MRM sexual assault evidence assay” that targeted the 
identification of human saliva, seminal fluid, and vaginal secretions. To this end, a QQQ 
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multiplex assay for the detection of these optimal ions was then developed. While this 
approach yields very dependable single pass results, the method design and development 
process involves a substantial amount of effort to identify biologically relevant protein 
targets, optimal tryptic peptides as well as the specific product ions which the QQQ-
MRM assay can measure. The first two requirements were completed as part of the 
biomarker discovery and verification stages of the current project  
From the Q-TOF verification study, several biologically relevant proteins in 
saliva, seminal fluid, and vaginal fluid were identified as consistently detected in an 
expanded sample of human donors with little to no detection in non-target body fluids.  
Using these data (Table 8) three markers were selected for the MRM assay for each body 
fluid including: cystatin SA, statherin, and submaxillary gland androgen-regulated 
protein 3B as markers for saliva; SAP and Sg-I/II for seminal fluid; and cornulin, 
Ly6/PLAUR domain-containing protein 3, and neutrophil gelatinase-associated lipocalin 
as markers for vaginal fluid. Since these markers had been examined previously, the 
optimal peptides for each protein were already known (Tables 7A-7E) and were readily 
ported for the development of a QQQ assay. This is because the peptides that had been 
selected for the Q-TOF assay were consistently detected in all donors in our sample 
population; displayed strong signal intensity; had high database match statistics; were 
unique to their parent protein; were devoid of missed cleavage sites; and did not include 
peptides with potential amino acid modifications including those with methionine, 
cystine, or N-Terminus glutamic acid residues. 
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The final aspect of assay design involved selection of product ions from the 
peptide fragmentation. Peptide exact mass as well as a unique fragmentation pattern was 
what the Q-TOF used to confirm the detection of a specific marker. The MRM assay used 
the same fragmentation mechanism but only detected specific product ions (i.e., 
precursor-product ion pair or transition) rather than the entire product ion spectra. As a 
result, selection of the most abundant ions is needed to ensure that the greatest level of 
detection and sensitivity is achieved. Figure 37 presents the sequence-specific 
fragmentation pattern generated on the Q-TOF for the peptide 
FGYGYGPYQPVPEQPLYPQPYQPQYQQYTF which is diagnostic for the salivary 
protein marker statherin. The m/z for this peptide is 1215.2332 with a charge of +3. For 
product ion selection, high-abundance ions which are larger than the precursor m/z are 
selected.  From the fragmentation in Figure 37 the product ions 1462.6 and 1229.5 m/z 
were targeted for this Statherin peptide. Figure 38 shows the QQQ raw dataset in which a 
much cleaner signal was obtained as compared to that obtained with the Q-TOF. Using 
this same approach, the optimal precursor-product ion pairs were determined for each 




Figure 37 - In a Q-TOF assay, inclusion list precursor ions are only isolated in the first quadrupole (Q1). After the 
isolated precursor ions are fragmented in the collision cell all product ions reach the detector. These fragments 
generate a complex fragmentation spectrum which can be analyzed to confirm the presence of a particular protein 
biomarker in a database. 
 
Figure 38 - When using a QQQ in MRM mode, target-ion list precursor ions are isolated in the first quadrupole (Q1); 
fragmented and then sent to the second quadrupole (Q2) which acts as a second filter for the isolation of specific 
product ions. This two-fold filtration process greatly improves the signal-to-noise ratio for target ion detection and 
increases the sensitivity of the assay by 10-100 fold. Shown are two product ions (1462.6 and 1229.5 m/z) from 
salivary biomarker statherin peptide FGYGYGPYQPVPEQPLYPQPYQPQYQQYTF. 
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Table 12 - QQQ-MRM Transition List Targeting Seminal Fluid, Saliva and Vaginal Fluid. 
 
From the transition list in Table 12, a 16-minute method was developed. The 
assay was first run using pooled samples of saliva, seminal fluid, and vaginal fluid to 
alleviate variation between individuals. The pooled data were acquired during a single 
time segment where the instrument cycles between all precursor-product ion pairs during 
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the chromatographic run. Using this unsegmented method the instrument scans for all 
potential biomarkers across the entire chromatographic separation without taking into 
account the exact elution times for any one precursor-product ion pair. Monitoring many 
compounds simultaneously lowered the dwell (accumulation of ions) time for each 
individual precursor-product ion pair causing a loss in sensitivity. While this method was 
not optimal, it did allow for the discovery of the retention times for each of the peptides.  
Using the known retention times a method was developed to divide the targets into three 
time segments which allowed the instrument to only target ions which elute during that 
specific time segment – thereby increasing the allowable dwell time. Table 13 shows all 
targeted peptides and their location in the three time segments. 
Table 13 – Segmented Method Dividing the MRM Acquisition into Three Time Segments.  
Segment Protein Accession Peptide RT (min)
Ly6/PLAUR domain-containing protein 3 O95274 GCVQDEFCTR 5.71
Ly6/PLAUR domain-containing protein 3 O95274 TLSESAEGACGSQESGSLHSGASQELGEGQR 6.61
Cornulin Q9UBG3 ISPQIQLSGQTEQTQK 7.6
Ly6/PLAUR domain-containing protein 3 O95274 DGVTGPGFTLSGSCCQGSR 8.5
Prostatic acid phosphatase P15309 FQELESETLKSEEFQK 8.57
Cystatin_SA P09228 IIEGGIYDADLNDER 8.957
Semenogelin-2 Q02383 DVSQSSISFQIEK 9.16
Semenogelin-1 P04279 KQGGSQSSYVLQTEELVANK 9.65
Prostatic acid phosphatase P15309 SPIDTFPTDPIK 10.28
Neutrophil gelatinase-associated lipocalin P80188 SYPGLTSYLVR 10.9
Neutrophil gelatinase-associated lipocalin P80188 TFVPGCQPGEFTLGNIK 11.85
Semenogelin-1 P04279 DIFSTQDELLVYNK 11.93
Semenogelin-2 Q02383 DIFTTQDELLVYNK 11.93
Cystatin_SA P09228 QLCSFQIYEVPWEDR 13.26
Submaxillary gland P02814 IPPPPPAPYGPGIFPPPPPQP 13.47
Prostatic acid phosphatase P15309 ELSELSLLSLYGIHK 14
Statherin P02808 FGYGYGPYQPVPEQPLYPQPYQPQYQQYTF 14.41





4.2.2 Method Evaluation 
Using the segmented method, a series of single source samples were run to 
evaluate the consistency of the assay on the QQQ platform. Additionally, these samples 
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were used to develop preliminary interpretation guidelines using the Agilent Quantitative 
Analysis software to evaluate the subsequent results from the mixed and casework-type 
samples.  
A representative example of results obtained using a QQQ-MRM multiplex assay 
to identify human seminal fluid can be seen in Figure 39. Examples of assay results 
obtained for a known saliva sample (Figure 40) and a known vaginal fluid sample 
(Figure 41) illustrate the specificity and accuracy the MRM-QQQ multiplex assay.  
 
Figure 39 - QQQ-MRM multiplex results showing seminal fluid.  The assay achieved clear detection of all target ions 
indicating the high-confidence confirmatory identification of Human seminal fluid. No biomarkers indicative of 





Figure 40 - QQQ-MRM multiplex results showing a saliva hit.  The assay achieved clear detection of all target ions 
indicating the high-confidence confirmatory identification of Human saliva. No biomarkers indicative of other body 
fluids were detected. 
 
 
Figure 41 - QQQ-MRM multiplex results of a three component mixture.  The assay achieved clear detection of all 
target ions indicating the high-confidence confirmatory identification of Human vaginal fluid. No biomarkers 
indicative of other body fluids were detected. 
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While the Q-TOF identification was confirmed through matching the entire 
product ion spectra to a protein database, the QQQ identification criteria was based on 
the response of only the selected transitions for the protein.  Therefore, before analysis of 
the results, an analysis method was designed using Agilent’s Quantitative Analysis 
software. To do this, a mixture of all three samples was run and loaded into the analysis 
software. From the mixed reference sample, the retention time as well as relative 
response ratios were determined and used to analyze the rest of the samples in the batch.  
The outcomes of these experiments were consistent with results from previous 
studies conducted using a Q-TOF assay. However, because of the increased sensitivity 
associated with the QQQ platform, it became possible to detect protein biomarkers which 
might have fallen below the level of detection of the Q-TOF platform. As a result, the 
QQQ-MRM assay will provide a means of further confirming the specificity of the 
selected protein biomarkers.  
Tables 14 and 15 provide summaries of the results from the ten single-source 
assays using two different identification parameters. Table 14 shows a low-stringency 
assay in which biomarker detection was based on the presence of at least one peptide per 
protein. In contrast to this, Table 15 shows the assay results where detection was based 
on the confident identification of all peptides associated with that biomarker. Since each 
biomarker (aside from statherin) can be identified using two peptides and their associated 
fragments, the detection of both peptides represents a more stringent and thus more 




Table 14 - Frequency of protein identification in reference samples of saliva, seminal fluid and vaginal fluid (ten 
samples each). Protein identification in this table is based on at least one targeted peptide per biomarker.  
 
Table 15 - Frequency of protein identification in reference samples of saliva, seminal fluid and vaginal fluid (ten 
samples each). Protein identification in this table is based on the detection of two targeted peptides per biomarker. 
 
Detection of both peptides for a protein identification (Table 15) results in an 
identification pattern similar to what was standardized using the Q-TOF assay – although 
the QQQ-MRM assay still achieved greater sensitivity. An example of the impact of the 
greater sensitivity QQQ-MRM platform was seen with the detetction of, Ly6 which had 
initially appeared promising as a vaginal fluid biomarker. While this protein had also 
been previously identified using a Q-TOF platform in a small number of casework-type 
samples which contained saliva, its robust and unambiguous identification using the 
QQQ-MRM was to be expected.  
Biomarker identification based on the detection of only a single peptide results in 
a more complicated interpretation. Cornulin, which is involved with mucosal/epithelial 
immune response, was also detected with one peptide in three of the ten saliva reverence 
samples. While this protein had not been detected in previous experiments, it has been 
previously characterized in the esophagus where it is thought to have an association with 
oral cancer
[212, 213]
.  Its presence in a salivary sample, therefore, is not unreasonable.  
Cystatin_SA Statherin Submax Gland Semenogelin-1 Semenogelin-2 Prostatic Acid Cornulin Ly6 Neutrophil Gel
Saliva 100.00% 90.00% 100.00% 0.00% 10.00% 0.00% 30.00% 100.00% 0.00%
Seminal Fluid 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00%
Vaginal fluid 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00%







Saliva Seminal Fluid Vaginal fluid
Cystatin_SA Statherin Submax Gland Semenogelin-1 Semenogelin-2 Prostatic Acid Cornulin Ly6 Neutrophil Gel
Saliva 100.00% 90.00% 100.00% 0.00% 0.00% 0.00% 0.00% 80.00% 0.00%
Seminal Fluid 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00%
Vaginal fluid 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00%
Biomarker Identificaion - Two Peptides Detected









Detection of a semenogelin-2 peptide in a single saliva sample was unanticipated 
in an assumed “saliva only" sample and has never been seen in previous assays involving 
either the Q-TOF or QQQ.   Figure 42 shows the raw data comparing the semenogelin-2 
peptide detection in saliva sample SA044 as well as a representative hit from seminal 
fluid sample SE022. By appearance alone, it is clear that three fragment ion peaks are 
present in both samples, but the response (peak area) of the peptide in the seminal fluid 
sample is approximately 1,700 times larger. While the peak height and response are 
significantly higher in the seminal fluid sample, other qualitative information leads to the 
conclusion that the peak detected in this one saliva sample is real regardless of whether it 
is an endogenous salivary protein or not.  
Using quantitative analysis software (Table 16), the signal-to-noise ratio of the 
peptide was calculated to be 18.81 in SA044 compared to 255.57 in SE022. Typically, a 
lower limit of detection requires a signal-to-noise ratio greater than 5 to be valid. 
Additionally, the ratio between the responses of all three product ions must be within an 
accepted error limit. In this case. an uncertainly of 20% is acceptable compared to the 
reference samples. Lastly, the retention times must be the same. Using these qualifying 
parameters, there is every indication that this peptide is genuine in both the saliva and 
seminal fluid samples. While this result was not expected, there is some potential 
corroborating support in the biomedical literature.  Using an RT-PCR approach, 
Semenogelin transcripts were detected in the trachea as well as the salivary gland
[214]
. 
Whether this represents a peptide that can be reproducibly detected in a broad range of 
humans at very low levels versus an unrecognized artifact in a single study remains to be 
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determined. In addition, it is possible that this result is merely an artifact from sample 
carryover. Moving forward, this must be assessed in a full developmental validation 
study. 
 
Figure 42 - Detection of Semenogelin-2 peptide DVSQSSISFQIEK in saliva (top) and seminal fluid (bottom) 
Table 16 - Quantitative software generated values from corresponding Semenogelin-2 peptide 
DVSQSSISFQIEK hit. This information is used to determine the accuracy of a peptide identification. 
 
In order for a protein biomarker to be confidently identified, therefore, it is the 
opinion of the author that that good practice dictates that both peptides must be detected 
in a sample. It is also suggested that more samples be run in the future and that external 
standards be used as a quantitative means of assessing analyte concentrations. Finally, it 
should be noted that these samples were run on an older microflow LC-MS/MS system 
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and not on a nanoflow LC-MS/MS. If a nano LC-QQQ were to be employed on the same 
samples, sufficient sensitivity may be achieved to confidently ID the missing peptides 
and thus confidently demonstrate the presence of a given biomarker.  
4.2.3 Casework-Type Samples 
The QQQ-MRM multiplex body fluid identification assay has been successfully 
tested on a series of samples representing all targeted body fluids and a variety of 
casework-type biological stains. These included both single-source and mixed-source 
body fluid samples deposited onto a variety of substrates including denim, leather and 
nylon. To assess the potential impact of environmental/chemical insult on assay 
performance, biological stains were subjected to commonly encountered agents including 
gasoline, soil, laundry detergent and personal lubricants. The complete list of casework-
type samples that were tested can be found in Table 17.  




Positive protein identification requires both target peptides to be valid. 
 
Cystatin_SA Statherin Submaxi Gland Semenogelin-1 Semenogelin-2 Prostatic Acid Cornulin Ly6 Neutrophil Gel
CW01 - Saliva Swab
CW02 - Semen Swab
CW03 - Vaginal Swab
CW04 - Vaginal Fluid on Cotton
CW05 - Vaginal fluid on Nylon
CW06 - Seminal Fluid on Denim
CW07 - Seminal fluid on Leather
CW08 - Saliva on Cigraette
CW09 - Saliva on Bottle
CW10 - Semain Fluid with Spermicide
CW11 - Saliva with Chewing Tobacco
CW12 - Mixture Swab 1SA:3VS
CW13 - Mixture Swab 1SA:1VS
CW14 - Mixture Swab 3SA:1VS
CW15 - Mixture Swab 1SE:3SA
CW16 - Mixture Swab 1SE:1SA
CW17 - Mixture Swab 3SE:1SA
CW18 - Mixture Swab 1SE:3VS
CW19 - Mixture Swab 1SE:1VS
CW20 - Mixture Swab 3SE:1VS
CW21 - 3 Component Mixture Swab 
CW22 - 3 Component 2 Fold Dilution
CW23 - 3 Component 4 Fold Dilution 
CW24 - 3 Component 8 Fold Dilution
Biomarkers







The data obtained using casework-type samples were consistent with expected 
results as well as the results of previous Q-TOF studies. Irrespective of substrate and/or 
chemical contaminant, all of the targeted protein biomarkers appeared in the appropriate 
sample. Mixture studies were performed using cotton swabs onto which 2-component 
body fluid mixtures were prepared at three volumetric different ratios (1:3, 1:1, 3:1). At 
every mixture ratio assayed, all expected biomarkers were detected. The only 
identification of a non-specific protein occurred with the 1:1 and 1:3 seminal fluid:saliva 
mixture swabs where the vaginal fluid marker Ly6 was detected. This has been 
previously observed on the Q-TOF as well with the QQQ reference samples. This marker 
is clearly non-specific for vaginal fluids and thus should be removed in future studies.   
Finally additional dilution studies to assess matrix effects on the lower limit of detection 
for each body fluid are clearly indicated as a focus for additional study. 
4.2.4 Combined DNA and Serological Analysis 
The current research has shown that biological stain identification using a QQQ-
MRM to assay material from a variety of casework-type samples is both precise and 
reliable. However, in order for a mass spectrometry assay for serological analysis to be 
implemented into routine forensic casework it must also be possible to recover a DNA 
profile from the same sample. To demonstrate the feasibility of this, a modified protocol 
similar to a differential extraction was developed (Figure 43). Similar to previous 
casework-type samples, unfractionated body fluid aliquots were added to cotton swabs 
and dried troroughly. The cotton swab containing the dried biological material was then 
rehydrated in PBS and place in a microfuge spin basket to separate and recover the liquid 
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form the cottom matrix of the swab. A high-speed centrifugation step was used to pellet 
cellular and any other insoluble material. The protein rich supernatant fraction was 
processed for QQQ-MRM analysis while the cellular (DNA rich) fraction was extracted 
using the EZ1 BioRobot, quantified using Quantifiler
®
 Duo, and used to develop an STR 




Figure 43 – Generation of a full STR profile and stain identification for a mixed stain containing seminal fluid and 
saliva mixture. Swab was rehydrated in phosphate buffer saline and placed in a filter basket to remove retained 
fluid. Sample was then spun at high speed to pellet the cellular material for STR analysis The DNA-depleted 
supernatant was processed for proteomic analysis. DNA was quantified using ABI Quantifiler® duo and a full DNA 
profile was generated using ABI Identifiler® Plus kit. Protein concentration was determined using Pierce micro BCA 




In total, six swabs were processed using the modified protocol – two reference 
samples from semen and vaginal fluid as well as four male/female mixed samples. For 
the mixed samples a semen/saliva swab, semen/vaginal fluid swab, saliva/vaginal fluid 
swab, as well as a semen/peripheral blood swab were prepared. QQQ-MRM analyses of 
these swabs resulted in the successful identification of all targeted proteins from both 
single- and mixed-source body fluid samples (Table 18).  
Table 18 – Results of DNA/Protein samples processed for joint genetic and serological analysis. For each 
swab the fluid was confidently identified. Green cells indicate positive identification of target protein 
via two specific peptides. Red cells indicate no peptides were found. (M) and (F) represents male and 
female source, respectively.  
 
Genetic analyses (i.e., STR-based DNA profiles) using the Identifiler
®
 Plus kit 
were able to successfully produce the expected single- and mixed-source profiles for all 
samples tested (Table 19). In all reference and mixed-source samples, the major 
contributor was represented by a complete STR profile. The saliva/vaginal fluid sample 
also resulted in a full profile for the minor contributor. In the semen/saliva as well as the 
semen/vaginal fluid samples, 50% of the minor contributor’s distinct alleles (i.e., not 
counting shared alleles) were present. In the semen/peripheral blood sample 79% of the 
minor contributor’s distinct alleles were present. The end result of this experiment 
provides ample support for the proposition that a mass spectrometry-based serological 
assay is compatible with existing STR profiling methodologies.  
 
Cystatin_SA Statherin Submaxi Gland Semenogelin-1 Semenogelin-2 Prostatic Acid Cornulin Ly6 Neutrophil Gel
Semen (M) Saliva (F)
Semen (M) Vaginal (F)
Saliva (M) Vaginal (F)
Semen (M) Peripheral Blood (F)
Semen Refrence (M)
Vaginal Refrence (F)




Table 19 – Summary Table of STR DNA Results using the Identifiler kit. “NR”= No results, “NT”= Not 


































































































10,12 10,11 15,17 6,7 10,12 11,12 17,24 13,14 17,18 8,11 11,15 X,Y 11,12 20,24 
Female Donor 
(Vaginal) 
14,15 29,30 10,11 10,11 15 6,9.3 11,12 9,12 19,21 13,15 17,18 8 16 X 11 25,27 





10,12 10,11 15,17 6,7 10,12 11,12 17,24 13,14 17,18 8,11 11,15 X,Y 11,12 20,24 
Semen/Saliva    
(m) 






10,12 10,11 15,17 6,7 10,12 11,12 17,24 13,14 17,18 8,11 11,15 X,Y 11,12 20,24 
Semen/Vaginal  
(m) 
14,15  11    11  21    16   25 





10,12 10,11 15,17 6,7 10,12 11,12 17,24 13,14 17,18 8,11 11,15 X,Y 11,12 20,24 
Saliva/Vaginal   
(m) 
14,15 29,30 11   9.3 11 9 19,21 15   16   25,27 
Semen/PBlood  
(M) 










The central objective of this phase of the dissertation research was to improve 
upon the previous Q-TOF assay by increasing the speed of analysis and to test the 
feasibility of a mass-spectrometry based assay for stain identification for routine 
casework testing. A prototype QQQ-MRM “sexual assault assay” was designed to 
provide for the rapid and confirmatory identity of seminal fluid, saliva, and vaginal fluid.  
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Starting with the data from the Q-TOF studies, the four most promising 
biomarkers for the three fluids were selected for use in the prototype QQQ-MRM assay. 
Because these proteins (and subsequent peptides) had already been evaluated previously, 
the only task that remained was to identify the optimal product ions for inclusion in the 
QQQ-MRM assay. Once selected, the transitions were integrated into a QQQ-MRM 
triplex biological stain assay. The assay accurately identified seminal fluid, saliva, and 
vaginal secretions on the basis of 12 high-specificity protein biomarkers with an 
instrument run time of 18 minutes. Compared to the previous Q-TOF assay, this achieves 
more than a 75% reduction in total analysis time.  
The QQQ-MRM three-stain assay was tested using single-source samples (7 
samples each) as well as a series of casework-type samples.  Data from these experiments 
confirmed the accuracy and consistency of the biomarkers on this high-speed platform. In 
addition to the single source laboratory samples, a protocol was developed to co-extract 
the DNA and protein fractions from a single swab. This protocol was able to identify the 
specific body fluid stains present as well as to generate accurate STR profiles. In 
summary, a high speed QQQ assay for stain identification can act as a launching point for 
the subsequent full developmental validation of a six-body fluid multiplex for forensic 
casework on a QQQ-MRM platform. 
 
4.4 Future Directions and Impact on the Criminal Justice System 
Forensic practitioners in the US have repeatedly stressed that the identification of 
biological stains can be a significant challenge for forensic serologists. Currently, there 
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are no means of readily or reliably identifying stains such as vaginal secretions or 
differentiating between peripheral vs. menstrual blood. Additionally, many tests provide 
only presumptive results (e.g., α-amylase assay for saliva) and can consume significant 
quantities of precious evidence.  
A sensitive, multiplex compatible, reliable, human-specific approach for the 
confirmatory identification of questioned biological stains could overcome the limitations 
of the methods that analysts now employ. Therefore, future work should focus on the 
developmental validation of a mass spectrometry based multiplex assay for forensic stain 
identification. The obvious choice for this validation will employ a single, well-
established analytical technology – targeted-ion mass spectrometry on a triple quadrupole 
mass spectrometer – a technology which was shown to be reliable in this dissertation 
research and is already employed in many forensic laboratories for toxicology and drug 
identification. 
The implementation of this technology has the potential to modernize serological 
screening. As compared to traditional methodologies, results obtained are confirmatory 
for human stains through the identification of multiple fluid-specific protein biomarkers. 
Additionally, stain detection is far more reliable since identification is based on the 
unique chemical composition and subsequent mass spectra. Thus, assay results are not 
compromised by dependence on a single diagnostic protein, antibody cross reactivity, 
false negative results from undetected hook effects, or potentially compromised results 
from the visualization of chemical or enzyme reactions. The multiplex design eliminates 
the need to perform separate tests on an unknown stain. In addition, the entire assay from 
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sample extraction to data analysis is more amenable to automation and the 
implementation of robotics. This makes mass spectrometry-based testing better suited for 
batch processing.  
This work has the potential to significantly improve the accuracy and sensitivity 
of forensic serological testing. In short, the successful completion of the developmental 
validation and downstream implementation of this research will provide the forensic 
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Appendix A: ProteoSep™ 2D Protein Identification Results  












18 303.34 37.2  2.83E+10 P04279  Semenogelin-1 precursor  
15 230.45 27.3  8.80E+09 Q02383  Semenogelin-2 precursor 
6 109.76 10.5  2.41E+08 P04264  Keratin, type II cytoskeletal 1 
4 57.15 6.2  1.18E+08 P35908  
Keratin, type II cytoskeletal 2 
epidermal 
6 95.35 10.2  1.60E+08 P13645  Keratin, type I cytoskeletal 10 
1 14.42 1.9  1.14E+07 P02533  Keratin, type I cytoskeletal 14 
1 14.42 1.9  1.14E+07 P08779  Keratin, type I cytoskeletal 16 
6 90.52 9.2  7.12E+07 P02788  Lactotransferrin  
6 88.65 12.9  7.10E+07 P10909  Clusterin  
3 46.79 7.2  4.23E+07 P15309  Prostatic acid phosphatase  
3 45.76 5.2  3.86E+07 P02768  Serum albumin  
3 45.36 49.1  3.96E+07 P06702  Protein S100-A9  




























32 561.94 63.7  2.79E+09 P02768  Serum albumin  
10 155.15 39.6  1.21E+08 P25311  Zinc-alpha-2-glycoprotein 
8 153.58 2.4  6.00E+08 P98160  
Basement membrane-specific 
heparan sulfate proteoglycan 
protein  
6 111.72 16.7  1.23E+09 P02760  Protein AMBP  
6 104.17 9.8  1.83E+08 Q14624  
Inter-alpha-trypsin inhibitor 
heavy chain H4  
5 77.59 8.3  1.53E+08 P01042  Kininogen-1  
4 59.89 10.6  1.46E+08 P07602  Proactivator polypeptide  
4 58.86 35.5  4.55E+07 P05451  Lithostathine-1-alpha  
2 32.74 13.8  3.40E+07 P48304  Lithostathine-1-beta  
3 57.26 11.7  1.23E+08 P10451  Osteopontin  
4 54.88 25.1  1.21E+10 P00761  Trypsin 
3 53.21 5.3  5.09E+07 P55290  Cadherin-13  
3 49.91 6.2  2.55E+07 P13645  Keratin, type I cytoskeletal 10  
3 48.83 5.4  4.96E+07 P04264  Keratin, type II cytoskeletal 1  
1 14.86 2 3.31E+07 P19013  Keratin, type II cytoskeletal 4  
1 14.86 2.2  3.31E+07 P05787  Keratin, type II cytoskeletal 8  
1 14.86 2.3  3.31E+07 P08729  Keratin, type II cytoskeletal 7  
1 14.86 2.4  3.31E+07 Q6KB66  Keratin, type II cytoskeletal 80  
1 14.86 2.5  3.31E+07 P14136  Glial fibrillary acidic protein  
3 48.68 14.1  7.39E+07 P06870  Kallikrein-1  
4 47.36 66 3.05E+07 P01834  Ig kappa chain C region 
2 45.33 25.8  3.31E+07 Q14508  
WAP four-disulfide core domain 
protein 2 
3 44.7 10.9  5.89E+07 P28799  Granulins  
2 36.06 5.1  2.14E+07 P01833  
Polymeric immunoglobulin 
receptor  
2 34.04 3.3  7.05E+07 P01133  Pro-epidermal growth factor  
2 31.1 17.3  1.28E+07 P41222  Prostaglandin-H2 D-isomerase  
2 29.7 16.4  4.09E+07 P02753  Retinol-binding protein 4  
2 28.93 23.8  3.39E+06 P02766  Transthyretin  
2 28.52 18.7  9.68E+07 P13987  CD59 glycoprotein  
2 25.8 7 2.95E+07 P01876  Ig alpha-1 chain C region  




1 21.07 4.7  1.81E+07 P04156  Major prion protein  
1 21.01 2.3  2.26E+07 P05060  Secretogranin-1 O 
1 19.38 5.9  1.73E+06 P05452  Tetranectin  
1 17.8 2.9  1.06E+07 Q9ULV1  Frizzled-4  
1 15.91 1.6  9.02E+06 O75339  
Cartilage intermediate layer 
protein 1  
1 15.23 6.2  4.84E+06 Q7Z3B1  Neuronal growth regulator 1  
1 14.51 10.8  1.71E+07 P31151  Protein S100-A7  
1 14.51 10.8  1.71E+07 Q86SG5  Protein S100-A7A  
1 14.4 9.5  8.04E+06 P09564  T-cell antigen CD7  
1 14.34 5.4  4.05E+07 Q9UNN8  Endothelial protein C receptor  
1 14.03 5.1  1.94E+07 Q9BT78  
COP9 signalosome complex 
subunit  
1 13.31 2.1  7.41E+06 Q14574  Desmocollin-3  
1 13.26 3.3  1.34E+07 Q6NXE6  
Armadillo repeat-containing 





























4 62.41 48.3  6.71E+07 P02808  
Statherin precursor - Homo 
sapiens (Human) 
2 35.56 3.7  8.29E+06 P04264  Keratin, type II cytoskeletal 1 
1 17.04 1.8  8.25E+06 P35908  
Keratin, type II cytoskeletal 2 
epiderma 
2 34.81 5.2  6.57E+06 P13645  Keratin, type I cytoskeletal 10 
1 21.17 8.1  1.40E+06 P61626  Lysozyme C precursor  
1 17.68 10.2  3.13E+05 P02810  
Salivary acidic proline-rich 
phosphoprotein 1/2  
1 17.16 3.5  4.80E+07 P14314  
Glucosidase 2 subunit beta 
precursor  
1 16.53 6 9.94E+06 Q96DU7  Inositol-trisphosphate 3-kinase C 
1 15.98 5.8  4.24E+07 Q9UM11  Fizzy-related protein homolog - 
1 15.44 17.5  1.98E+05 P15515  Histatin-1 OS=Homo sapiens 
1 14.79 4.2  2.94E+05 P24158  Myeloblastin OS=Homo sapiens  
1 14.4 9.7  5.68E+06 Q9UK76  
Hematological and neurological 
expressed 1 protein 
1 13.77 0.2  2.72E+06 P49792  E3 SUMO-protein ligase RanBP2  
1 13.77 0.5  2.72E+06 Q53T03  
RANBP2-like and GRIP domain-
containing protein 6  
1 13.77 0.5  2.72E+06 Q99666  
RANBP2-like and GRIP domain-
containing protein 5  
1 13.77 0.5  2.72E+06 A6NKT7  
RANBP2-like and GRIP domain-
containing protein 3  
1 13.77 0.5  2.72E+06 Q7Z3J3  
RANBP2-like and GRIP domain-
containing protein 4 
1 13.77 0.5  2.72E+06 Q68DN6  
RANBP2-like and GRIP domain-
containing protein 1  
1 13.77 0.9  2.72E+06 Q9H0B2  
RANBP2-like and GRIP domain-
containing protein 7  



















18 301.33 37.1  1.87E+09 P02768  Serum albumin precursor  
15 250.88 38.7  5.00E+09 P30740  Leukocyte elastase inhibitor  
1 17.92 2.4  3.82E+07 O75830  Serpin I2  
1 17.92 2.6  3.82E+07 P50452  Serpin B8  
1 17.92 2.6  3.82E+07 P50453  Serpin B9  
13 205.85 32.1 1.05E+09 P07476 Involucrin  
10 172.07 29.4  6.32E+08 P07355  Annexin A2 
8 130.66 24.1  4.01E+08 A6NMY6  Putative annexin A2-like protein  
11 167.88 20.7  1.20E+09 P13646  Keratin, type I cytoskeletal 13 
5 83.51 9.2  4.66E+08 P19012  Keratin, type I cytoskeletal 15 
3 50.89 4.8  1.55E+08 P02533  Keratin, type I cytoskeletal 14 
3 50.89 4.8  1.55E+08 P08779  Keratin, type I cytoskeletal 
2 30.68 2.5  5.90E+07 P35900  Keratin, type I cytoskeletal 20  
2 30.68 2.5  5.90E+07 Q04695  Keratin, type I cytoskeletal 17  
2 25.96 3.8  8.75E+07 Q99456  Keratin, type I cytoskeletal 12  
2 25.77 2 1.56E+08 P13645  Keratin, type I cytoskeletal 10  
1 15.23 2.2  8.94E+06 P08727  Keratin, type I cytoskeletal 19  
1 15.23 3 8.94E+06 Q8N1A0  Keratin-like protein KRT222  
1 14.96 2 1.14E+08 Q2M2I5  Keratin, type I cytoskeletal 24  
10 153.97 16.9  4.57E+08 P05164  Myeloperoxidase  
9 140.8 31.7  1.20E+09 P29508  Serpin B3  
1 13.29 3 2.30E+07 Q9UIV8  Serpin B13  
8 116.33 27.1  9.32E+08 P48594  Serpin B4  
8 131.35 31.2  3.82E+08 P04083  Annexin A1  
7 114.87 12.8  2.84E+08 P04264  Keratin, type II cytoskeletal 1 
1 13.22 2 2.26E+06 P05787  Keratin, type II cytoskeletal 8  
6 104.98 13.1  1.06E+09 P02538  Keratin, type II cytoskeletal 6A -  
6 101.44 13.1  5.51E+08 P04259  Keratin, type II cytoskeletal 6B -  
5 85.83 10.4  5.40E+08 P48668  Keratin, type II cytoskeletal 6E 
4 70.18 7.9  4.14E+08 P13647  Keratin, type II cytoskeletal 5  
7 111.65 53.5  2.69E+10 P06702  Protein S100-A9  





6 81.1 5.4  1.47E+08 A8K2U0  
Alpha-2-macroglobulin-like 
protein 1 
5 61.68 23.3  1.23E+08 P01857  Ig gamma-1 chain C region  
2 22.99 6.3  3.99E+07 P01860  Ig gamma-3 chain C region  
2 22.42 9.7  3.00E+07 P01861  Ig gamma-4 chain C region  
3 52.48 32.6  1.47E+08 P02766  Transthyretin  
3 50.41 5.7  1.21E+08 P02787  Serotransferrin  
3 49.55 28.4  6.16E+08 Q9UBC9  Small proline-rich protein 3  
3 48.85 4.4  7.43E+07 P11021  
78 kDa glucose-regulated protein 
precursor 
3 43.94 31.1  1.72E+08 P05109  Protein  
3 39.41 7 9.41E+07 P13796  Plastin-2  
1 14.47 1.4  3.31E+07 P13797  Plastin-3  
1 14.47 1.4  3.31E+07 Q14651  Plastin-1  
2 36.42 16.2  3.50E+07 P61626  Lysozyme C  
2 36.19 11.1 8.94E+07 Q9UBG3 Cornulin  
2 31 24 4.12E+07 Q9HD89  Resistin  
2 28.87 6.6  1.26E+08 P07951  Tropomyosin beta chain  
2 28.87 7.6  1.26E+08 P67936  Tropomyosin alpha-4 chain  
1 14.82 3.5  7.18E+07 P06753  Tropomyosin alpha-3 chain  
1 14.82 3.5  7.18E+07 P09493  Tropomyosin alpha-1 chain  
2 28.49 2.9  5.99E+07 P02788  Lactotransferrin OS 
2 27.99 17.7  5.90E+07 Q14508  
WAP four-disulfide core domain 
protein 
2 27.48 34.8  9.57E+07 P35321  Cornifin-A  
2 27.3 34.8  7.56E+07 P22528  Cornifin-B  
2 25.23 1.4 2.83E+07 O60437 Periplakin OS 
2 25.06 7.5 9.35E+07 P08670 Vimentin  
1 18.22 3.5  6.32E+07 Q96LW4  Coiled-coil domain-containing  
1 18.12 1.7  1.14E+07 O00391  Sulfhydryl oxidase 1  
1 17.15 1.7  1.82E+07 P34931  Heat shock 70 kDa protein 1L 
1 17.15 1.7  1.82E+07 P08107  Heat shock 70 kDa protein 1  
1 17.03 12.3  8.59E+07 P10599  Thioredoxin OS=Homo sapiens  
1 16.53 2 4.11E+07 Q2M2Z5  Uncharacterized protein C20orf19  
1 16.21 18 3.95E+07 P35326  Small proline-rich protein 2A  






1 16.19 4.5  2.41E+07 O15519  
CASP8 and FADD-like apoptosis 
regulator  
1 15.69 1.2  9.89E+06 Q9NQ38  
Serine protease inhibitor Kazal-type 
5  
1 15.62 8.5  4.81E+06 P04632  Calpain small subunit 1  
1 14.98 4.1  1.82E+07 O95948  One cut domain family member 2  
1 14.57 3.6  6.85E+05 P35527  Keratin, type I cytoskeletal 9  
1 13.56 2.2  3.06E+06 Q8IV53  DENN domain-containing protein  
1 13.54 1.2  1.24E+07 P06731  
Carcinoembryonic antigen-related 
cell adhesion molecule 5  
1 13.54 1.7  1.24E+07 P13688  
Carcinoembryonic antigen-related 
cell adhesion molecule 1  
1 13.54 2.5  1.24E+07 P31997  
Carcinoembryonic antigen-related 
cell adhesion molecule 8  
1 13.33 2.2  5.19E+07 P42261  Glutamate receptor 1  
1 13.33 2.2  5.19E+07 P42263  Glutamate receptor 3  
1 13.33 2.2  5.19E+07 P48058  Glutamate receptor 4  




























38 647.31 35.2  5.91E+09 P01024  Complement C3  
33 523.43 35.6  4.88E+09 P01023  Alpha-2-macroglobulin  
4 59.92 3.5  6.40E+08 P20742  Pregnancy zone protein  
22 373.98 41.2  4.60E+09 P02787  Serotransferrin  
16 271.67 54.6  1.16E+10 P02647  Apolipoprotein A-I  
16 263.75 37.6  2.14E+09 P02675  Fibrinogen beta chain  
17 261.74 29.4  1.75E+09 P00450  Ceruloplasmin  
15 240.5 46.8  4.26E+09 P01009  Alpha-1-antitrypsin  
15 234.68 15.1  6.75E+08 P0C0L5  Complement C4-B  
15 234.68 15.1  6.75E+08 P0C0L4  Complement C4-A  
11 178.42 37.8  3.40E+09 P02790  Hemopexin  
1 20.35 3.4  1.70E+07 P20058  Hemopexin  
10 167.17 77.5  1.68E+10 P68871  Hemoglobin subunit beta  
8 133.25 62.5  8.07E+09 P02042  Hemoglobin subunit delta  
9 144.91 31.2  1.31E+09 P02774  Vitamin D-binding protein  
9 139.82 28.9  2.16E+09 P02679  Fibrinogen gamma chain  
8 137.61 30.7  8.06E+08 P00738  Haptoglobin  
4 73.02 14.6  4.86E+08 P00739  Haptoglobin-related protein 
9 130.79 11.3  3.68E+08 P08603  Complement factor H  
7 121.94 64 6.42E+09 P69905  Hemoglobin subunit alpha  
8 121.8 3.1  3.00E+08 P04114  Apolipoprotein B-100  
7 120.93 24.2  3.08E+07 P30740  Leukocyte elastase inhibitor  
6 101.04 32.4  4.84E+08 P02749  Beta-2-glycoprotein 1  
5 96.27 17.1  4.60E+08 P01019  Angiotensinogen  
6 88.06 13.2  1.74E+08 P00751  Complement factor B  
5 80.28 17.1  5.16E+08 P04217  Alpha-1B-glycoprotein  
5 80.08 7.8  3.46E+08 P02671  Fibrinogen alpha chain  
5 77.37 27.7  2.89E+07 P32119  Peroxiredoxin-2  
1 15.62 5.5  1.07E+07 Q06830  Peroxiredoxin-1  
4 74.91 21 3.39E+07 P00915  
Carbonic anhydrase 1 OS=Homo 
sapiens GN=CA1 PE=1 SV=2 
4 67.01 21.5  1.01E+09 P02765  Alpha-2-HS-glycoprotein  





4 63.4 10.5  3.09E+08 P01042  Kininogen-1 
4 60.11 6.5  1.88E+08 P19823  
Inter-alpha-trypsin inhibitor heavy 
chain H2  
4 55.39 13.4  9.81E+07 P01871  Ig mu chain C region  
3 38.64 11.5  8.85E+07 P04220  Ig mu heavy chain disease protein  
3 50.98 18.9  7.13E+08 P02763  Alpha-1-acid glycoprotein 1  
2 32.08 12.9  3.84E+08 P19652  Alpha-1-acid glycoprotein 2  
4 49.62 66 2.05E+08 P01834  Ig kappa chain C region  
3 47.89 7.2  1.35E+08 P00734  Prothrombin OS=Homo sapiens 
3 47.6 9.6  1.06E+08 P04004  Vitronectin OS=Homo sapiens  
3 47.03 5.1  2.99E+08 P19827  
Inter-alpha-trypsin inhibitor heavy 
chain H1  
3 41.72 11.5  1.17E+08 P10909  Clusterin  
2 39.68 4.8  8.11E+07 P01833  Polymeric immunoglobulin receptor  
2 37.96 23.8  5.87E+07 P02766  Transthyretin  
2 37.47 5 6.49E+06 Q13228  Selenium-binding protein 1  
2 37.33 16.8  4.56E+07 P00441  Superoxide dismutase [Cu-Zn]  
2 35.13 7.8  2.03E+08 P01011  Alpha-1-antichymotrypsin  
2 30.6 27.2  4.04E+08 P02656  Apolipoprotein C-III  
2 29.64 7.9  5.77E+07 P01008  Antithrombin-III  
2 29.2 20.5  4.50E+06 Q9NZT1  Calmodulin-like protein 5 
2 28.98 17.7  7.92E+07 Q14508  
WAP four-disulfide core domain 
protein 2  
2 28.39 6.5  1.05E+08 P02760  Protein AMBP  
2 24.16 7.7  1.19E+07 P00761  Trypsin 
1 21.5 1.8  1.37E+06 P35908  
Keratin, type II cytoskeletal 2 
epidermal  
1 21.5 2 1.37E+06 P13647  Keratin, type II cytoskeletal 5  
1 21.5 2.1  1.37E+06 P02538  Keratin, type II cytoskeletal 6A  
1 21.5 2.1  1.37E+06 P04259  Keratin, type II cytoskeletal 6B  
1 21.5 2.1  1.37E+06 P48668  Keratin, type II cytoskeletal 6C  
1 21.5 2.1  1.37E+06 O95678  Keratin, type II cytoskeletal 75  
1 21.5 2.2  1.37E+06 Q5XKE5  Keratin, type II cytoskeletal 79  
1 20.65 2.3  6.86E+07 Q14624  
Inter-alpha-trypsin inhibitor heavy  
chain 
1 20.02 4.5  3.62E+06 P13645  Keratin, type I cytoskeletal 10  
1 17.58 1.8  1.47E+06 P04264  Keratin, type II cytoskeletal 1  







1 16.65 9 6.14E+07 P03973  Antileukoproteinase 
1 16.06 11.8  1.81E+06 Q01469  
Fatty acid-binding protein, 
epidermal  
1 15.88 1 9.21E+07 O00160  Myosin-If  
1 15.75 3.2  1.56E+07 P06727  Apolipoprotein A-IV  
1 15.69 8.5  4.06E+07 P80188  Neutrophil gelatinase-associated  
1 15.44 2.7  1.20E+06 P07476  Involucrin 
1 15.37 4.1  2.53E+06 Q61468  Mesothelin  
1 15.21 6.8  3.89E+07 Q6PII5  
Hydroxyacylglutathione hydrolase-
like protein  
1 15 15.7  2.98E+07 P22528  Cornifin-B  
1 15 15.7  2.98E+07 P35321  Cornifin-A  
1 14.83 4.2  3.25E+07 P68133  Actin, alpha skeletal muscle  
1 14.83 4.2  3.25E+07 P68032  Actin, alpha cardiac muscle 1  
1 14.83 4.2  3.25E+07 P62736  Actin, aortic smooth muscle  
1 14.83 4.2  3.25E+07 P63267  
Actin, gamma-enteric smooth 
muscle  
1 14.56 5.3  3.65E+07 P01860  Ig gamma-3 chain C region  
1 14.47 18.4  1.49E+07 P61769  Beta-2-microglobulin 
1 14.38 1.7  2.12E+07 P04196  Histidine-rich glycoprotein  
1 14.33 1.1  9.85E+07 Q9P1Z9  Uncharacterized protein KIAA1529  
1 14.26 0.6  1.02E+06 Q9BTC0  Death-inducer obliterator 1  
1 14.18 3.2  3.02E+06 Q8R4E9  DNA replication factor Cdt1 
1 14.14 3.4  5.55E+06 Q9NZN3  EH domain-containing protein 3  
1 14.09 0.8  4.00E+07 Q9P212  
1-phosphatidylinositol-4,5-
bisphosphate phosphodiesterase  
1 13.94 5.8  2.74E+06 P28289  Tropomodulin-1  
1 13.64 7.1  9.06E+07 P25311  Zinc-alpha-2-glycoprotein  
1 13.56 0.6  1.80E+06 Q13535  Serine/threonine-protein kinase ATR  
1 13.4 4.3  2.34E+06 Q9H0R3  Transmembrane protein 222  
1 13.36 3.9  5.82E+06 Q8N807  
Protein disulfide-isomerase-like 
protein of the testis 
1 13.26 1.4  6.21E+06 P01031  Complement C5  
1 13.17 3.5  4.82E+06 Q86UB2  
Basic immunoglobulin-like variable 
motif-containing protein  
1 13.13 1 1.38E+08 Q702N8  
Xin actin-binding repeat-containing 
protein 1  

















32 584.65 61.5  2.51E+10 P02768  Serum albumin  
32 557.01 40.4  4.46E+09 P08603  Complement factor H  
3 50.51 13.3  1.48E+08 Q03591  
Complement factor H-related 
protein 1  
19 344.32 55 3.66E+09 P02774  Vitamin D-binding protein 
13 244.61 33.1  9.66E+08 P04196  Histidine-rich glycoprotein  
15 231.06 42.8 2.37E+09 P02790 Hemopexin  
12 214.92 31.6  1.32E+09 P00751  Complement factor B 
12 205.55 5 4.47E+08 P04114  Apolipoprotein B-100  
12 202.1 24.9  4.57E+08 P00747  Plasminogen 
12 200.29 12.3 7.95E+08 P01024 Complement C3  
8 143.68 69.3  2.35E+09 P02766  Transthyretin  
7 111.8 10.7  2.07E+08 P00450  Ceruloplasmin  
7 106.06 26.7  7.40E+08 P01008  Antithrombin-III  
6 87.77 12 2.50E+08 Q14624  
Inter-alpha-trypsin inhibitor heavy 
chain H4  
4 64.15 32.3  4.36E+08 P02753  Retinol-binding protein 4 
3 54.93 10.1  7.16E+07 P43652  Afamin OS=Homo sapiens  
2 39.75 2.9  1.11E+08 P0C0L5  Complement C4-B  
2 39.75 2.9  1.11E+08 P0C0L4  Complement C4-A  
1 18.85 3.5  1.82E+07 P01019  Angiotensinogen  
1 15.85 1.4  3.84E+07 P01023  Alpha-2-macroglobulin  
1 15.64 7.2  8.72E+06 P02749  Beta-2-glycoprotein 1  
1 15.64 3.4  2.80E+07 P08697  Alpha-2-antiplasmin  
1 14.62 10.3  3.76E+07 P05452  Tetranectin  
1 14.18 4.2  1.45E+08 Q3MIP1  
Inositol 1,4,5-triphosphate 
receptor-interacting protein-like 2  
1 14.01 3.9  1.88E+08 P40818  
Ubiquitin carboxyl-terminal 
hydrolase 8  
1 13.86 0.9  3.15E+07 P35498  
Sodium channel protein type 1 
subunit alpha  
1 13.06 9.7  6.99E+06 O14626  
Probable G-protein coupled 






Appendix B: ProteoSep™ 1D Protein Identification Results  












16 281.63 35.6  6.65E+06 P02788  Lactotransferrin  
11 196.27 28.5  1.26E+08 P04279  Semenogelin-1  
10 190.82 22.6  1.35E+08 Q02383  Semenogelin-2  
10 161.67 31.3  8.09E+06 P15309  Prostatic acid phosphatase 
8 138.07 6.9  1.11E+06 P02751  Fibronectin  
8 132.47 20.6  5.82E+06 P02768  Serum albumin 
7 111.84 51.3  4.58E+06 P12273  Prolactin-inducible protein  
6 108.85 16.4  3.98E+06 P10909  Clusterin  
4 87.07 36.7  6.20E+06 P07288  Prostate-specific antigen 
2 38.88 6.7  8.03E+04 P49221  
Protein-glutamine gamma-
glutamyltransferase 4  
2 35.24 25.8  1.25E+06 P61916  Epididymal secretory protein E1  
1 22.49 4.6  9.85E+05 P16870  Carboxypeptidase E  
1 21.67 5.4  1.06E+06 P25311  Zinc-alpha-2-glycoprotein  
1 15.48 5 1.34E+05 P80303  Nucleobindin-2  
1 15.33 7.1  1.06E+05 P04406  
Glyceraldehyde-3-phosphate 
dehydrogenase  
1 14.87 18.4  4.47E+05 P61769  Beta-2-microglobulin  
























17 322.36 38 2.78E+07 P02768  Serum albumin  
7 140.98 27.2  1.29E+08 P02760  Protein AMBP  
5 93.39 28.7  4.71E+05 P01857  Ig gamma-1 chain C region  
2 40.77 11.6  2.73E+05 P01861  Ig gamma-4 chain C region  
1 21.03 4.2  1.61E+05 P01860  Ig gamma-3 chain C region  
4 74.5 11.6  3.35E+05 P01833  Polymeric immunoglobulin receptor  
4 73.21 60.3  1.57E+07 P01834  Ig kappa chain C region  
4 72.3 19.1  4.00E+05 P19961  Alpha-amylase 2B  
3 53.5 13.3  1.03E+05 P04745  Alpha-amylase 1  
3 52.98 14 3.60E+05 P04746  Pancreatic alpha-amylase  
3 61.55 6.3  8.98E+04 P10253  Lysosomal alpha-glucosidase  
3 60.07 7.3  5.36E+05 Q14624  
Inter-alpha-trypsin inhibitor heavy 
chain H4  
3 58.76 9.1  9.14E+05 P01042  Kininogen-1  
3 55.54 12.1  4.82E+05 P10451  Osteopontin  
3 55.36 8.9  1.16E+06 Q6EMK4  Vasorin  
3 52.4 11.4  1.32E+05 P05155  Plasma protease C1 inhibitor  
3 45.54 6.5  1.86E+07 P07911  Uromodulin  
2 42.82 17.3  7.73E+07 P41222  Prostaglandin-H2 D-isomerase  
2 36.83 0.6  1.34E+05 P98160  
Basement membrane-specific 
heparan sulfate proteoglycan core 
protein  
2 35.66 3.1  1.14E+05 P01133  Pro-epidermal growth factor  
2 35.28 18 1.35E+05 P24855  Deoxyribonuclease-1  
2 34.83 9.3  1.83E+05 P10153  Non-secretory ribonuclease  
2 33.29 22.2  9.56E+04 Q7Z5L0  
Vitelline membrane outer layer 
protein 1 homolog  
2 31.03 6.5  1.20E+05 P00734  Prothrombin  
2 30.6 7.8  5.70E+04 P01009  Alpha-1-antitrypsin 
2 26.74 10.1  1.34E+05 P01859  Ig gamma-2 chain C region  
2 25.26 9.2  8.00E+04 Q9UNN8  Endothelial protein C receptor  
1 21.72 5.3  6.21E+04 Q12907  
Vesicular integral-membrane 
protein VIP36  
1 19.54 33.8  1.35E+05 P60022  Beta-defensin 1 
1 19.14 2.3  1.40E+05 P14543  Nidogen-1  
1 18.11 9.5  4.57E+04 P09564  T-cell antigen CD7  
1 17.52 7.6  1.90E+05 Q8WVN6  
Secreted and transmembrane 




1 17.21 3 2.76E+04 P02671  Fibrinogen alpha chain  
1 16.82 6.3  1.81E+05 Q16769  Glutaminyl-peptide cyclotransferase  
1 16.52 3.8  6.66E+04 P15309  Prostatic acid phosphatase 
1 16.28 7.6  2.03E+04 O75594  Peptidoglycan recognition protein  
1 16.27 4.6  1.71E+05 P02774  Vitamin D-binding protein  
1 16.11 24.2  1.68E+05 P55000  
Secreted Ly-6/uPAR-related protein 
1  
1 15.73 18.4  4.54E+05 P61769  Beta-2-microglobulin  
1 15.1 15.7  3.48E+04 P01593  Ig kappa chain V-I region AG  
1 15.1 15.7  3.48E+04 P01594  Ig kappa chain V-I region AU  
1 15.1 15.7  3.48E+04 P01607  Ig kappa chain V-I region Rei  
1 15.1 15.7  3.48E+04 P01610  Ig kappa chain V-I region WEA  
1 15.1 15.7  3.48E+04 P01599  Ig kappa chain V-I region Gal  
1 15.1 15.7  3.48E+04 P01608  Ig kappa chain V-I region Roy  
1 15.1 15.7  3.48E+04 P01609  Ig kappa chain V-I region Scw  
1 15.1 15.7  3.48E+04 P80362  Ig kappa chain V-I region WAT  
1 15.1 15.7  3.48E+04 P01600  Ig kappa chain V-I region Hau  
1 14.56 15.5  2.53E+04 P04206  Ig kappa chain V-III region GOL  
1 14.56 15.5  2.53E+04 P01622  Ig kappa chain V-III region Ti  
1 14.56 15.5  2.53E+04 P01620  Ig kappa chain V-III region SIE  
1 14.56 15.5  2.53E+04 P01623  Ig kappa chain V-III region WOL  
1 14.23 3.7  2.73E+04 P36896  Activin receptor type-1B  
























16 277.08 35.3  1.89E+09 P02768  Serum albumin  
15 246.71 40.7  3.29E+09 P04745  Alpha-amylase 1  
11 173.74 31.7  1.96E+09 P04746  Pancreatic alpha-amylase  
13 207.25 40.5  2.42E+09 P19961  Alpha-amylase 2B  
11 180.57 21.7  9.85E+08 P01833  Polymeric immunoglobulin receptor  
11 166.48 19.7  3.50E+08 P02787  Serotransferrin  
8 147.41 63.1  1.60E+10 P01036  Cystatin-S  
2 31.47 20.5  5.75E+08 P01037  Cystatin-SN  
3 52.95 31.2  2.16E+08 P09228  Cystatin-SA  
9 143.58 43.3  4.77E+08 P25311  Zinc-alpha-2-glycoprotein 
1 13.24 4.9  6.41E+07 A8MT79  
Putative zinc-alpha-2-glycoprotein-
like 1  
7 123.98 60.9  3.74E+09 P12273  Prolactin-inducible protein  
7 116.69 36.2  1.92E+09 P01876  Ig alpha-1 chain C region  
5 83.89 27.3  9.92E+08 P01877  Ig alpha-2 chain C region  
4 68.01 60.3  8.79E+08 P01834  Ig kappa chain C region  
4 50.31 11.7  6.90E+07 P01871  Ig mu chain C region  
3 39.91 10.4  6.41E+07 P04220  Ig mu heavy chain disease protein  
3 48.98 11.4  2.03E+08 P68133  Actin, alpha skeletal muscle  
3 48.98 11.4  2.03E+08 P68032  Actin, alpha cardiac muscle 1  
2 34.68 8.4  1.99E+08 P62736  Actin, aortic smooth muscle  
2 34.68 8.5  1.99E+08 P63267  
Actin, gamma-enteric smooth 
muscle  
2 33.23 2.5  1.00E+08 A5A3E0  
POTE ankyrin domain family 
member F  
2 33.23 2.5  1.00E+08 Q6S8J3  
POTE ankyrin domain family 
member E  
2 33.23 7.2  1.00E+08 Q9BYX7  Beta-actin-like protein 3  
2 33.23 7.2  1.00E+08 P63261  Actin, cytoplasmic 2 
2 33.23 7.2  1.00E+08 P60709  Actin, cytoplasmic 1 
1 18.93 4.2  9.56E+07 Q562R1  Beta-actin-like protein 2 
3 48.65 51.4  2.30E+08 P01842  Ig lambda chain C regions  
3 38.1 28.4  6.94E+07 P01591  Immunoglobulin J chain  
2 36.67 11.5  2.05E+07 Q6P5S2  Uncharacterized protein C6orf58  
2 35.37 6.6  7.89E+07 P06733  Alpha-enolase  




2 29.06 10.3  3.61E+07 P06870  Kallikrein-1  
2 27.57 7.1  2.38E+07 P02790  Hemopexin  
2 25.62 7.8  1.40E+07 P01857  Ig gamma-1 chain C region 
1 18.53 10.7  1.10E+07 P18510  
Interleukin-1 receptor antagonist 
protein  
1 17.65 10 4.12E+07 Q96DA0  
Zymogen granule protein 16 
homolog B  
1 17.1 15.7  3.11E+07 P01593  Ig kappa chain V-I region AG  
1 17.1 15.7  3.11E+07 P01594  Ig kappa chain V-I region AU 
1 17.1 15.7  3.11E+07 P01607  Ig kappa chain V-I region Rei  
1 17.1 15.7  3.11E+07 P01610  Ig kappa chain V-I region WEA  
1 17.1 15.7  3.11E+07 P01599  Ig kappa chain V-I region Gal  
1 17.1 15.7  3.11E+07 P01608  Ig kappa chain V-I region Roy  
1 17.1 15.7  3.11E+07 P01609  Ig kappa chain V-I region Scw  
1 17.1 15.7  3.11E+07 P80362  Ig kappa chain V-I region WAT  
1 17.1 15.7  3.11E+07 P01600  Ig kappa chain V-I region Hau  
1 16.67 13.1  2.26E+07 P06702  Protein S100-A9 
1 16.48 15 2.84E+07 P01766  Ig heavy chain V-III region BRO  
1 16.48 15.1  2.84E+07 P01777  Ig heavy chain V-III region TEI  
1 16.4 12.3  5.09E+07 P10599  Thioredoxin  
1 15.76 1.9  9.35E+06 Q02487  Desmocollin-2  
1 15.41 6.3  6.50E+06 Q9Y5Z4  Heme-binding protein 2  
1 15.27 12.2  2.39E+07 P04080  Cystatin-B OS=Homo sapiens  
1 14.43 4.5  1.48E+08 P23280  Carbonic anhydrase 6  
1 13.87 1.5  5.71E+06 P02671  Fibrinogen alpha chain  
1 13.16 11.8  8.05E+06 P05109  Protein S100-A8  
1 13.09 15.3  1.57E+07 P01776  Ig heavy chain V-III region WAS  
1 13.09 15.1  1.57E+07 P01774  Ig heavy chain V-III region POM  
1 13.09 15.5  1.57E+07 P01779  Ig heavy chain V-III region TUR  
1 13.09 15.6  1.57E+07 P01765  Ig heavy chain V-III region TIL  




















22 403.3 89.9  5.74E+10 Q9UBC9  Small proline-rich protein 3  
16 304.09 39.5  9.17E+09 P02768  Serum albumin  
16 285.9 45.3  8.96E+09 P29508  Serpin B3  
7 128.07 17.6  5.01E+09 P48594  Serpin B4  
18 269.92 22 4.13E+09 A8K2U0  Alpha-2-macroglobulin-like protein 1  
15 245.67 4.6  2.76E+09 Q09666  
Neuroblast differentiation-
associated protein AHNAK  
13 244.73 33.1  5.31E+09 P07476  Involucrin OS=Homo sapiens 
13 239.57 30.3  8.02E+09 P19013  Keratin, type II cytoskeletal 4  
1 21.92 2.2  2.71E+08 Q86Y46  Keratin, type II cytoskeletal 73  
1 15.99 2.3  6.07E+08 P08729  Keratin, type II cytoskeletal 7  
1 15.99 2.4  6.07E+08 Q6KB66  Keratin, type II cytoskeletal 80  
1 15.99 2.5  6.07E+08 P14136  Glial fibrillary acidic protein  
12 212.68 43.3  2.54E+09 P07355  Annexin A2  
8 138.64 26.8  1.95E+09 A6NMY6  Putative annexin A2-like protein  
10 184 48.6  3.76E+09 Q9UBG3  Cornulin  
9 157.66 48.4  8.12E+09 P01857  Ig gamma-1 chain C region  
4 61.96 19.5  8.33E+08 P01861  Ig gamma-4 chain C region  
4 59.82 15.3  1.17E+09 P01860  Ig gamma-3 chain C region  
8 131.52 50.5  3.14E+09 P80188  
Neutrophil gelatinase-associated 
lipocalin  
6 111.71 23.6  1.87E+09 P04083  Annexin A1  
7 104.24 14.5  4.00E+08 P01833  Polymeric immunoglobulin receptor  
6 92.53 52.6  5.02E+09 P06702  Protein S100-A9  
5 88.78 79.2  5.17E+09 P01834  Ig kappa chain C region  
4 74.83 15.5  1.72E+09 Q16610  Extracellular matrix protein 1  
4 67.62 44.4  3.24E+09 Q01469  
Fatty acid-binding protein, 
epidermal  
1 16.43 20.7  5.17E+08 A8MUU1  
Putative fatty acid-binding protein 5-
like protein 3  
4 62.36 66.3  1.96E+09 P01040  Cystatin-A  
3 58.81 51.6  6.70E+09 P22528  Cornifin-B  
2 38.13 34.8  5.23E+09 P35321  Cornifin-A  
4 56.17 18 5.14E+08 P01859  Ig gamma-2 chain C region  
3 52.1 39.7  1.56E+08 P32320  Cytidine deaminase  




2 36.01 43 6.15E+08 P22531  Small proline-rich protein 2E  
3 50.53 61.1  1.04E+09 P35325  Small proline-rich protein 2B  
2 46.86 11.2  3.75E+09 O95274  
Ly6/PLAUR domain-containing 
protein  
3 46.73 10 2.30E+08 O60235  
Transmembrane protease, serine 
11D  
3 43.3 29.5  3.28E+08 P10599  Thioredoxin  
3 37.77 51.4  8.17E+08 P01842  Ig lambda chain C regions  
2 37.38 16.2  2.01E+08 P61626  Lysozyme C  
2 35.26 23.6  8.17E+08 P05109  Protein S100-A8  
2 32.49 7.8  3.08E+07 P13796  Plastin-2  
2 31.89 9.6  6.21E+07 P31947  14-3-3 protein sigma  
2 30.36 3.5  5.40E+07 P02787  Serotransferrin  
2 28.37 30.6  1.49E+08 P31151  Protein S100-A7 
2 27.88 43 4.32E+08 P22532  Small proline-rich protein 2D  
1 13.36 25 1.04E+07 Q96RM1  Small proline-rich protein 2F  
2 24.97 2.7  2.03E+07 P12110  Collagen alpha-2(VI) chain  
1 21.35 29.2  1.50E+07 Q9UGL9  Cysteine-rich C-terminal protein 1  
1 21.21 23.3  6.07E+08 P00441  Superoxide dismutase [Cu-Zn]  
1 20.94 3.1  2.34E+08 P00751  Complement factor B  
1 20.1 6.5  1.31E+08 P54108  Cysteine-rich secretory protein 3  
1 19.71 3.3  2.17E+08 P01009  Alpha-1-antitrypsin  
1 19.67 15.2  5.67E+07 P31949  Protein S100-A11  
1 19.35 4.9  7.22E+07 P53634  Dipeptidyl-peptidase 1  
1 17.69 7.7  1.65E+07 P09488  Glutathione S-transferase Mu 1  
1 17.69 7.7  1.65E+07 P46439  Glutathione S-transferase Mu 5  
1 17.69 7.7  1.65E+07 Q03013  Glutathione S-transferase Mu 4  
1 17.04 7.8  4.45E+08 P04792  Heat shock protein beta-1  
1 17.02 0.6  1.79E+08 Q8TD57  Dynein heavy chain 3, axonemal  
1 16.82 12.2  8.06E+07 P04080  Cystatin-B  
1 16.22 0.9  2.71E+07 O60437  Periplakin  
1 16.07 22.9  7.02E+07 P07108  Acyl-CoA-binding protein  
1 16.02 0.4  1.14E+08 P20930  Filaggrin  
1 15.91 10.7  6.72E+07 P18510  
Interleukin-1 receptor antagonist 
protein  






1 14.92 18.8  3.43E+07 P19957  Elafin  
1 14.77 1.6  3.67E+07 P05164  Myeloperoxidase  
1 14.73 10.3  9.42E+06 P17900  Ganglioside GM2 activator 
1 14.66 9.4  4.78E+07 P01764  Ig heavy chain V-III region VH26  
1 14.64 7.1  1.61E+08 P25311  Zinc-alpha-2-glycoprotein  
1 14.54 10.5  2.22E+08 Q8N4C7  Syntaxin-19  
1 14.51 3.7  1.70E+08 P08238  Heat shock protein HSP 90-beta  
1 14.37 1.2  8.55E+07 Q9BXL7  
Caspase recruitment domain-
containing protein 11  
1 14.3 7 2.15E+08 Q8IUQ0  
Retinaldehyde-binding protein 1-
like protein 1  
1 14.12 4.2  8.12E+07 P01876  Ig alpha-1 chain C region  
1 13.93 17.5  3.83E+07 P60903  Protein S100-A10  
1 13.88 3.4  2.86E+08 Q02108  
Guanylate cyclase soluble subunit 
alpha-3  
1 13.79 1.4  9.01E+07 Q8WWQ8  Stabilin-2  
1 13.75 2.4  2.26E+07 P10909  Clusterin  
1 13.73 4.5  2.88E+07 Q8N4F0  
Bactericidal/permeability-
increasing protein-like 1  
1 13.7 1.3  8.77E+07 Q96C24  Synaptotagmin-like protein 4  
1 13.66 3 1.54E+08 Q8IYU2  E3 ubiquitin-protein ligase HACE1  
1 13.6 2.1  5.14E+06 P00450  Ceruloplasmin  
1 13.56 9.5  2.72E+07 P09211  Glutathione S-transferase P  
1 13.51 3.9  2.42E+07 Q9UBX7  Kallikrein-11  
1 13.44 2.7  8.82E+07 Q6AI39  Uncharacterized protein KIAA0240  
1 13.35 3.4  1.97E+07 Q8IYM0  Protein FAM186B  
1 13.33 6.3  4.96E+07 P02649  Apolipoprotein E  
1 13.23 1 1.78E+08 P21333  Filamin-A  
1 13.21 15 2.83E+07 P01766  Ig heavy chain V-III region BRO  
1 13.21 15.1  2.83E+07 P01777  Ig heavy chain V-III region TEI  
1 13.12 4.2  9.18E+07 P38646  Stress-70 protein, mitochondrial  
1 13.09 1 1.29E+08 Q8N3P4  
Vacuolar protein sorting-associated 




















48 911.81 76.1  1.95E+11 P02768  Serum albumin  
39 665.17 36.3  6.03E+09 P01024  Complement C3  
33 528.17 35.6  5.75E+09 P01023  Alpha-2-macroglobulin  
4 59.92 3.5  7.58E+08 P20742  Pregnancy zone protein  
26 467.91 46.7  8.70E+09 P02787  Serotransferrin  
19 310.25 62.5  1.42E+10 P02647  Apolipoprotein A-I  
16 266.69 50.4  5.98E+09 P01009  Alpha-1-antitrypsin  
16 263.75 37.6  2.14E+09 P02675  Fibrinogen beta chain  
17 262.95 29.4  1.96E+09 P00450  Ceruloplasmin  
13 247.81 89.7  1.45E+11 P68871  Hemoglobin subunit beta  
1 16.36 6.8  1.89E+10 P02100  Hemoglobin subunit epsilon 
1 16.36 6.8  1.89E+10 P69891  Hemoglobin subunit gamma-1 
1 16.36 6.8  1.89E+10 P69892  Hemoglobin subunit gamma-2  
11 204.24 80.9  6.30E+10 P02042  Hemoglobin subunit delta  
15 234.68 15.1  7.06E+08 P0C0L5  Complement C4-B  
15 234.68 15.1  7.06E+08 P0C0L4  Complement C4-A 
10 186.53 83.8  7.38E+10 P69905  Hemoglobin subunit alpha  
11 186.08 44.5  6.53E+09 P01857  Ig gamma-1 chain C region  
8 123.09 41.1  2.35E+09 P01859  Ig gamma-2 chain C region 
6 95.06 20.4  1.44E+09 P01860  Ig gamma-3 chain C region 
6 86.13 24.1  1.75E+09 P01861  Ig gamma-4 chain C region  
10 163.96 34.6  3.44E+09 P02790  Hemopexin  
9 145.45 31.2  1.53E+09 P02774  Vitamin D-binding protein 
9 139.82 28.9  2.53E+09 P02679  Fibrinogen gamma chain  
8 137.61 30.7  8.06E+08 P00738  Haptoglobin OS=Homo sapiens  
4 73.02 14.6  4.86E+08 P00739  Haptoglobin-related protein  
9 130.79 11.3  3.68E+08 P08603  Complement factor H  
8 121.8 3.1  3.25E+08 P04114  Apolipoprotein B-100  
6 101.04 32.4  4.84E+08 P02749  Beta-2-glycoprotein 1 
7 98.1 16.4  1.91E+08 P00751  Complement factor B  
5 96.27 17.1  5.22E+08 P01019  Angiotensinogen  






5 80.28 17.1  5.16E+08 P04217  Alpha-1B-glycoprotein 
4 73.77 66 2.94E+09 P01834  Ig kappa chain C region  
5 70.31 19 2.28E+08 P01871  Ig mu chain C region  
3 38.64 11.5  1.59E+08 P04220  Ig mu heavy chain disease protein  
4 67.01 21.5  1.01E+09 P02765  Alpha-2-HS-glycoprotein  
4 64.87 6.5  3.41E+08 P02671  Fibrinogen alpha chain  
4 63.4 10.5  3.09E+08 P01042  Kininogen-1  
4 60.11 6.5  1.88E+08 P19823  
Inter-alpha-trypsin inhibitor heavy 
chain H2  
3 54.3 47.1  5.24E+08 P0CG04  Ig lambda-1 chain C regions  
3 54.3 47.1  5.24E+08 P0CG05  Ig lambda-2 chain C regions  
3 54.3 47.1  5.24E+08 P0CG06  Ig lambda-3 chain C regions  
2 33.65 28.3  3.26E+08 P0CF74  Ig lambda-6 chain C region  
1 15.99 14.1  1.43E+08 A0M8Q6  Ig lambda-7 chain C region  
3 50.98 18.9  7.13E+08 P02763  Alpha-1-acid glycoprotein 1  
2 32.08 12.9  3.84E+08 P19652  Alpha-1-acid glycoprotein 2  
3 49.71 19.2  2.62E+08 P01876  Ig alpha-1 chain C region  
2 34.03 15.5  1.77E+08 P01877  Ig alpha-2 chain C region  
3 47.6 9.6  1.06E+08 P04004  Vitronectin  
3 47.03 5.1  2.99E+08 P19827  
Inter-alpha-trypsin inhibitor heavy 
chain H1  
3 44.64 21 2.01E+08 P00915  Carbonic anhydrase 1  
3 43.49 11.5  1.81E+08 P10909  Clusterin  
3 42.4 12.5  6.99E+07 P01008  Antithrombin-III  
2 39.68 4.8  1.80E+08 P01833  Polymeric immunoglobulin receptor  
2 35.13 7.8  2.03E+08 P01011  Alpha-1-antichymotrypsin 
2 31.36 5.6  1.30E+08 P00734  Prothrombin  
2 30.6 27.2  4.04E+08 P02656  Apolipoprotein C-III  
2 30 19.5  7.72E+07 Q9UBC9  Small proline-rich protein 3  
2 28.62 16.1  8.17E+07 P80188  
Neutrophil gelatinase-associated 
lipocalin  
2 28.39 6.5  1.05E+08 P02760  Protein AMBP  
2 25.2 19.1  6.42E+07 P59666  Neutrophil defensin 3  
2 25.2 19.1  6.42E+07 P59665  Neutrophil defensin 1  
2 24 1.9  2.58E+08 Q7Z442  
Polycystic kidney disease protein 1-
like 2  
1 20.65 2.3  6.86E+07 Q14624  
Inter-alpha-trypsin inhibitor heavy 





1 19.59 14.9  4.97E+07 P02766  Transthyretin O 
1 18.06 0.9  2.62E+07 Q86VH2  Kinesin-like protein KIF27  
1 16.65 9 6.14E+07 P03973  Antileukoproteinase  
1 15.75 3.2  1.56E+07 P06727  Apolipoprotein A-IV  
1 15 15.7  2.98E+07 P22528  Cornifin-B  
1 15 15.7  2.98E+07 P35321  Cornifin-A  
1 14.83 4.2  3.25E+07 P68133  Actin, alpha skeletal muscle  
1 14.83 4.2  3.25E+07 P68032  Actin, alpha cardiac muscle 1  
1 14.83 4.2  3.25E+07 P62736  Actin, aortic smooth muscle  
1 14.83 4.2  3.25E+07 P63267  
Actin, gamma-enteric smooth 
muscle  
1 14.47 18.4  1.49E+07 P61769  Beta-2-microglobulin  
1 14.38 1.7  2.12E+07 P04196  Histidine-rich glycoprotein  
1 13.64 7.1  9.06E+07 P25311  Zinc-alpha-2-glycoprotein  
1 13.49 3.3  2.92E+08 Q8NB16  
Mixed lineage kinase domain-like 
protein 
1 13.26 1.4  6.21E+06 P01031  Complement C5  


















Appendix C: Unfractionated Protein Identification Results 












28 541.87 54.2  7.25E+07 P02788  Lactotransferrin 
28 496.3 57.1  2.23E+08 P02768  Serum albumin 
26 467.91 57.7 1.09E+09 P04279 Semenogelin-1 
22 404.47 42.2 7.34E+08 Q02383 Semenogelin-2 
9 170.5 29.5  4.74E+07 P15309  Prostatic acid phosphatase 
10 168.46 28.7  3.01E+07 P10909  Clusterin 
9 160.45 7.3  1.00E+07 P02751  Fibronectin 
9 159.21 57.4 5.73E+07 P07288 Prostate-specific antigen 
9 151.06 63 1.07E+08 P12273 Prolactin-inducible protein 
8 131.22 7.5  1.07E+07 Q6W4X9  Mucin-6 
4 68.39 21.4  1.18E+07 P25311  Zinc-alpha-2-glycoprotein 
1 14.26 4.9  2.66E+05 A8MT79  
Putative zinc-alpha-2-glycoprotein-
like 1 
3 62.69 32.4 4.36E+07 P61916 Epididymal secretory protein E1 
3 54.64 7.3  4.71E+06 P02787  Serotransferrin 
3 47.14 25.3  1.02E+06 P01034  Cystatin-C 
3 39.52 8.3  9.22E+05 Q16610  Extracellular matrix protein 1 
2 35.97 18.8 2.74E+06 P09466 Glycodelin 
2 35.89 9.1  1.48E+06 P07602  Prosaposin 
2 28.62 38.7  1.99E+05 Q14508  
WAP four-disulfide core domain 
protein 2 
2 26.28 19.1  1.06E+05 P49223  Kunitz-type protease inhibitor 3 
1 23.79 8 7.42E+06 P54107  Cysteine-rich secretory protein 1 
1 20.93 4.6  1.80E+06 P16870  Carboxypeptidase E 
1 17.34 18.4  9.10E+06 P61769  Beta-2-microglobulin 
1 15.99 2.2  3.71E+04 Q08380  Galectin-3-binding protein 
1 15.08 4 5.70E+05 P01009  Alpha-1-antitrypsin 
1 14.62 15.2  1.97E+06 P41222  Prostaglandin-H2 D-isomerase 
1 14.22 14.7  8.09E+05 P07998  Ribonuclease pancreatic 
1 14.03 14.7  1.91E+04 P49913  Cathelicidin antimicrobial peptide 


















33 609.38 62.5  1.48E+08 P02768  Serum albumin  
13 267.7 49.1  6.65E+07 P02760  Protein AMBP  
13 200.77 22.6  7.21E+06 P04264  Keratin, type II cytoskeletal 1  
2 34.77 3.2  2.07E+06 Q7Z794  Keratin, type II cytoskeletal 1b  
5 72.43 8.5  1.40E+06 P04259  Keratin, type II cytoskeletal 6B  
12 186.83 24.6  9.41E+06 P07911  Uromodulin  
9 162.52 44.8  5.12E+06 P01857  Ig gamma-1 chain C region  
3 55.76 14.6  3.30E+06 P01861  Ig gamma-4 chain C region  
3 48.19 9 2.63E+06 P01860  Ig gamma-3 chain C region  
4 57.21 15.6  2.86E+06 P01859  Ig gamma-2 chain C region  
9 154.59 34.2  2.03E+06 P04745  Alpha-amylase 1 
8 137.56 29.5  2.14E+06 P04746  Pancreatic alpha-amylase  
9 147.8 15.3  9.84E+06 P01042  Kininogen-1  
8 144.38 12.2  8.22E+06 Q14624  
Inter-alpha-trypsin inhibitor heavy 
chain H4  
8 126.26 36.3  1.38E+07 P10451  Osteopontin  
7 120.82 2.4  3.48E+06 P98160  
Basement membrane-specific 
heparan sulfate proteoglycan core 
protein  
6 119.93 24.6  3.38E+06 P01009  Alpha-1-antitrypsin  
7 114.17 16.7  6.05E+06 Q6EMK4  Vasorin  
7 110.66 13.3  2.39E+06 P35527  Keratin, type I cytoskeletal 9 
6 110.11 15.3  1.75E+06 P01833  
Polymeric immunoglobulin 
receptor  
5 94.22 79.2  2.30E+07 P01834  Ig kappa chain C region  
5 85.37 24.4  1.26E+06 P25311  
Zinc-alpha-2-glycoprotein 
OS=Homo sapiens  
1 13.26 4.9  1.46E+05 A8MT79  
Putative zinc-alpha-2-glycoprotein-
like 1  
5 79.53 16.6  4.32E+05 P05155  Plasma protease C1 inhibitor  
5 79.32 24.7  1.91E+06 Q12907  
Vesicular integral-membrane 
protein VIP36  
5 75.62 5.9  6.02E+05 P01133  Pro-epidermal growth factor 
4 73.04 11 1.97E+06 P00734  Prothrombin 
4 72.69 23.4  2.73E+05 P02749  Beta-2-glycoprotein 1 
5 70.77 8.5  1.08E+06 P02538  Keratin, type II cytoskeletal 6A  
5 70.77 8.5  1.08E+06 P48668  Keratin, type II cytoskeletal 6C  




2 29.6 3.5  6.07E+05 Q5XKE5  Keratin, type II cytoskeletal 79  
3 42.21 5.6  2.63E+05 P19013  Keratin, type II cytoskeletal 4  
5 70.49 13.7  6.84E+05 P08779  Keratin, type I cytoskeletal 16  
3 46.09 6.7  4.59E+05 P02533  Keratin, type I cytoskeletal 14  
3 46.09 7 4.59E+05 P19012  Keratin, type I cytoskeletal 15  
2 30.35 4.6  3.04E+05 Q04695  Keratin, type I cytoskeletal 17  
2 27.71 5 2.62E+05 P13646  Keratin, type I cytoskeletal 13  
1 18.38 2.2  1.97E+05 P08727  Keratin, type I cytoskeletal 19  
4 69.37 36.6  3.25E+05 Q7Z5L0  
Vitelline membrane outer layer 
protein 1 homolog 
4 67.81 27.7  1.13E+06 P02765  Alpha-2-HS-glycoprotein  
4 65.5 17.2  1.17E+06 P01876  
Ig alpha-1 chain C region OS=Homo 
sapiens GN=IGHA1 PE=1 SV=2 
3 48.28 14.4  7.96E+05 P01877  Ig alpha-2 chain C region  
3 63.27 32.6  1.67E+07 P41222  Prostaglandin-H2 D-isomerase  
3 61.55 6.3  1.21E+05 P10253  Lysosomal alpha-glucosidase  
3 59.66 11.6  1.99E+06 P15309  Prostatic acid phosphatase  
4 59.07 6.3  1.54E+05 P00450  Ceruloplasmin  
3 56.69 16.3  1.12E+06 Q9UNN8  Endothelial protein C receptor  
3 55.51 4.1  1.13E+06 P16070  CD44 antigen  
3 49.93 16.4  5.06E+05 P02750  Leucine-rich alpha-2-glycoprotein  
3 49.34 21.4  3.08E+05 O75594  Peptidoglycan recognition protein  
3 43.97 19.5  7.77E+06 P13987  CD59 glycoprotein  
2 41.46 30.2  1.01E+06 P04206  Ig kappa chain V-III region GOL  
2 41.46 30.2  1.01E+06 P01622  Ig kappa chain V-III region Ti  
2 41.46 30.2  1.01E+06 P01620  Ig kappa chain V-III region SIE  
2 41.46 30.2  1.01E+06 P01623  Ig kappa chain V-III region WOL  
1 22.69 12.4  8.99E+05 P18135  Ig kappa chain V-III region HAH  
1 22.69 12.4  8.99E+05 P18136  Ig kappa chain V-III region HIC  
2 39.17 28.3  1.72E+06 P0CG04  Ig lambda-1 chain C regions  
2 39.17 28.3  1.72E+06 P0CG05  Ig lambda-2 chain C regions  
2 39.17 28.3  1.72E+06 P0CF74  Ig lambda-6 chain C region  
2 39.17 28.3  1.72E+06 P0CG06  Ig lambda-3 chain C regions  
1 17.36 14.1  2.73E+05 A0M8Q6  Ig lambda-7 chain C region  





2 38.98 14.5  6.68E+05 Q8WVN6  
Secreted and transmembrane 
protein 1  
2 38.92 21.8  3.00E+05 P19652  Alpha-1-acid glycoprotein 2 
2 37.92 9.6  1.35E+05 P08571  
Monocyte differentiation antigen 
CD14  
2 37.2 13.8  3.99E+05 Q16270  
Insulin-like growth factor-binding 
protein 7  
2 37.12 14.2  2.14E+05 Q9UBC9  Small proline-rich protein 3  
2 36.8 5 3.68E+05 P02671  Fibrinogen alpha chain  
2 35.97 18 2.17E+05 P24855  Deoxyribonuclease-1  
2 34.83 9.3  2.09E+05 P10153  Non-secretory ribonuclease  
2 34.28 31.8  2.29E+05 P01617  Ig kappa chain V-II region TEW  
1 15.86 9.7  1.52E+05 P06310  Ig kappa chain V-II region RPMI 6410  
1 15.86 11.3  1.52E+05 P01614  Ig kappa chain V-II region Cum  
1 15.86 11.1  1.52E+05 P06309  
Ig kappa chain V-II region GM607 
(Fragment)  
2 33.11 10.2  6.24E+05 Q16769  Glutaminyl-peptide cyclotransferase  
2 32.82 3.4  8.09E+05 P14543  Nidogen-1  
2 32.44 13.2  5.00E+05 P05090  Apolipoprotein D  
2 32.41 37.8  7.26E+05 P55000  
Secreted Ly-6/uPAR-related protein 
1  
2 31.79 5.8  6.08E+04 P02787  Serotransferrin  
2 31.52 4.8  7.40E+04 P04217  Alpha-1B-glycoprotein  
2 28.05 4.9  4.15E+05 P05154  Plasma serine protease inhibitor  
2 27.98 30.1  1.75E+06 P07998  Ribonuclease pancreatic  
2 26.79 8 2.99E+05 P07288  Prostate-specific antigen  
1 21.58 15.7  1.56E+05 P01593  Ig kappa chain V-I region AG  
1 21.58 15.7  1.56E+05 P01594  Ig kappa chain V-I region AU  
1 21.58 15.7  1.56E+05 P01607  Ig kappa chain V-I region Rei  
1 21.58 15.7  1.56E+05 P01610  Ig kappa chain V-I region WEA  
1 21.58 15.7  1.56E+05 P01599  Ig kappa chain V-I region Gal  
1 21.58 15.7  1.56E+05 P01608  Ig kappa chain V-I region Roy  
1 21.58 15.7  1.56E+05 P01609  Ig kappa chain V-I region Scw  
1 21.58 15.7  1.56E+05 P80362  Ig kappa chain V-I region WAT  
1 21.58 15.7  1.56E+05 P01600  Ig kappa chain V-I region Hau 
1 20.23 14.9  3.51E+04 P01625  Ig kappa chain V-IV region Len 
1 19.71 3 4.28E+04 P04279  Semenogelin-1  





1 19.54 33.8  1.94E+06 P60022  Beta-defensin 1  
1 19.32 1.5  1.06E+05 P55290  Cadherin-13  
1 18.39 4.6  4.84E+05 P02774  Vitamin D-binding protein  
1 18.24 6.9  2.85E+05 P02763  Alpha-1-acid glycoprotein 1  
1 17.92 18.4  1.00E+06 P61769  Beta-2-microglobulin  
1 17.82 11.2  2.53E+05 Q14508  
WAP four-disulfide core domain 
protein 2  
1 17.23 2.9  6.61E+04 Q08380  Galectin-3-binding protein  
1 16.1 5.1  5.26E+04 P10909  Clusterin  
1 15.81 15.5  3.80E+04 Q01469  
Fatty acid-binding protein, 
epidermal  
1 15.81 20.7  3.80E+04 A8MUU1  
Putative fatty acid-binding protein 5-
like protein 3 
1 15.12 3.1  1.00E+05 Q8WZ75  Roundabout homolog 4  
1 15.05 3.8  2.65E+04 P22792  Carboxypeptidase N subunit 2  
1 14.51 13.1  6.25E+04 P06702  Protein S100-A9  
1 14.33 1.4  1.67E+05 Q8IWU5  
Extracellular sulfatase Sulf-2 
OS=Homo sapiens  
1 14.23 3.7  2.73E+04 P36896  Activin receptor type-1B  
1 14.2 20.4  3.57E+04 Q9H299  
SH3 domain-binding glutamic acid-
rich-like protein 3  
1 14.04 2 2.60E+04 P12830  Cadherin-1 
1 13.87 29.6  6.38E+04 P11684  Uteroglobin  
1 13.82 3.8  4.82E+04 Q9BRK3  
Matrix-remodeling-associated 
protein 8 
1 13.36 1.7  6.71E+04 P39060  Collagen alpha-1(XVIII) chain  
1 13.25 21 2.99E+04 P62988  Ubiquitin  























41 689.84 11.3  2.50E+07 Q9HC84  Mucin-5B  
3 48.8 0.7  3.84E+05 P98088  Mucin-5AC (Fragments)  
33 532.82 58.9  2.97E+07 P02768  Serum albumin  
25 507.56 67.1  3.71E+08 P04745  Alpha-amylase 1  
18 363.52 46.7  2.23E+08 P19961  Alpha-amylase 2B  
17 344.83 45.4  2.07E+08 P04746  Pancreatic alpha-amylase  
19 333.39 35.8  1.41E+07 P01833  
Polymeric immunoglobulin 
receptor  
11 198.38 61.7  3.00E+07 P01876  Ig alpha-1 chain C region 
8 139.51 39.4  2.56E+07 P01877  Ig alpha-2 chain C region  
9 151.85 39.2  3.66E+06 P25311  Zinc-alpha-2-glycoprotein  
3 39.44 13.2  1.98E+05 A8MT79  
Putative zinc-alpha-2-glycoprotein-
like 1 
9 147.94 32.5  4.69E+06 Q8N4F0  
Bactericidal/permeability-
increasing protein-like 1 
8 124.34 34.1  2.50E+06 Q96DR5  
Short palate, lung and nasal 
epithelium carcinoma-associated 
protein 2 
7 118.85 45.1  7.10E+06 Q96DA0  
Zymogen granule protein 16 
homolog  
6 115.61 61.7  4.01E+07 P01036  Cystatin-S  
6 115.35 60.2  2.77E+07 P01037  Cystatin-SN  
4 69.47 42.5  1.23E+07 P09228  Cystatin-SA  
6 106.13 43.1  6.81E+06 P12273  Prolactin-inducible protein  
6 102.13 22 3.40E+06 P23280  Carbonic anhydrase 6  
6 101.26 79.2  5.33E+06 P01834  Ig kappa chain C region  
6 93.21 61.2  7.04E+06 P28325  Cystatin-D  
5 80.69 44.3  3.12E+06 P31025  Lipocalin-1  
2 26.49 11.1  1.40E+06 Q5VSP4  Putative lipocalin 1-like protein 1  
4 75.43 65 3.70E+06 P0CG05  Ig lambda-2 chain C regions  
4 75.43 65 3.70E+06 P0CG06  Ig lambda-3 chain C regions  
3 60.73 46.2  1.91E+06 P0CF74  Ig lambda-6 chain C region 
3 56.91 47.1  3.02E+06 P0CG04  Ig lambda-1 chain C regions 
2 38.67 32 1.47E+06 A0M8Q6  Ig lambda-7 chain C region 
4 73.04 39.8  3.17E+06 P61626  Lysozyme C  
4 70.51 14.4  2.94E+06 P13646  Keratin, type I cytoskeletal 13  
2 37.45 3.8  2.24E+06 Q99456  Keratin, type I cytoskeletal 12  




4 67.27 7.3  5.10E+05 P02788  Lactotransferrin  
3 60.54 14.8  9.72E+05 P01857  Ig gamma-1 chain C region 
1 16.99 4.2  4.50E+05 P01860  Ig gamma-3 chain C region 
1 16.99 4.8  4.50E+05 P01861  Ig gamma-4 chain C region 
4 59.36 29.5  8.11E+05 P01591  Immunoglobulin J chain 
2 45.17 65.8  9.07E+07 P02814  
Submaxillary gland androgen-
regulated protein 3B 
3 43.96 9 1.60E+06 Q8TAX7  Mucin-7 OS=Homo sapiens  
3 42.2 37.7  1.99E+05 P06702  Protein S100-A9 
2 38.83 26.8  6.19E+05 P61769  Beta-2-microglobulin  
2 37.37 12.2  3.15E+05 P63261  Actin, cytoplasmic 2  
2 37.37 12.2  3.15E+05 P60709  Actin, cytoplasmic 1  
1 16.64 1.4  1.27E+05 A5A3E0  
POTE ankyrin domain family 
member F  
1 16.64 1.4  1.27E+05 Q6S8J3  
POTE ankyrin domain family 
member E  
1 16.64 4.2  1.27E+05 P68133  Actin, alpha skeletal muscle  
1 16.64 4.2  1.27E+05 P68032  Actin, alpha cardiac muscle 1  
1 16.64 4.2  1.27E+05 Q9BYX7  Putative beta-actin-like protein 3  
1 16.64 4.2  1.27E+05 P62736  Actin, aortic smooth muscle  
1 16.64 4.2  1.27E+05 Q562R1  Beta-actin-like protein 2  
1 16.64 4.2  1.27E+05 P63267  
Actin, gamma-enteric smooth 
muscle  
2 36.36 11.2  7.75E+05 Q6P5S2  UPF0762 protein C6orf58  
2 33.2 19.1  6.37E+05 P01034  Cystatin-C 
2 33.02 9.7  7.40E+05 P54108  Cysteine-rich secretory protein 3  
2 32.09 3.3  2.58E+05 P22079  Lactoperoxidase  
2 29.81 33.6  8.38E+05 P04080  Cystatin-B 
2 28.67 20.4  9.55E+04 P03973  Antileukoproteinase  
1 19.48 2.8  1.63E+05 P19013  Keratin, type II cytoskeletal 4  
1 19.19 0.5  9.45E+05 Q9UGM3  
Deleted in malignant brain tumors 1 
protein  
1 18.7 4.7  1.68E+05 P04259  Keratin, type II cytoskeletal 6B  
1 18.7 4.7  1.68E+05 P02538  Keratin, type II cytoskeletal 6A  
1 18.7 4.7  1.68E+05 P48668  Keratin, type II cytoskeletal 6C  
1 18.34 5 1.10E+05 P80303  Nucleobindin-2  
1 18.21 2.7  1.86E+05 P20061  Transcobalamin-1 




1 16.77 9.7  1.72E+05 P06310  Ig kappa chain V-II region RPMI 6410  
1 16.77 11.3  1.72E+05 P01614  Ig kappa chain V-II region Cum  
1 16.77 11.1  1.72E+05 P06309  Ig kappa chain V-II region GM607  
1 16.77 11.5  1.72E+05 P01617  Ig kappa chain V-II region TEW  
1 16.09 48.3  3.41E+07 P02808  Statherin  
1 15.83 28 2.29E+05 P15515  Histatin-1  
1 15.7 15 1.94E+05 P01766  Ig heavy chain V-III region BRO  
1 15.7 15.1  1.94E+05 P01777  Ig heavy chain V-III region TEI  
1 15.03 12.4  7.14E+04 P18135  Ig kappa chain V-III region HAH  
1 15.03 12.4  7.14E+04 P18136  Ig kappa chain V-III region HIC  
1 15.03 14.6  7.14E+04 P04206  Ig kappa chain V-III region GOL  
1 15.03 14.6  7.14E+04 P01622  Ig kappa chain V-III region Ti  
1 15.03 14.6  7.14E+04 P01620  Ig kappa chain V-III region SIE  
1 15.03 14.6  7.14E+04 P01623  Ig kappa chain V-III region WOL  
1 13.68 2 1.34E+05 P02787  Serotransferrin  
1 13.37 2.4  8.73E+04 P01871  Ig mu chain C region 




























52 847.87 13.3  4.79E+07 Q09666  
Neuroblast differentiation-
associated protein AHNAK  
42 753.16 70.9  1.05E+09 P02768  Serum albumin 
25 423.88 88.7  4.89E+08 Q9UBC9  Small proline-rich protein 3 
24 419.66 68.4  5.78E+07 P07355  Annexin A2  
17 285.75 46 3.90E+07 A6NMY6  Putative annexin  
24 414.07 58.9  7.78E+07 P13646  Keratin, type I cytoskeletal 13  
3 57.83 5.4  1.85E+07 Q99456  Keratin, type I cytoskeletal 12  
3 49.5 4.2  5.12E+06 P35900  Keratin, type I cytoskeletal 20  
1 19.31 3 1.49E+06 Q8N1A0  Keratin-like protein KRT222 
1 15.11 2 6.39E+05 Q2M2I5  Keratin, type I cytoskeletal 24  
8 123.93 12.5  1.41E+07 P19012  Keratin, type I cytoskeletal 15  
4 69.46 6.7  6.11E+06 P02533  Keratin, type I cytoskeletal 14  
4 69.46 6.7  6.11E+06 P08779  Keratin, type I cytoskeletal 16  
3 50.82 4.6  4.56E+06 Q04695  Keratin, type I cytoskeletal 17  
5 80.89 9.5  2.32E+06 P13645  Keratin, type I cytoskeletal 10  
23 412.11 47.1  2.68E+07 P02788  Lactotransferrin  
22 389.74 39.9  2.19E+07 P02787  Serotransferrin  
21 376.19 52.3  6.90E+07 P29508  Serpin B3  
12 194.04 33.8  3.89E+07 P48594  Serpin B4  
18 314.26 53.1  5.37E+07 P04083  Annexin A1 
19 309.55 34.5  4.13E+07 P02538  Keratin, type II cytoskeletal 6A  
3 41.32 3.6  1.55E+06 P12035  Keratin, type II cytoskeletal 3  
2 29.48 1.8  1.32E+06 Q01546  Keratin, type II cytoskeletal 2 oral  
2 29.48 2.1  1.32E+06 O95678  Keratin, type II cytoskeletal 75  
2 29.48 2.2  1.32E+06 Q5XKE5  Keratin, type II cytoskeletal 79  
1 18.81 2.9  1.08E+05 Q14CN4  Keratin, type II cytoskeletal 72  
17 263.55 29.9  2.63E+07 P04259  Keratin, type II cytoskeletal 6B  
11 170.1 19.4  1.74E+07 P13647  Keratin, type II cytoskeletal 5  
3 50.1 3.7  3.24E+06 P35908  Keratin, type II cytoskeletal 2  
2 32.47 4.1  3.98E+06 P05787  Keratin, type II cytoskeletal 8  
20 304.68 21.3  7.53E+06 P01023  Alpha-2-macroglobulin  





17 283.75 27.3  3.56E+07 P04264  Keratin, type II cytoskeletal 1  
1 20.62 2 1.92E+06 Q7Z794  Keratin, type II cytoskeletal 1b  
1 18.57 2.3  2.95E+06 P08729  Keratin, type II cytoskeletal 7  
1 18.57 2.4  2.95E+06 Q6KB66  Keratin, type II cytoskeletal 80  
1 18.57 2.5  2.95E+06 P14136  Glial fibrillary acidic protein  
12 189.75 23 2.30E+07 P19013  Keratin, type II cytoskeletal 4  
12 244.23 88.4  5.64E+07 P68871  Hemoglobin subunit beta 
1 18.47 6.8  2.44E+06 P02100  Hemoglobin subunit epsilon  
1 18.47 6.8  2.44E+06 P69891  Hemoglobin subunit gamma-1  
1 18.47 6.8  2.44E+06 P69892  Hemoglobin subunit gamma-2  
7 146.42 48.9  3.33E+07 P02042  Hemoglobin subunit delta 
13 237.08 48.8  5.43E+07 Q9UBG3  Cornulin OS=Homo sapiens  
12 233.38 53 9.33E+07 P01857  Ig gamma-1 chain C region  
8 131.82 35.8  1.62E+07 P01859  Ig gamma-2 chain C region  
7 125.84 33.9  2.10E+07 P01861  Ig gamma-4 chain C region  
13 233.3 70.3  6.72E+07 Q01469  
Fatty acid-binding protein, 
epidermal  
2 42.47 26.7  1.63E+07 A8MUU1  
Putative fatty acid-binding protein 5-
like protein 3 
16 233.19 15.8  6.26E+06 A8K2U0  Alpha-2-macroglobulin-like protein 1  
13 218 31.4  4.20E+06 P13796  Plastin-2 
3 46.9 5.5  1.17E+06 P13797  Plastin-3 
2 32.04 3.4  7.47E+05 Q14651  Plastin-1  
15 207.5 9.8  2.86E+06 P01024  Complement C3  
11 204.17 62.3  3.94E+07 P31151  Protein S100-A7  
3 57.35 23.7  1.86E+07 Q86SG5  Protein S100-A7A  
12 194.91 4.7  6.12E+06 Q9Y6R7  IgGFc-binding protein  
11 174.31 27.6  1.50E+07 P07476  Involucrin  
10 168.05 61.1  3.26E+07 P80188  
Neutrophil gelatinase-associated 
lipocalin 
7 124.77 64 5.57E+07 P69905  Hemoglobin subunit alpha 
8 123.28 29.3  1.48E+07 P63261  Actin, cytoplasmic 2 
8 123.28 29.3  1.48E+07 P60709  Actin, cytoplasmic 1 
4 57.89 9.5  4.11E+06 P68133  Actin, alpha skeletal muscle  
4 57.89 9.5  4.11E+06 P68032  Actin, alpha cardiac muscle 1  






4 57.89 9.5  4.11E+06 P63267  
Actin, gamma-enteric smooth 
muscle  
3 47.44 2.7  4.58E+06 A5A3E0  
POTE ankyrin domain family 
member F  
3 47.44 2.7  4.58E+06 Q6S8J3  
POTE ankyrin domain family 
member E  
3 47.44 2.7  4.58E+06 P0CG38  
POTE ankyrin domain family 
member I  
2 27.54 1.8  1.70E+06 P0CG39  
POTE ankyrin domain family 
member J  
1 17.22 3.4  1.42E+06 Q9BYX7  Putative beta-actin-like protein 3  
7 116.59 36.2  1.05E+07 P01876  Ig alpha-1 chain C region 
4 63.78 21.4  4.12E+06 P01877  Ig alpha-2 chain C region 
7 111.57 14.3  2.67E+06 P01833  Polymeric immunoglobulin receptor 
7 106.6 19.9  1.91E+06 Q9UIV8  Serpin B13 
5 103.33 64.1  6.95E+07 P01834  Ig kappa chain C region  
6 97.2 87.6  7.92E+07 P22528  Cornifin-B  
5 80.41 78.6  7.53E+07 P35321  Cornifin-A 
6 96.59 45.6  6.72E+07 P06702  Protein S100-A9  
6 93.59 23.2  2.58E+06 P12429  Annexin A3  
7 93.18 11.3  2.73E+06 P14780  Matrix metalloproteinase-9 
5 88.11 21.6  2.36E+06 P02790  Hemopexin 
4 85.66 65 2.77E+07 P0CG05  Ig lambda-2 chain C regions  
4 85.66 65 2.77E+07 P0CG06  Ig lambda-3 chain C regions 
3 65.99 47.1  2.00E+07 P0CG04  Ig lambda-1 chain C regions  
3 65.55 46.2  2.49E+07 P0CF74  Ig lambda-6 chain C region  
2 40.77 32 1.03E+07 A0M8Q6  Ig lambda-7 chain C region  
6 85.62 18.5  1.63E+06 P02675  Fibrinogen beta chain  
5 85.06 44 2.09E+07 P05109  Protein S100-A8  
4 83.58 64.7  1.07E+07 P31949  Protein S100-A11  
5 81.66 5.1  1.73E+06 Q9NQ38  
Serine protease inhibitor Kazal-type 
5  
4 77.65 21.9  1.10E+07 O95274  
Ly6/PLAUR domain-containing 
protein  
5 76.99 24.3  1.94E+06 P02647  Apolipoprotein A-I  
4 74.65 32.3  3.95E+06 P02763  Alpha-1-acid glycoprotein 1  
2 33.8 12.9  1.94E+06 P19652  Alpha-1-acid glycoprotein 2 
4 72.92 66.6  3.61E+07 P35326  Small proline-rich protein 2A  
1 17.82 17.8  2.63E+07 Q9BYE4  Small proline-rich protein 2G  




3 48.95 54.1  3.04E+07 P22532  Small proline-rich protein 2D  
3 51.55 66.6  3.28E+07 P22531  Small proline-rich protein 2E  
4 65.82 75.5  6.95E+06 P01040  Cystatin-A 
4 62.89 6.3  1.36E+06 P05164  Myeloperoxidase 
4 62.47 39.7  3.70E+06 P04080  Cystatin-B  
3 61.15 38 6.01E+06 P10599  Thioredoxin  
3 60.69 35.1  7.39E+06 P61626  Lysozyme C OS=Homo sapiens  
4 56.7 14 1.85E+06 P00738  Haptoglobin OS=Homo sapiens  
2 28.75 6.8  3.41E+05 P00739  Haptoglobin-related protein  
3 55.79 13.7  1.95E+06 P04406  
Glyceraldehyde-3-phosphate 
dehydrogenase  
3 55.66 22.4  4.64E+05 P30086  
Phosphatidylethanolamine-binding 
protein 1  
3 51.45 20.5  2.98E+06 P08246  Neutrophil elastase  
2 50.87 17.9  1.62E+06 P54108  Cysteine-rich secretory protein 3 
3 49.79 24.2  7.85E+05 P18510  
Interleukin-1 receptor antagonist 
protein 
3 49.27 4.1  1.67E+05 P00450  Ceruloplasmin  
3 48.99 17.1  4.44E+05 P32119  Peroxiredoxin-2  
3 48.92 9.2  4.89E+05 P01871  Ig mu chain C region  
2 26.68 6.6  1.83E+05 P04220  Ig mu heavy chain disease protein  
3 48.41 11.9  8.05E+05 Q9UKR3  Kallikrein-13  
3 46.49 52.8  2.51E+06 P07108  Acyl-CoA-binding protein  
3 42.8 29 1.18E+06 P19957  Elafin 
2 41.75 30.2  1.82E+06 P04206  Ig kappa chain V-III region GOL  
2 41.75 30.2  1.82E+06 P01622  Ig kappa chain V-III region Ti  
2 41.75 30.2  1.82E+06 P01620  Ig kappa chain V-III region SIE  
2 41.75 30.2  1.82E+06 P01623  Ig kappa chain V-III region WOL  
1 20.34 12.4  4.86E+05 P18135  Ig kappa chain V-III region HAH  
1 20.34 12.4  4.86E+05 P18136  Ig kappa chain V-III region HIC  
2 39.18 0.7  5.01E+05 Q9HC84  Mucin-5B  
2 37.04 13.1  3.13E+05 Q92876  Kallikrein-6 
2 36.24 24.1  3.13E+06 P01766  Ig heavy chain V-III region BRO  
1 21.57 15.1  2.96E+06 P01777  Ig heavy chain V-III region TEI  
1 14.67 9.5  1.77E+05 P01767  Ig heavy chain V-III region BUT  






2 36.2 19.1  1.07E+07 P59666  Neutrophil defensin 3  
2 36.2 19.1  1.07E+07 P59665  Neutrophil defensin 1 
2 33.97 22.9  7.76E+05 P04792  Heat shock protein beta-1 
2 33.78 5.9  6.52E+05 O95171  Sciellin  
2 33.78 11.7  6.76E+05 P08311  Cathepsin G  
2 32.92 36.1  6.55E+06 Q96RM1  Small proline-rich protein 2F  
2 32.56 4.6  1.25E+06 Q16610  Extracellular matrix protein 1  
2 32.25 4.9  3.17E+05 P29401  Transketolase 
2 31.65 5.9  1.95E+05 P22894  Neutrophil collagenase 
2 31.62 4.5  4.08E+05 P14618  Pyruvate kinase isozymes M1/M2  
2 30.83 7.1  5.92E+05 P37837  Transaldolase  
2 29.54 20.4  2.69E+06 P03973  Antileukoproteinase  
2 28.69 7 6.36E+05 P07951  Tropomyosin beta chain  
2 28.69 8 6.36E+05 P67936  Tropomyosin alpha-4 chain  
1 14.42 3.5  5.55E+05 P06753  Tropomyosin alpha-3 chain  
1 14.42 3.5  5.55E+05 P09493  Tropomyosin alpha-1 chain  
2 28.26 12.9  6.82E+05 Q6UWP8  Suprabasin  
2 27.75 6.6  2.74E+05 P24158  Myeloblastin  
2 27.02 3 1.20E+06 P0CG48  Polyubiquitin-C  
2 27.02 9.1  1.20E+06 P0CG47  Polyubiquitin-B  
2 27.02 13.4  7.91E+05 P62979  
Ubiquitin-40S ribosomal protein 
S27a  
2 27.02 16.4  7.91E+05 P62987  Ubiquitin-60S ribosomal protein L40  
2 26.63 7.4  1.34E+06 P04075  Fructose-bisphosphate aldolase A  
2 25.38 10.4  9.06E+05 P16402  Histone H1.3  
2 25.38 10.5  9.06E+05 P10412  Histone H1.4  
2 25.38 10.7  9.06E+05 P16403  Histone H1.2 
1 23.21 15.7  6.14E+05 P01593  Ig kappa chain V-I region AG  
1 23.21 15.7  6.14E+05 P01594  Ig kappa chain V-I region AU  
1 23.21 15.7  6.14E+05 P01607  Ig kappa chain V-I region Rei  
1 23.21 15.7  6.14E+05 P01610  Ig kappa chain V-I region WEA  
1 23.21 15.7  6.14E+05 P01599  Ig kappa chain V-I region Gal  
1 23.21 15.7  6.14E+05 P01608  Ig kappa chain V-I region Roy  







1 23.21 15.7  6.14E+05 P80362  Ig kappa chain V-I region WAT  
1 23.21 15.7  6.14E+05 P01600  Ig kappa chain V-I region Hau  
1 21.86 15.7  2.71E+06 Q9NZT1  Calmodulin-like protein 5  
1 21.51 4.2  1.35E+05 Q9UL52  
Transmembrane protease serine 
11E  
1 21.09 19.5  5.04E+05 P80511  Protein S100-A12  
1 18.83 29.2  3.42E+05 Q9UGL9  Cysteine-rich C-terminal protein 1  
1 18.52 2.6  3.35E+05 P02679  Fibrinogen gamma chain  
1 18.36 1.9  3.29E+05 P22735  
Protein-glutamine gamma-
glutamyltransferase K  
1 18.2 15.3  5.87E+04 P01776  Ig heavy chain V-III region WAS  
1 18.2 15.1  5.87E+04 P01774  Ig heavy chain V-III region POM  
1 18.2 15.5  5.87E+04 P01779  Ig heavy chain V-III region TUR  
1 18.2 15.6  5.87E+04 P01765  Ig heavy chain V-III region TIL  
1 17.97 8.8  1.83E+05 P02766  Transthyretin  
1 17.54 11.4  3.54E+05 P62158  Calmodulin  
1 17.24 4.6  1.18E+06 P02774  Vitamin D-binding protein  
1 16.68 11.4  9.20E+05 P07737  Profilin-1  
1 16.59 0.8  5.16E+04 P0C0L5  Complement C4-B  
1 16.59 0.8  5.16E+04 P0C0L4  Complement C4-A  
1 16.28 13.6  8.12E+05 P32320  Cytidine deaminase  
1 16.25 7.8  2.71E+05 P14174  
Macrophage migration inhibitory 
factor  
1 16.08 21.4  2.51E+05 P00441  Superoxide dismutase [Cu-Zn]  
1 15.75 15.7  3.70E+05 Q5VTM1  Protein FAM25 
1 15.61 9.7  2.63E+05 P06310  
Ig kappa chain V-II region RPMI 
6410  
1 15.61 11.3  2.63E+05 P01614  Ig kappa chain V-II region Cum  
1 15.61 11.1  2.63E+05 P06309  
Ig kappa chain V-II region GM607 
(Fragment) 
1 15.61 11.5  2.63E+05 P01617  Ig kappa chain V-II region TEW  
1 15.48 7.8  2.93E+05 P22392  Nucleoside diphosphate kinase B  
1 15.48 7.8  2.93E+05 P15531  Nucleoside diphosphate kinase A  
1 14.9 12.2  7.46E+04 P35754  Glutaredoxin-1  
1 14.82 9.4  9.36E+04 P47914  60S ribosomal protein L29  
1 14.45 3 1.37E+04 Q6XPR3  Repetin 
1 14.43 43.1  2.55E+05 Q08EQ4  
Putative thymosin beta-4-like 
protein  





1 14.43 43.1  2.55E+05 P62328  Thymosin beta-4  
1 14.43 43.1  2.55E+05 A9Z1Y9  
Putative thymosin beta-4-like 
protein 6 
1 14.4 4.6  6.36E+04 Q9BW04  
Specifically androgen-regulated 
gene protein  
1 14.27 0.6  2.15E+05 P48552  
Nuclear receptor-interacting protein 
1  
1 14.18 6.4  1.36E+05 P49913  Cathelicidin antimicrobial peptide  
1 14.09 9.7  4.38E+05 P62805  Histone H4  
1 13.86 2.3  1.28E+05 Q05639  Elongation factor 1-alpha 2  
1 13.86 2.3  1.28E+05 Q5VTE0  
Putative elongation factor 1-alpha-
like 3  
1 13.86 2.3  1.28E+05 P68104  Elongation factor 1-alpha 1  
1 13.67 4.3  4.41E+05 P52209  
6-phosphogluconate 
dehydrogenase, decarboxylating  
1 13.65 12.2  3.73E+04 P61019  Ras-related protein Rab-2A  
1 13.64 27.4  3.10E+05 Q14508  































28 488.77 54.5  6.82E+07 P02768  Serum albumin  
28 482.75 56.4  2.10E+07 P02788  Lactotransferrin  
22 408.31 56.3  1.32E+08 P13646  Keratin, type I cytoskeletal 13  
6 108.41 10.5  6.22E+07 P19012  Keratin, type I cytoskeletal 15  
2 42.5 3.8  7.40E+06 Q99456  Keratin, type I cytoskeletal 12  
2 40.79 6.2  8.84E+06 P08727  Keratin, type I cytoskeletal 19  
2 35.98 2.5  1.33E+07 P35900  Keratin, type I cytoskeletal 20  
2 35.98 2.5  1.33E+07 Q04695  Keratin, type I cytoskeletal 17  
1 18.14 3 1.55E+06 Q8N1A0  Keratin-like protein KRT222  
1 17.64 2 2.26E+06 Q2M2I5  Keratin, type I cytoskeletal 24  
9 147.59 21.2  7.75E+06 P13645  Keratin, type I cytoskeletal 10  
5 90.22 10.7  3.07E+07 P08779  Keratin, type I cytoskeletal 16  
4 75.25 6.7  3.00E+07 P02533  Keratin, type I cytoskeletal 14  
19 336.92 35.1  7.22E+07 P02538  Keratin, type II cytoskeletal 6A  
5 84.44 7.4  1.87E+07 O95678  Keratin, type II cytoskeletal 75  
4 65.21 4.7  9.41E+06 P12035  Keratin, type II cytoskeletal 3  
4 64.74 5.7  1.36E+07 Q5XKE5  Keratin, type II cytoskeletal 79  
3 48.6 2.9  6.21E+06 Q01546  Keratin, type II cytoskeletal 2 oral  
18 309.07 33.3  6.65E+07 P48668  Keratin, type II cytoskeletal 6C  
17 298.89 30.3  6.09E+07 P04259  Keratin, type II cytoskeletal 6B  
11 183.65 17.7  3.00E+07 P13647  Keratin, type II cytoskeletal 5  
6 107.08 7.9  2.16E+07 P35908  
Keratin, type II cytoskeletal 2 
epidermal  
3 54.81 5.5  8.64E+06 P05787  Keratin, type II cytoskeletal 8  
13 282.18 89.7  8.56E+08 P68871  Hemoglobin subunit beta  
1 18.52 6.8  7.69E+07 P02100  Hemoglobin subunit epsilon 
10 203.79 72.1  2.24E+08 P02042  Hemoglobin subunit delta  
3 57.89 23.8  7.80E+07 P69891  Hemoglobin subunit gamma-1  
3 57.89 23.8  7.80E+07 P69892  Hemoglobin subunit gamma-2  
16 258.57 16.9  1.75E+07 P01023  Alpha-2-macroglobulin 
1 16.96 0.8  1.27E+06 P20742  Pregnancy zone protein  
16 253.88 48.3  2.71E+07 P02647  Apolipoprotein A-I  





2 41.05 3.2  8.46E+06 Q7Z794  Keratin, type II cytoskeletal 1b  
1 22.48 2.4  1.55E+06 Q6KB66  Keratin, type II cytoskeletal 80  
1 22.48 2.5  1.55E+06 P14136  Glial fibrillary acidic protein  
8 133.15 20.2  9.51E+06 P19013  Keratin, type II cytoskeletal 4  
3 52.38 5.7  3.87E+06 P08729  Keratin, type II cytoskeletal 7  
16 244.61 30.7  8.24E+06 P05164  Myeloperoxidase  
2 24.86 2.9  4.77E+05 P11678  Eosinophil peroxidase  
14 233.13 37.6  9.93E+06 P02675  Fibrinogen beta chain  
14 213.77 11.4  5.14E+06 P01024  Complement C3  
10 197.45 45.8  2.29E+07 P63261  Actin, cytoplasmic 2 
10 197.45 45.8  2.29E+07 P60709  Actin, cytoplasmic 1  
5 111.44 6.8  1.21E+07 Q6S8J3  
POTE ankyrin domain family 
member E  
5 91.69 15.1  1.26E+07 P68133  Actin, alpha skeletal muscle  
5 91.69 15.1  1.26E+07 P68032  Actin, alpha cardiac muscle 1  
4 87.98 4.7  1.10E+07 A5A3E0  
POTE ankyrin domain family 
member F  
3 69.95 10.6  7.68E+06 Q9BYX7  Putative beta-actin-like protein 3  
4 68.59 12.2  9.30E+06 P62736  Actin, aortic smooth muscle 
4 68.59 12.2  9.30E+06 P63267  
Actin, gamma-enteric smooth 
muscle  
3 65.99 3.2  8.02E+06 P0CG38  
POTE ankyrin domain family 
member I  
2 47.96 2.3  4.71E+06 P0CG39  
POTE ankyrin domain family 
member J  
2 35.17 6.3  4.97E+06 Q562R1  Beta-actin-like protein 2 
8 168 83.8  4.49E+08 P69905  Hemoglobin subunit alpha 
10 152.37 26.8  5.61E+06 P08670  Vimentin OS=Homo sapiens 
9 147.8 20 9.36E+06 P02787  Serotransferrin 
8 133.99 36.7  3.98E+06 P04083  Annexin A1  
7 125.13 27.8  1.07E+07 Q9UBG3  Cornulin  
8 122.74 6.8  1.04E+06 P35579  Myosin-9  
1 13.54 0.5  9.82E+04 P35580  Myosin-10  
1 13.4 0.8  1.75E+05 Q7Z406  Myosin-14  
1 13.4 0.8  1.75E+05 P35749  Myosin-11  
6 114.3 55.2  3.59E+07 P06702  Protein S100-A9 
7 106.99 23.8  4.43E+06 P02679  Fibrinogen gamma chain  





3 45.95 12.3  7.37E+05 P00739  Haptoglobin-related protein  
6 100.79 20.5  1.87E+06 Q5VTE0  
Putative elongation factor 1-alpha-
like 3  
6 100.79 20.5  1.87E+06 P68104  Elongation factor 1-alpha 1  
3 49.92 6.6  7.25E+05 Q05639  Elongation factor 1-alpha 2  
6 96.79 18.4  7.44E+06 P01009  Alpha-1-antitrypsin  
6 94.82 33 2.56E+06 P01857  Ig gamma-1 chain C region  
2 28.63 11.6  6.41E+05 P01861  Ig gamma-4 chain C region  
3 45.88 15.1  2.11E+06 P01860  Ig gamma-3 chain C region  
7 93.14 19.7  1.23E+06 P68363  Tubulin alpha-1B chain  
6 81.25 16.9  1.07E+06 Q9BQE3  Tubulin alpha-1C chain  
5 71.76 15.6  7.07E+05 P68366  Tubulin alpha-4A chain  
5 65.28 13.7  1.00E+06 Q71U36  Tubulin alpha-1A chain 
3 38.44 9.7  5.31E+05 Q13748  Tubulin alpha-3C/D chain 
3 38.44 9.7  5.31E+05 Q6PEY2  Tubulin alpha-3E chain  
2 30.95 7.1  2.97E+05 Q9NY65  Tubulin alpha-8 chain 
1 15.97 5.8  6.47E+04 Q9H853  
Putative tubulin-like protein alpha-
4B  
1 15.92 2 1.44E+05 A6NHL2  Tubulin alpha chain-like 3  
4 83.3 37.4  6.36E+06 P08246  Neutrophil elastase  
5 80.88 41.7  1.66E+07 P62805  Histone H4  
5 75.16 40.3  1.23E+06 P60660  Myosin light polypeptide 6  
2 30.32 11.5  8.20E+05 P14649  Myosin light chain 6B  
5 74.41 21.5  1.34E+06 Q9BVA1  Tubulin beta-2B chain  
5 74.41 21.5  1.34E+06 Q13885  Tubulin beta-2A chain  
5 74.41 21.5  1.34E+06 P68371  Tubulin beta-2C chain  
5 74.41 21.6  1.34E+06 P07437  Tubulin beta chain  
5 74.41 21.6  1.34E+06 P04350  Tubulin beta-4 chain  
2 28.84 6.8  3.84E+05 Q13509  Tubulin beta-3 chain  
2 28.27 6.2  1.41E+05 Q9BUF5  Tubulin beta-6 chain 
1 14.58 3.1  7.63E+04 Q3ZCM7  Tubulin beta-8 chain  
1 14.58 3.1  7.63E+04 A6NNZ2  Tubulin beta-8 chain B  
1 14.58 3.7  7.63E+04 A6NKZ8  
Putative tubulin beta chain-like 
protein ENSP00000290377 
5 72.14 28.6  2.01E+06 P01876  Ig alpha-1 chain C region 






4 69.78 39.8  1.59E+06 P20160  Azurocidin  
5 69.64 22.8  1.13E+06 P63104  14-3-3 protein zeta/delta  
2 21.96 7 6.17E+05 P62258  14-3-3 protein epsilon  
2 21.96 7.2  6.17E+05 P61981  14-3-3 protein gamma  
2 21.96 7.3  6.17E+05 Q04917  14-3-3 protein eta  
2 21.96 7.3  6.17E+05 P31946  14-3-3 protein beta/alpha  
2 21.96 7.3  6.17E+05 P27348  14-3-3 protein theta  
4 55.74 16.9  1.26E+06 P31947  14-3-3 protein sigma 
4 69.26 6.9  5.07E+05 P02730  Band 3 anion transport protein  
3 58.1 24.7  2.19E+07 P05109  Protein S100-A8  
4 56.99 19.6  5.29E+06 P02790  Hemopexin 
3 55.36 43.8  2.68E+06 P04908  Histone H2A type 1-B/E  
3 55.36 43.8  2.68E+06 Q7L7L0  Histone H2A type 3  
3 55.36 43.8  2.68E+06 P20671  Histone H2A type 1-D  
3 55.36 43.8  2.68E+06 Q93077  Histone H2A type 1-C  
3 55.36 43.8  2.68E+06 P0C0S8  Histone H2A type 1  
3 55.36 44.1  2.68E+06 Q9BTM1  Histone H2A.J  
3 55.36 44.5  2.68E+06 Q99878  Histone H2A type 1-J  
3 55.36 44.5  2.68E+06 Q96KK5  Histone H2A type 1-H  
2 35.35 26.5  1.89E+06 P16104  Histone H2A.x  
2 35.35 29.2  1.89E+06 Q8IUE6  Histone H2A type 2-B  
1 13.09 6.8  1.05E+06 Q96QV6  Histone H2A type 1-A  
1 13.09 7 1.05E+06 P0C0S5  Histone H2A.Z  
1 13.09 7 1.05E+06 Q71UI9  Histone H2A.V  
3 52.39 43.8  2.14E+06 Q6FI13  Histone H2A type 2-A 
3 52.39 44.1  2.14E+06 Q16777  Histone H2A type 2-C  
3 53.14 8.3  2.17E+05 P06576  
ATP synthase subunit beta, 
mitochondrial  
3 52.82 50.9  4.15E+06 P01834  Ig kappa chain C region  
3 51.35 10.1  6.28E+05 P02774  Vitamin D-binding protein  
4 50.97 17.9  8.53E+05 P27797  Calreticulin  
3 50.61 6.6  5.93E+05 P00747  Plasminogen  
3 50.57 27.8  1.93E+06 P04792  Heat shock protein beta-1  








3 47.5 4.5  4.72E+06 P00450  Ceruloplasmin  
3 47.49 20.3  6.51E+05 P00915  Carbonic anhydrase 1 
4 47.44 2 5.83E+05 P15924  Desmoplakin  
3 45.57 9.6  1.06E+06 P04004  Vitronectin  
3 45.33 27.1  4.21E+05 P07737  Profilin-1 
3 44.18 11.3  1.23E+06 P24158  Myeloblastin  
3 41.93 8.4  3.51E+05 P07237  Protein disulfide-isomerase 
3 41.01 45.9  7.97E+05 P04080  Cystatin-B  
3 39.68 32.3  6.20E+05 P47929  Galectin-7  
2 38.53 19 1.20E+07 Q99879  Histone H2B type 1-M 
2 38.53 19 1.20E+07 Q99880  Histone H2B type 1-L 
2 38.53 19 1.20E+07 P33778  Histone H2B type 1-B 
2 38.53 19 1.20E+07 P57053  Histone H2B type F-S  
2 38.53 19 1.20E+07 P58876  Histone H2B type 1-D 
2 38.53 19 1.20E+07 Q99877  Histone H2B type 1-N  
2 38.53 19 1.20E+07 Q16778  Histone H2B type 2-E  
2 38.53 19 1.20E+07 Q5QNW6  Histone H2B type 2-F  
2 38.53 19 1.20E+07 Q8N257  Histone H2B type 3-B 
2 38.53 19 1.20E+07 P23527  Histone H2B type 1-O  
2 38.53 19 1.20E+07 P62807  Histone H2B type 1-C/E/F/G/I  
2 38.53 19 1.20E+07 P06899  Histone H2B type 1-J  
2 38.53 19 1.20E+07 Q93079  Histone H2B type 1-H  
2 38.53 19 1.20E+07 O60814  Histone H2B type 1-K  
1 17.34 7 8.48E+06 Q96A08  Histone H2B type 1-A  
3 38.23 6.5  3.58E+05 P11021  78 kDa glucose-regulated protein  
2 36.68 33 5.46E+05 P0CG04  Ig lambda-1 chain C regions  
2 36.68 33 5.46E+05 P0CG05  Ig lambda-2 chain C regions  
2 36.68 33 5.46E+05 P0CG06  Ig lambda-3 chain C regions  
1 19.96 14.1  3.21E+05 A0M8Q6  Ig lambda-7 chain C region  
1 19.96 14.1  3.21E+05 P0CF74  Ig lambda-6 chain C region  
2 36.25 4.6  3.23E+05 Q8N1N4 Keratin, type II cytoskeletal 78  
2 35.43 11.9  1.27E+06 P02765  Alpha-2-HS-glycoprotein  






Peripheral Blood Unfractionated Protein Identification Results 
2 33.75 4.8  4.12E+05 P01042  Kininogen-1  
2 33.68 21.7  3.00E+05 P29373  
Cellular retinoic acid-binding protein 
2  
2 33.67 5.7  7.04E+05 P01871  
Ig mu chain C region OS=Homo 
sapiens  
2 33.67 6.6  7.04E+05 P04220  Ig mu heavy chain disease protein  
2 33.03 25.9  6.00E+05 Q01469  
Fatty acid-binding protein, 
epidermal  
1 13.44 20.7  2.45E+05 A8MUU1  
Putative fatty acid-binding protein 5-
like protein 3 
2 32.55 1.6  9.04E+05 P02751  Fibronectin  
2 32.28 8.6  3.25E+05 P10909  Clusterin OS=Homo sapiens  
2 29.64 25.7  4.30E+05 P31949  Protein S100-A11  
2 29.23 19.1  6.54E+05 P59666  Neutrophil defensin 3  
2 29.23 19.1  6.54E+05 P59665  Neutrophil defensin 1 
2 29.01 24.8  3.06E+05 P62937  Peptidyl-prolyl cis-trans isomerase A 
1 14.45 8.5  6.49E+04 Q9Y536  
Peptidylprolyl cis-trans isomerase A-
like 4A/B/C O 
2 28.71 7.3  2.17E+05 P14923  Junction plakoglobin  
2 27.57 1.7  2.79E+05 P08603  Complement factor H 
2 27.27 18.9  9.31E+05 Q9UBC9  Small proline-rich protein 3  
2 25.94 9.5  3.09E+05 P32119  Peroxiredoxin-2  
1 21.94 5.1  8.46E+04 P30101  Protein disulfide-isomerase A3  
1 20.67 19.5  7.80E+04 P80511  Protein S100-A12  
1 20.36 20 1.43E+06 P02652  Apolipoprotein A-II  
1 20 3 2.65E+05 P04217  Alpha-1B-glycoprotein  
1 19.46 8.8  2.04E+05 P02766  Transthyretin  
1 19.4 3.4  1.15E+05 P08697  Alpha-2-antiplasmin  
1 19.2 3.7  1.01E+05 P25705  
ATP synthase subunit alpha, 
mitochondrial  
1 18.67 8.2  1.73E+05 P08311  Cathepsin G  
1 18.27 6.6  3.63E+05 P02749  Beta-2-glycoprotein 1  
1 17.87 1.1  7.94E+04 P11215  Integrin alpha-M  
1 17.68 0.6  4.41E+04 P21333  Filamin-A  
1 17.63 23.5  3.44E+05 P68431  Histone H3.1  
1 17.52 5.3  5.58E+04 P02649  Apolipoprotein E  
1 16.05 1.3  1.07E+05 O43707  Alpha-actinin-4  
1 16.05 1.3  1.07E+05 P12814  Alpha-actinin-1  





1 17.32 4.8  5.15E+05 P01861  Ig gamma-4 chain C region 
2 34.22 2.1  4.16E+05 P0C0L4  Complement C4-A 
2 34.22 2.1  4.16E+05 P0C0L5  Complement C4-B 
2 30.5 0.6  3.68E+05 P04114  Apolipoprotein B-100 
2 29.14 3.6  2.94E+05 P00734  Prothrombin 
2 24.93 7.3  8.85E+05 P01011  Alpha-1-antichymotrypsin 
2 24.9 5.5  5.18E+05 P06727  Apolipoprotein A-IV 
1 18.85 0.9  1.65E+05 Q14624  
Inter-alpha-trypsin inhibitor heavy 
chain H4 
1 17.77 3.1  2.92E+05 P06396  Gelsolin 
1 17.72 3.3  1.59E+05 P01871  Ig mu chain C region 
1 17.72 3.8  1.59E+05 P04220  Ig mu heavy chain disease protein 
1 16.73 3.1  3.56E+05 P02760  Protein AMBP 
1 16.42 3.1  4.24E+05 P04004  Vitronectin 
1 15.88 4.9  2.84E+05 P02749  Beta-2-glycoprotein 1 
1 14.86 2 5.00E+05 P05155  Plasma protease C1 inhibitor 
1 14.53 5.1  3.01E+05 P10909  Clusterin 
1 14.49 3 4.87E+05 P04217  Alpha-1B-glycoprotein 
1 13.29 3.4  2.13E+06 P04040  Catalase 
 
 
 
 
